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Summary 
 
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide and 
can lead to liver cirrhosis and hepatocellular carcinoma. The current standard therapy of 
chronic hepatitis C (CHC) consists of a combination of pegylated interferon alpha (pegIFNα) 
and ribavirin. However, sustained viral clearance is achieved in only 50-60% of patients. The 
underlying mechanism of failure of pegIFNα based therapy remains unknown and no 
molecular or genetic markers have been identified that could predict the treatment outcome. 
The overall aim of the study described in this thesis is to understand the molecular basis for 
failure of IFNα based therapies in patients with CHC. The study has focused on the IFN-
induced Jak-STAT (janus kinase-signal transducer and activator of transcription) signaling 
pathway. To address the molecular basis of treatment response to IFN therapy, three 
experimental approaches have been employed. 
  
The first approach involved the analysis of IFNα signaling and expression of interferon 
stimulated genes (ISGs) in liver biopsies and peripheral blood mononuclear cells (PBMCs) of 
HCV patients undergoing pegIFNα treatment. Paired liver biopsies and PBMCs from 16 
patients were collected before and 4 hours after the first injection of pegIFNα, and were 
subjected to analysis of global gene expression using Affymetrix arrays. Further, activation 
of the IFN-induced Jak-STAT signaling pathway was analyzed by immunoblotting, 
immunohistochemistry and gel shift assays. The correlation of these biochemical and 
molecular data with the clinical response to treatment demonstrated that in the liver of 
patients with a rapid response pegIFNα induced a strong upregulation of ISGs, whereas in 
patients that did not respond to therapy, induction of IFN-dependent gene expression was 
impaired. Surprisingly, the non-responders had maximally induced ISG expression already 
before treatment with pegIFNα. Furthermore, the analyses of STAT1 phosphorylation, 
nuclear localization and DNA binding confirmed that the endogenous IFN signaling pathway 
in non-responders is pre-activated and refractory to further stimulation. In contrast to liver 
samples, ISG expression in PBMCs was stimulated by pegIFNα in both responders and non-
responders, indicating that PBMCs are not a good surrogate marker for IFNα responses in the 
liver and that chronic HCV infection has strong local effects on the IFN system in liver. Our 
findings support an interesting concept that activation of the endogenous IFN system in CHC 
not only is ineffective in clearing the infection, but may also impede the response to therapy, 
most likely by inducing a refractory state of the IFN signaling pathway in the liver. 
 3 
In the second approach we addressed the mechanisms underlying the pre-activation of the 
endogenous IFN system in a defined group of HCV patients (future non-responders). For this 
purpose, we analyzed ISG expression by quantitative RT-PCR and nuclear localization of 
STAT1 by immunohistochemistry in a cohort of 112 patients with CHC. By subdividing this 
cohort according to the HCV genotype (GT), we discovered that patients infected with HCV 
GT 1 and 4 more often show hepatic ISG preactivation than GT 2 and 3 patients, thus 
providing an explanation for the poor response to IFN therapy seen in GT 1/4 patients. We 
analyzed the possible involvement of viral sensory pathways in type I IFN production and 
ISG upregulation. Previously, the viral HCV NS3-4A protease was shown to interfere with 
viral sensory pathways by cleaving and thereby inactivating an important adaptor molecule, 
Cardif. We therefore assessed Cardif cleavage in liver biopsies of HCV patients and found 
that cleavage more often occurred in patients infected with HCV GTs 2 and 3. Our findings 
support a concept that the success of the virus in preventing the induction of the endogenous 
IFN system in the livers of these patients would, however, come at the cost of being more 
susceptible to IFNα therapies as is the case with GT 2/3 patients. 
  
In the third approach we designed an experimental model to study the molecular basis of 
refractoriness of IFN signaling in vivo. Previously, cell culture experiments demonstrated a 
long lasting desensitization period, which followed the initial activation of the IFNα 
signaling pathway. In the approach used here, we established a mouse model in which 
continuous presence of IFNα in vivo was achieved by multiple subcutaneous injections, 
mimicking the constitutively high serum levels achieved by pegIFNα in patients. 
Interestingly, this resulted in refractoriness of IFNα signaling. Activation of STAT1 and 
STAT2, but not STAT3, in the mouse liver was desensitized by continuous IFNα stimulation. 
To elucidate the mechanism of this refractoriness, the role of negative regulators of the Jak-
STAT signaling pathway was investigated. IFN signaling remained refractory in mice 
deficient in suppressor of cytokine signaling (SOCS) 3 and persisting refractoriness was also 
observed in mice deficient in IL-10, a strong inducer of SOCS3. Ubiquitin specific peptidase 
18 (USP18/UBP43) was recently identified as novel negative regulator of IFNα signal 
transduction. Interestingly, refractoriness could be overcome in USP18/UBP43 knockout 
mice. These data strongly indicate that UBP43 is the decisive factor in inducing a refractory 
state in the IFNα signaling pathway in vivo. 
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1. Introduction 
 
 
1. 1 Hepatitis C virus infection 
 
 
1.1.1 HCV epidemiology 
 
Hepatitis C virus (HCV) is the cause for chronic hepatitis C (CHC), a liver disease previously 
called non-A non-B hepatitis. CHC can lead to liver cirrhosis and hepatocellular carcinoma 
(HCC). An estimated 170 million people worldwide, approximately 3% of the global 
population, are infected with HCV (reviewed in (1)). Since a protective vaccine against HCV 
does not yet exist and the therapeutic options remain limited, the number of patients 
presenting with long-term complications of CHC, including liver cancer, is expected to 
increase further over the next 20 years (2).  
As HCV was discovered only in 1989 (3), blood transfusions represented the highest 
risk factor for HCV infection before 1990. The establishment of an efficient blood-screening 
system has then drastically decreased the incidence of post-transfusion hepatitis in developed 
countries (4). Blood-screening measures based on the detection of HCV antibodies carry a 
residual risk resulting from a delay of approximately 12 weeks between a possible infection 
and the generation of antibodies. This diagnostic gap after primary HCV infection can be 
decreased by more sensitive screening methods based on polymerase chain reaction (PCR) of 
HCV-RNA (5). New cases of HCV infection continue to occur mainly as a result of injection 
drug use. Maternal-fetal transmission is a rare event and mainly seen in mothers who are co-
infected with HIV-1 (6). Current guidelines for pregnant women recommend normal 
childbirth and breast-feeding, both associated with only minimal risk of HCV transmission. 
Likewise, the sexual transmission of HCV is infrequent but its risk increases upon co-
infection with HIV-1 (7). Nosocomial transmission of the virus is possible and includes 
needle-stick injuries among health care workers, infection during surgery, colonoscopy or 
dialysis. In one third of cases, however, the transmission route of the disease remains unclear. 
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1.1.2 Model systems in HCV research 
 
HCV was first identified in an infected chimpanzee by expression cloning of RNA isolated 
from its serum and screening with human serum from a non-A non-B hepatitis patient (3). 
Soon after, an assay for HCV antibody detection was developed (8). Subsequently, it was 
demonstrated that intrahepatic injection of RNA transcripts from HCV cDNA clones into 
chimpanzees resulted in viral replication and the development of hepatitis (9, 10). The 
chimpanzee (Pan troglodytes) remains the only suitable animal model for studying HCV 
infection in vivo, although not widely applicable due to ethical and economical concerns. So 
far, no suitable small animal model of HCV infection has been developed, and moreover an 
efficient system for HCV replication in cell culture is available only since 1999. Lack of 
these models has hampered both research on HCV function and the development of 
therapeutic measures for HCV infection. In 1999, an HCV subgenomic replicon system in 
human hepatoma derived Huh7 cells was established (11), which however did not allow 
production of infectious virions. It was only in 2005 when an in vitro model of HCV 
replication that reproduces the full viral lifecycle (12, 13), including production of infectious 
virus, in permissive Huh7 cells was developed. Wakita and colleagues transfected an HCV 
genotype (GT) 2a clone isolated from a Japanese patient with fulminant hepatitis C, 
designated JFH-1 (for Japanese fulminant hepatitis), into Huh7 cells leading to production of 
virus (designated HCVcc for cell-culture-derived HCV) that was infectious for naïve Huh7 
cells. The group of Charles M. Rice used a viral genome of a chimaeric HCV GT 2a 
sequence termed FL-J6/JFH that showed robust replication with production of 105 infectious 
units/ml and this replication could be inhibited by interferon-alpha (IFNα) and several HCV-
specific antiviral compounds. 
Owing to the development of the infectious system, there is rapid progress in 
understanding previously unexplored steps of the HCV lifecycle including viral entry, 
genome packaging, virion assembly, maturation and release. For instance, Evans and 
colleagues have recently identified Claudin-1, a tight junction component highly expressed in 
the liver, as co-receptor required for HCV entry (14). 
Transgenic mice carrying cDNA covering the entire coding region of the HCV 
genome have been generated, but in this model replication of the virus does not take place 
(15, 16). In 2001 the first murine model suitable for studying the human HCV in vivo has 
been established by transplanting normal human hepatocytes into SCID (severe combined 
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immunodeficiency) mice. These mice developed prolonged HCV infections after inoculation 
with infected human serum (17). The SCID/albumin (Alb)-urokinase plasminogen activator 
mouse model might therefore become a useful tool for investigating an in vivo efficacy of 
anti-HCV drugs. 
 
 
1.1.3 Structure of HCV 
 
HCV is a positive-stranded RNA virus and is classified in the Hepacivirus genus within the 
family of flaviviruses (reviewed in (18)). Based on electron microscopy studies, HCV 
particles are approximately 55 nm in diameter (19). Six distinct but related genotypes (GTs) 
of HCV have been documented (20). In Western Europe and the United States GTs 1a and 1b 
are most common, followed by GTs 2 and 3. The GTs 4, 5 and 6 are hardly ever found in 
these countries but are common in other areas such as Egypt or South Africa. The six major 
GTs differ by up to 35% in their sequence. 
The genome of HCV is approximately 9.6 kb long and contains a single large open 
reading frame (ORF) that encodes a polyprotein of slightly more than 3000 amino acids (aa) 
(reviewed in (21)). This precursor protein is processed by a combination of host- and virus-
encoded proteases into at least 10 individual proteins, representing both structural and non-
structural components of HCV. Structural proteins (Core, E1 and E2), which form the viral 
envelope, are located at the N-terminus, while non-structural proteins involved in viral 
replication (NS2-NS5b) occupy the rest of the polyprotein (Scheme 1).  
The core protein is considered to form a nucleocapsid, while E1/E2 are glycoproteins 
integrated into the lipid envelope and are likely to be responsible for the binding and entry of 
the virus to target cells (22). These structural components are followed by p7, a polypeptide 
reported to form an ion channel (23). Mutation of two conserved basic residues, previously 
shown to be important for the ion channel activity of p7 in vitro, drastically impaired 
infectious virus production (24). The proteins mentioned above are cleaved by host signal 
peptidases (25), while the proteins located downstream of p7 are processed by autocatalytic 
mechanisms.  
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Scheme 1. Structure of the HCV-genome. 
Core, envelope (E) proteins, p7, non-structural (NS) proteins, IFN-sensitivity determining region (ISDR), 
untranslated region (UTR), internal ribosomal entry site (IRES). See text for further details. 
 
 
The major part of the NS2 protein and the N-terminal part of the NS3 protein form a 
viral metalloprotease (NS2-3 protease) that cleaves at the NS2/3 junction. The cleavage of 
the remaining non-structural proteins is catalyzed by a serine protease (NS3-4A protease) that 
is a part of the NS3 protein (26). In addition, the C-terminal portion of NS3 contains 
sequences for a nucleoside triphosphatase (NTPase) and RNA helicases that are considered to 
regulate the replication of viral RNA (27). The NS4A polypeptide acts as a cofactor for the 
NS3 serine protease. All HCV proteins are associated to intracellular membranes. The 
processing of the polyprotein occurs at the endoplasmic reticulum (ER). Moreover, it is 
currently hypothesized that the formation of the membrane-associated viral replication 
complex occurs at altered cellular membranes possibly derived from the ER. NS4B was 
reported to induce the formation of these so-called membranous webs (28, 29). 
The phosphorylation state of NS5A affects HCV-RNA replication (30, 31) and 
current evidence indicates that NS5A might function as a molecular switch between viral 
replication and assembly. Further, it has been reported that a mutation in the C-terminal part 
of NS5A increases the sensitivity to IFNα, used as the main antiviral drug (see chapter 1.1.6). 
Therefore this region is termed the IFN sensitivity-determining region (ISDR) (32). NS5A 
interacts with the IFN-induced protein kinase PKR via the ISDR and inhibits PKR activity, 
leading to a decrease of the IFN-mediated response to viral infection (33, 34). NS5B is the 
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key component in HCV replication since it contains a domain acting as RNA-dependent 
RNA-polymerase (RdRp) (35). 
 The highly conserved untranslated regions (UTRs) are required for viral replication. 
The 5' UTR contains an internal ribosomal entry site (IRES) that can initiate translation of the 
viral polyprotein in a cap-independent manner. It was recently reported that the liver-specific 
micro-RNA miR-122 base-pairs to the 5’-UTR of the genomic RNA of HCV and positively 
regulates replication of HCV-RNA in vitro (36). The 3' UTR of HCV is divided into three 
regions, two of which have been shown to be required for virus in vivo replication (37). 
 
 
1.1.4 Pathogenesis 
 
Hepatocytes and, possibly, B-lymphocytes as well as dendritic cells are the natural targets of 
HCV. CD81 is considered to function as a cell surface receptor recognized by the E2 protein 
of the virus (38). CD81 may not be sufficient for viral entry (39) and it has been postulated 
that additional roles are played by the low-density-lipoproteins receptor (LDLR) binding an 
unknown component of the viral envelope (40) and the scavenger receptor class B type I (SR-
BI) (41). The LDLR is an attractive candidate receptor because HCV can be associated to 
LDLs (reviewed in (42)). Claudin-1 was recently identified as co-receptor required at a late 
stage of HCV entry (14). 
 Viral replication is extremely efficient and is catalyzed by the C-terminal RNA-
polymerase. The HCV half-life is estimated as only a few hours with a production of as much 
as 1012 virions per day (43). Since the RdRp lacks a "proofreading" function, this results in a 
high diversity of transcripts and generation of multiple HCV-quasispecies within an infected 
person. This diversity poses major difficulties in HCV therapy and provides a strong rationale 
for the development and implementation of antiviral combination treatments in analogy to 
therapies used in HIV infection. 
 The immune system is known to play an important role in the development of 
hepatitis. T lymphocytes can be found within the infected hepatic parenchyma and it has been 
suggested that they are mobilized to control and possibly eliminate the virus. However, the 
result of their presence in the liver is a collateral damage through the secretion of 
inflammatory cytokines (44). Inflammation may also be related to clearance of HCV infected 
cells by activated cytotoxic T cells (45).  
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 Viral proteins may influence proliferation of infected host cells. The most important 
pathogenic function has been documented for HCV core protein (46). Its effects include 
activation of the ras/raf kinase pathway (47), the transcription factor NFκB and modulation 
of apoptosis by suppressing the activation of caspase 8 (48). In addition, core protein may 
have a transforming ability in cooperation with ras oncogene and epidermal growth factor 
EGF receptor signaling (49). In addition, an interaction of core protein with lipid droplets 
might affect lipid metabolism, contributing to the development of liver steatosis, which is 
often seen in patients infected with HCV genotype 3 (50). The envelope protein E2 was 
shown to interfere with PKR function, while NS3 protein can interact with tumor suppressor 
p53 and has, similarly to NS4B, a cell transforming ability (45). Several proteins involved in 
viral pathogenesis are potential targets for the development of virus-specific inhibitors. These 
drug targets include the HCV NS2-3 and NS3-4A proteases (51), HCV helicases (52) and the 
NS5B RdRp as well as the IRES, the p7 polypeptide and the CD81 receptor (1). 
 
 
1.1.5 Clinical manifestations 
 
The course of disease varies widely among infected persons. HCV infection is hardly ever 
diagnosed during the acute phase. The majority of persons have either none or only mild and 
unspecific symptoms after exposure to HCV. Nevertheless, clinical manifestations of acute 
hepatitis consisting of jaundice, malaise and nausea can occur in some patients, usually 
within 7 to 8 weeks after infection (1).  
 Progression to chronic disease occurs in about 70-80% of infected persons, whereas 
20-30% show spontaneous recovery (Scheme 2). The early stage of chronic infection is 
typically characterized by a prolonged asymptomatic period. Spontaneous clearance of 
viremia, once chronic infection has been established, is rare. Most chronic infections will 
lead to hepatitis and to some degree of fibrosis. 10-20% of those infected chronically develop 
liver cirrhosis. At this stage of the disease the risk of developing hepatocellular carcinoma 
(HCC) is 1-4% per year (53).  
 
 Factors that increase the risk of clinical disease progression include alcohol intake, 
co-infection with hepatitis B virus (HBV) (54) or HIV-1 (55), male sex and older age at 
infection. In this high-risk group, cirrhosis can develop within 20 years or less after infection. 
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In contrary, low risk patients often do not have progressive liver disease until 30 or more 
years after infection. In HCV-infected patients a superinfection with hepatitis A virus (HAV) 
can lead to acute or even fulminant hepatitis (56). 
 
 
   
  Scheme 2. Disease progression. 
 
  
 In addition to hepatic disease, HCV infection is associated with important 
extrahepatic manifestations. As mentioned above the virus may target B cells, and indeed a 
number of B cell-mediated disorders are associated with HCV infection. For example, HCV 
is the major cause of essential mixed cryoglobulinemia. Cryoglobulins can be found in about 
50 % of HCV patients, but only 10-15% develop a symptomatic disease consisting of 
weakness, arthralgia and purpura (57, 58). Since cryoglobulins accumulate in kidney, 
membranoproliferative glomerulonephritis can occur as a serious complication (59). A higher 
incidence of B cell non-Hodgkin's lymphoma (60), Sjögren’s syndrome (61), autoimmune 
thyroiditis, idiopathic pulmonary fibrosis and dermatologic manifestations like Lichen planus 
and porphyria cutanea tarda in association with HCV infection has been observed (62). The 
pathogenic link between HCV infection and these disorders has been suggested on the basis 
of the frequently positive response to antiviral therapy. On the other hand, antiviral treatment 
with IFN has been suggested to be responsible for the induction of autoimmune thyroiditis 
since discontinuation of therapy can ameliorate this condition (63). 
1.1.6 Treatment of hepatitis C 
 
Since HCV infection is rarely diagnosed during the acute phase, data regarding the need for 
treatment of acute hepatitis are very limited. Some patients with acute symptomatic infection 
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show a spontaneous clearance suggesting that their treatment would have been unnecessary. 
However, recent studies indicate that early treatment with IFNα may be beneficial (64, 65). 
All patients with chronic HCV infection (defined as infection persisting over more 
than six months with positive HCV-antibody and HCV-RNA detectable in the serum) are 
candidates for therapy, but the risks and benefits of treatment have to be evaluated 
individually because of the typically slow course of natural infection and the high occurrence 
of treatment side effects. Therapy is recommended for patients with persistently elevated 
transaminase levels (alanine aminotransferase ALAT and aspartate aminotransferase ASAT), 
documented viral replication (HCV-RNA positivity in the serum), and fibrosis documented 
by liver histology (Metavir fibrosis stage F ≥ 2 out of maximally 4). Patients with normal 
ALAT levels and no or little histological signs of inflammation and fibrotis have an excellent 
prognosis without therapy (1). 
 Until 2001, the treatment of HCV infection consisted of IFNα in combination with 
the nucleoside analogue ribavirin. This combination therapy led to a sustained virologic 
response in 35-40% of patients (66). IFNα was administered subcutaneously (3 million units 
three times a week) and ribavirin was given orally twice a day (1000-1200 mg/day, 
depending on body weight). The serum concentrations of this unmodified IFNα (with an 
elimination half-life of 4 to 10 hours) declined below pharmacologically active levels in the 
second half of each 48 hour dosing interval (67, 68). 
 The introduction of a polyethylene glycol modified form of IFNα, called pegylated 
IFNα (pegIFNα), has resulted in a greater than 50% sustained response rate, if combined 
with ribavirin (69, 70). This combination has proven particularly efficient in the treatment of 
patients with poor prognosis due to infection with genotype 1, high baseline levels of HCV-
RNA or cirrhosis (Metavir staging F4). PegIFNα has an extended half-life compared to IFNα 
and therefore can be administered only once a week. There are currently two pegIFNα 
isoforms used for the treatment of CHC: pegIFNα2a (Pegasys®, administered in a dose of 
180µg/week) and pegIFNα2b (PegIntron®, given in a dose of 1.5µg/kg body weight). 
Pegasys is a 40kDa molecule with a half-life of 60-80 hours and PegIntron is a 15kDa 
molecule with a half-life of 40 hours. Despite these differences in half-life, both drugs are 
injected once a week. Hence, Pegasys is still found at high concentrations after 7 days before 
the injection of the next dosage, whereas PegIntron concentrations decrease to nearly baseline 
values during the weekly dosing interval. It is not clear whether these pharmacokinetic 
differences are relevant for the efficacy of therapy and it is assumed that both drugs are 
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equally effective. It is also unknown if the pharmacokinetic differences have an impact on the 
IFNα signaling and IFNα effector systems in the liver. Moreover, the reasons for an 
improved efficacy of pegIFNα compared to unmodified IFNα are not known, but it is 
assumed that the constantly high serum concentrations achieved with pegIFNα provide for 
un-interrupted antiviral activity through persistent stimulation of the IFN signaling pathway. 
The most frequent side effects of IFNα-based therapy consist of influenza-like 
symptoms (40-85%), digestive dysfunction, depression (5-10%), thyroid dysfunction (5-
10%), thrombocytopenia and neutropenia (Table 1). The concomitant use of ribavirin can 
lead to hemolysis with consecutive anemia in 30% of patients (71).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Side effects of HCV therapy (modified from [1]). 
 
Over the last years, HCV associated end-stage liver disease has become the most 
frequent cause for liver transplantation in Switzerland, Europe and the US (72). 
Transplantation is the only treatment option for patients with uncompensated cirrhosis or 
early stages of HCC. Although infection of the graft is inevitable, the survival rate does not 
differ from the one of patients with other common indications for liver transplantation.  
 Because of extreme sequence variability within the HCV genome, development of an 
effective vaccine against HCV infection has proven to be very difficult. Promising 
Frequency of Interferon alpha    Ribavirin    
side effects                 
 
>30%  Influenza-like symptoms        Hemolysis 
  -Headache, Fatigue               Nausea 
  -Fever                              Abdominal pain 
  -Myalgia, Rigors 
  Thrombocytopenia 
  Induction of autoantibodies 
 
1-30%  Anorexia                Anemia 
  Diarrhea, Abdominal pain        Nasal congestion 
  Depression,Insomnia                Cough, Laryngitis  
  Emotional lability, Irritability            Pruritus 
  Dermatological problems 
  Thyroid dysfunction 
  Leukocytopenia 
  Induction of autoimmune disease 
   
<1%  Polyneuropathy, Optic neuritis          Gout 
  Diabetes mellitus, Retinopathy 
  Paranoia or suicidal ideation 
  Cardiotoxicity, Seizures 
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approaches have been developed in chimpanzees: sera raised against HVR1, the most 
variable region of the HCV genome (located within the sequence encoding the E2 protein), 
protected against HCV infection (73). Other approaches to HCV vaccination include use of 
various attenuated viral vectors to enhance priming of immune responses to multiple HCV 
gene products expressed by the vector (74). The chimpanzee challenge model (in which 
animals are being inoculated with HCV after vaccination) is used to explore efficacy and 
safety of the candidate vaccines. 
Knowledge of the HCV GT is important because it helps to predict the outcome of 
antiviral therapy and influences the choice of the therapeutic regimen (75). Better responses 
are associated with GTs 2 and 3 than with 1 and 4. Treatment duration is 48 weeks for GTs 1 
and 4, and 24 weeks for GTs 2 and 3 (70). For GTs 2 and 3, even a 12-week treatment 
regimen was shown to be effective in patients who achieved a rapid virological response 
(RVR) (76). The cause for these differential responses to treatment is currently unknown. 
Other factors associated with non-response to treatment are high baseline viral load as well as 
high fibrosis stage, old age, male gender, African American race, obesity, alcohol intake and 
changes in the host immune response, e.g. high interleukin-8 (IL-8) and IL-10 serum levels 
(77). The number of NS5A/ISDR mutations have also been shown to be relevant to the 
outcome of anti-HCV therapy (78). The current definitions of treatment response are based 
on the viral load (Table 2). 
 
Rapid Virological Response (RVR) = Negative HCV-RNA in week 4 of treatment 
Early Virological Response (EVR) = HCV-RNA reduction > 2 log after 12 treatment weeks 
Primary Non-Response (PNR) = less than 2 log decrease of viral titer after 12 weeks 
End of Treatment Response (EoTR) = no detectable serum HCV-RNA at end of treatment 
End of Treatment Non-Response = detectable serum HCV-RNA at end of treatment 
Sustained Virological Response (SVR) = undetectable HCV-RNA 6 months after end of treatment 
Relapse = detectable HCV-RNA in serum at any time after having achieved EoTR 
 
 Table 2. Treatment outcome classification according to generally accepted terminology. 
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1.2 IFNα-signaling 
 
 
1.2.1 The IFN cytokine family and the IFN receptors 
 
Interferons are a heterogeneous group of cytokines that play an important role in mediating 
antiviral and antiproliferative responses and in modulating immune reactions. They are 
classified into two types, type I consisting of IFNα, IFN-beta (IFNβ) and IFN-omega (IFNω) 
and type II with IFN-gamma (IFNγ) as the only member (79). So far twelve different IFNαs 
have been characterized. Plasmocytoid dendritic cells (pDCs) are known to have an 
extraordinary capacity to produce type I IFNs (80). All type I IFNs bind to the same 
interferon alpha/beta receptor (IFNAR) that consists of two chains, IFNAR1 and IFNAR2. 
IFNγ is produced by T lymphocytes and natural killer (NK) cells (81). It binds to the IFNγ 
receptor (IFNGR) consisting of two subunits, IFNGR1 and IFNGR2 (82). Upon binding to 
these receptors, both type I and type II IFNs exert their effects by activating the Jak/STAT 
signal transduction pathway (see chapter 1.2.3). 
 
 
1.2.2 Antiviral effects of IFNα  
 
IFNα has multiple antiviral effects, based on both direct antiviral actions and modulation of 
the host immune response. The induction of antiviral mechanisms consists of transcriptional 
activation of interferon stimulated genes (ISGs) encoding proteins such as double-stranded 
RNA (dsRNA) activated protein kinase PKR, 2'-5' oligoadenylate synthetase (OAS) and Mx 
proteins (79). 
 PKR plays a role in the control of transcription and translation (83). In response to 
IFN, PKR becomes upregulated and subsequently activated by binding viral dsRNA and 
autophosphorylation. The best-characterized substrate of PKR is eIF2α, the α subunit of 
eukaryotic initiation factor. Its phosphorylation results in inhibition of translation of both 
viral and cellular proteins, explaining the antiviral and antiproliferative effect of IFN. Two 
HCV proteins are known to interact with PKR: NS5A via the ISDR and E2 via a region 
identical to the phosphorylation sites of PKR and eIF2α (84). These interactions lead to an 
inhibition of PKR activity and therefore may contribute to HCV mediated IFNα resistance. 
The OAS activates a multienzyme pathway leading to the cleavage of viral and cellular 
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single-stranded RNAs (ssRNAs) by RNase L (85). RNase L was recently shown to play an 
important role in positive feedback mechanisms enhancing the innate immune system by 
generation of small RNA cleavage products from self-RNA (86). Mx proteins are IFN-
inducible GTPases that interfere with replication of negative-stranded RNA viruses such as 
influenza (87). 
 Besides these direct antiviral actions, IFNα may exert its therapeutic effect by 
enhancing the immune response against infected hepatocytes and against the virus itself. An 
important immunomodulatory effect of IFNα is mediated through activation of NK cells that 
non-specifically recognize and lyse infected cells. An additional pathway may involve killing 
of infected cells by cytotoxic T lymphocytes, activity of which is increased in patients 
receiving IFNα treatment (88). This is supported by an IFN induced upregulation of MHC 
class I expression. Furthermore, IFNα can promote T helper cell 1 (TH1) responses including 
a positive feedback through enhancing expression of other IFN genes like that of IFNγ (89). 
 
 
1.2.3 Jak-STAT signal transduction pathway 
 
A large number of extracellular signaling proteins including polypeptide hormones, 
cytokines, growth factors and interleukins are using the Jak/STAT pathway for intracellular 
signal transduction, which results in transcriptional activation of target genes (90). 
Jaks (Janus kinases) are cytoplasmic tyrosine kinases containing two tandem tyrosine 
kinase domains. There are four identified mammalian Jak family members (Jak1, Jak2, Jak3 
and Tyk2) with molecular weights of approximately 120-140 kDa. Except for Jak3, found 
mainly in cells of myelocytic and lymphocytic lineages, the other three Jak members are 
ubiquitously expressed. Jaks contain seven conserved domains called JH1 to JH7 (Jak 
homology) (Scheme 3). JH1 is the tyrosine kinase domain at the carboxy-terminus and JH2 is 
a catalytically inactive kinase-like domain that might have a regulatory function and is 
considered to be a potential binding site for STATs (91). JH3-JH7 are located at the N-
terminus and important for specific receptor recognition and association. JH3 and JH4 
possess structural features of a potential SH2 (src homology 2)-like domain (92). Part of JH4 
and the JH5 to JH7 region was renamed FERM domain and is able to bind the cytoplasmatic 
tail of transmembrane receptors (93). 
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Scheme 3. Structure of Janus kinases (Jaks). 
Jak homology (JH) regions, src-homology 2 (SH2), FERM (band 4.1/ ezrin/ radixin/ moesin), Signal 
Transducer and Activator of Transcription (STAT). 
 
 
STATs (Signal Transducers and Activators of Transcription) act as both signalling 
molecules and transcription factors. They shuttle between cytoplasm and nucleus. In non-
stimulated cells STATs are predominantly located in the cytoplasm, whereas upon 
stimulation they are able to enter the nucleus where they stimulate transcription by binding to 
promoter response elements. So far, seven mammalian STATs have been identified (STAT1-
4, STAT5a, STAT5b and STAT6). STAT4 is mainly expressed in thymus and testes, whereas 
the remaining STAT proteins are ubiquitous (reviewed in (90, 94)). In Scheme 4, the 
functional domains of STAT proteins are described.  
The C-terminus is the autonomously functioning transcriptional activation domain 
containing tyrosine and serine residues that become phosphorylated upon activation. The 
potent transcriptional activators CBP and p300 interact with this domain (95). The SH2 
domain binds to the phosphotyrosine of a homo- or heterotypic STAT leading to the 
formation of dimers (96). The SH2 domain is also able to interact with cytokine receptors 
that have become tyrosine-phosphorylated upon ligand binding (97). The DNA binding 
domain has the structure of an immunoglobulin variable fold and is responsible for STAT-
DNA binding. The coiled-coil domain interacts with IRF9, a component of the interferon-
stimulated gene factor 3 (ISGF3). The N-terminal domain acts as a protein-protein interaction 
domain and has been implicated in the regulation of dephosphorylation of STAT1 on tyrosine 
701, the interaction with CBP/p300 and the regulation of nuclear translocation (98). 
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Scheme 4. Structure of Signal Transducers and Activators of Transcription (STATs). Interferon-
stimulated gene factor 3 (ISGF3), nuclear cofactor CBP. 
 
Cytokine receptors possess no intrinsic catalytic activity, and therefore depend on 
Jaks that are permanently associated to their cytoplasmic tails. Homodimeric and heteromeric 
receptors activate different combinations of Jaks. After having trans-phosphorylated each 
other, the Jaks proceed to phosphorylate the receptor subunit(s). Subsequently, STATs are 
brought to the proximity of the Jaks by binding to the receptor phosphotyrosine through their 
SH2 domain (97). After their phosphorylation, STATs are able to form homo- or 
heterodimers by mutual SH2-phosphotyrosine interactions. As dimers, they are able to 
translocate into the nucleus and to act as transcription factors. An alternative model of STATs 
pre-existing as dimers, and their activation leading to a conformational change, was recently 
proposed by Mao and colleagues (99).  
 
 
1.2.4 IFNα  as a trigger of the Jak-STAT pathway  
 
Binding of IFNα leads to the crosslinking of the receptor chains IFNAR1 and IFNAR2. 
Activated Jak1 and Tyk2 proceed to phosphorylate STAT1, STAT2 and STAT3 (97, 100). 
The activated STATs dissociate from the receptor and translocate to the nucleus where they 
act as transcription factors binding to specific regions in the promoters of IFN regulated 
genes (IRGs) (101). As shown in Scheme 5, there are two distinct pathways leading to 
transcription of IFNα target genes. The first involves the formation of STAT1-STAT2 
heterodimers, which translocate to the nucleus and there, after combining with IFN-
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regulatory factor (IRF)-9, form the IFN stimulated gene factor 3 (ISGF3). ISGF3 binds to the 
interferon-stimulated response element (ISRE) within the promoters of ISGs (90, 102). IFNα 
also activates homo- and heterodimers of STAT1 and STAT3, which bind to gamma-
activated sequence (GAS) response elements in the nucleus (103). 
 
 
 
Scheme 5. IFNα  induced Jak/STAT signaling. 
Interferon-α (IFNα) binds to the IFNα receptor (IFNAR1/2) leading to dimerization of the receptor 
chains. Activated (i.e. phosphorylated) Janus kinases (Jak1/Tyk2) phosphorylate IFNAR1/2, the 
Signal Transducers and Activators of Transcription (STAT1/2/3) become activated at the receptor-
kinase complex and form either the interferon-stimulated gene factor 3 (ISGF3) which binds to 
interferon-stimulated response element (ISRE) or the STAT1/3 homo- and hetero-dimers which bind 
to γ-activated sequence (GAS). These signaling cascades ultimately result in the transcription of 
interferon-stimulated genes (ISGs). Finally, STATs are dephosphorylated in the nucleus and exported 
into the cytoplasm. 
 
 
Besides inducing transcription of antiviral ISGs, IFNα can also upregulate genes 
involved in signaling, including STAT1, STAT2, IRF-9 and IFNα itself (104). This effect 
results in a positive feedback loop in the IFNα dependent Jak/STAT pathway.  
STAT1 activity is regulated by tyrosine phosphorylation (tyr-701), which is essential 
for dimer formation, nuclear translocation and DNA-binding. Serine phosphorylation (ser-
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727) is not essential but required for STAT1 to achieve its full transcriptional activity (105-
107). STAT activity in cytokine-treated cells is regulated by degradation and active shut-off 
mechanisms of which dephosphorylation plays the most important role. Dephosphorylation 
of STAT1 is catalyzed by several phosphatases (see chapter 1.2.5). Besides tyrosine and 
serine phosphorylation, STAT1 undergoes an additional posttranslational modification. The 
methylation of an arginine residue (arg-31) by protein arginine methyl-transferase (PRMT-1) 
is also required for transcriptional activation of STAT1 (108). Inhibition of PRMT-1 and, 
consequently, absence of arginine methylation leads to an increased association of the 
inhibitory protein PIAS1 with phosphorylated STAT1 dimers. Importantly, this interaction 
results in an impaired binding of STAT1 to response elements in the promoters of target 
genes. Abnormally elevated levels of 5’-methyl-thioadenosine (MTA), an inhibitor of 
PRMT-1, have been found in certain cancer cells and might be responsible for the lack of 
IFNα responsiveness observed in many malignancies. 
 
 
 
1.2.5 Negative regulation of IFNα signal transduction 
 
Negative regulation of cytokine signaling is crucial to control signal transduction cascades 
and prevent side effects as well as tumor transformation. For example, constitutively 
activated STATs were found in many hematological malignancies (109). 
The activation of the Jak/STAT pathway is tightly controlled by several negative 
regulatory mechanisms acting at different levels of the signaling cascade. The Suppressors of 
Cytokine Signaling (SOCS) prevent STAT activation by inhibiting Jaks or preventing STAT 
binding to the receptor (110). Further downstream, the protein inhibitor of activated STAT 
(PIAS) binds to hypomethylated STAT dimers and inhibits STAT-DNA interaction (108, 
111, 112). STATs are deactivated by the 45kDa isoform of nuclear phosphatase TC-PTP, 
followed by nuclear export (113) (114) (115). Further, an involvement of SH2-containing 
phosphatases 1 and 2 (SHP-1 and -2) (116) (117) is postulated. Previous work in our 
laboratory has demonstrated a role of protein phosphatase 2A (PP2A) in inhibiting the 
Jak/STAT pathway at the level of STAT-DNA interactions (118) (see chapter 1.2.7). 
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Scheme 6. Negative regulation of IFNα  induced Jak/STAT signaling. 
Ubiquitin-specific peptidase 18 (USP18/UBP43); Suppressor of cytokine signaling (SOCS); Protein 
inhibitor of activated STAT (PIAS). 
 
 
There is evidence that all these proteins negatively regulate IFNα signaling (Scheme 
6). For example, PIAS1 and PIAS3 associate with STAT1 and STAT3, respectively (111, 
119). Members of the SOCS family (SOCS1 and SOCS3) prevent phosphorylation and 
activation of IFNα induced STATs by inhibiting the IFN receptor associated Jak kinases or 
preventing STATs from binding to the cytoplasmic tails of the IFNAR. PIAS deficient mice 
show increased protection against viral and microbial infection consistent with a negative 
regulatory function of PIAS1 on a subset of type I IFN responsive genes (120). Mice with 
SOCS1 deletion die during the neonatal period due to severe hepatotoxicity and multiorgan 
inflammation (121) and SOCS3 deficient mice die in mid-gestation due to placental 
insufficiency (122). Recently, ubiquitin specific peptidase 18 (USP18/UBP43) has been 
described as negative regulator in type I IFN signaling. USP18/UBP43 was originally 
identified as a protease cleaving ubiquitin-like modifier ISG15 from target proteins, but was 
recently found to play a negative regulatory role independently of its ISG-deconjugating 
ability (123, 124). USP18/UBP43 was reported to inhibit the activation of Jak1 by interfering 
with its interaction with IFNAR2 (125). USP18/UBP43 is induced by IFNα (126, 127) and 
provides a negative feedback loop that restricts IFNα signals. UBP43 deficient mice show a 
severe phenotype characterized by brain cell injury, poly-(I:C) hypersensitivity, and 
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premature death (128, 129). Interestingly, they are resistant to otherwise fatal cerebral 
infections with LCMV and VSV (130). USP18/UBP43 is elevated in livers of future non-
responders to pegIFNα therapy (131). Moreover, USP18/UBP43 silencing in cells with a 
replicating chimeric HCV genome results in deregulation of STAT1 signaling and 
potentiation of IFNs ability to inhibit HCV-RNA replication (132). 
 
 
1.2.6 Clinical relevance of disrupted Jak-STAT signaling 
 
Interference of HCV proteins with the IFN-induced antiviral effector system (such as PKR) 
represents one mechanism of viral escape. Another strategy is based on the disruption of 
IFNα signaling. Indeed, decreased levels of IFNα receptor in the liver have been reported in 
HCV patients (133). Likewise, expression of the entire HCV ORF in cell lines impaired the 
formation of ISGF3 and its subsequent DNA binding (134). In melanoma cell lines resistant 
to IFNα treatment, multiple defects in Jak/STAT signaling have been described. Examples 
are the lack of a functional Tyk2 or lack of tyrosine phosphorylation of STAT1 and STAT3 
(135).  
 Mice deficient for components of the Jak/STAT signaling pathway have underlined 
the importance of a functional signal transduction. STAT1 deficient mice do not show any 
developmental defects, but are unresponsive to IFNs resulting in a high susceptibility to viral 
infections (136). Interestingly, STAT1 is activated by many ligands but seems to be essential 
only for IFN signaling. STAT3 deficiency in mice is lethal during embryonic development. 
Therefore, in order to study STAT3 function, mice with tissue specific deficiency in STAT3 
have been generated using the Cre recombinase/loxP recombination system (137, 138). 
SCID, severe combined immunodeficiency, is an example of a human disease 
associated with defects in the Jak/STAT signaling pathway caused by Jak3 or IL-2 receptor 
mutations. Likewise, human myeloproliferative disorders carry mutations in Jak2 (139). 
 
 
1.2.7 Role of PP2A in interference with Jak-STAT signaling 
 
Previous studies in our laboratory demonstrated that expression of HCV proteins in human 
osteosarcoma cell lines or in liver cells of transgenic mice inhibits IFNα induced intracellular 
signaling through the Jak/STAT pathway at the level of STAT-DNA interactions (16, 134). 
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Further experiments demonstrated that expression of HCV proteins in livers of mice and liver 
biopsies of patients with CHC induces an upregulation of the catalytic subunit of protein 
phosphatase 2A (PP2A) (118). This effect may serve as a mechanism of interference with the 
Jak/STAT signaling pathway and lead to an impaired response to IFNα in HCV infected 
cells. The overexpression of the catalytic subunit of PP2A in human hepatoma derived Huh7 
cells resulted in reduced activity of PRMT-1 (140), hypomethylation of STAT1, increased 
STAT1 association with the inhibitory protein PIAS1 and, consequently, inhibition of 
STAT1 binding to DNA. Scheme 7 summarizes our current model of HCV interference with 
IFNα induced Jak-STAT signaling. Interestingly, the PP2A induced inactivation of PRMT-1, 
and resulting hypomethylation of STAT1, can be reversed in vitro by the addition of the 
methyl-group donor S-adenosyl-methionine (SAME) (140). Based on these data, a clinical 
pilot study with 30 patients receiving pegIFNα, Ribavirin and SAME has been initiated at the 
Gastroenterology and Hepatology Department of the University Hospital Basel.  
 
 
 
 
Scheme 7. Inhibition of IFNα  induced Jak/STAT signaling by Hepatitis C virus 
CHC induces an upregulation of the catalytic subunit of protein phosphatase 2A (PP2Ac). PP2Ac 
inhibits the enzymatic activity of protein arginine methyltransferase 1 (PRMT-1) resulting in 
decreased methylation of STAT1. Hypomethylated STAT1 associates with the inhibitory protein 
PIAS1 (protein inhibitor of activated STAT1) leading to inhibition of STAT1-DNA binding and, 
therefore, reduced transcriptional activation of IFN target genes. 
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1.2.8 IFN signaling in HCV infection 
 
Over the last years, there is accumulating evidence that the endogenous IFN system is 
activated to various degrees in patients with CHC. Yu et al. (141) and MacQuillan et al. (142) 
found an upregulation of a number of ISGs in liver biopsies from HCV patients. There was a 
considerable variation of the extent of the upregulation of ISGs between patients. Chen et al 
(131) performed expression profiling with gene arrays on liver biopsy specimens taken 
before therapy comparing gene expression levels of 15 non-responders, 16 responders and 20 
normal liver biopsies. Surprisingly non-responders showed high baseline expression of ISGs, 
whereas responders to therapy (and those who relapsed) more closely resembled healthy 
controls. These findings suggest that non-responders have an upregulated and largely 
ineffective IFN response, suggesting little benefit from administration of exogenous INFα. 
The mechanisms responsible for a preactivated IFN system in the liver observed in a 
subgroup of HCV patients remain unknown. 
Similarly to humans, the analysis of intrahepatic gene expression during chronic HCV 
infection in chimpanzees revealed upregulation of many ISGs (143). Interestingly, the single 
HCV GT 3-infected animal analyzed exhibited reduced levels of ISG expression when 
compared to the GT 1-infected chimpanzees. Strong IFN responses have also been 
demonstrated in the livers of acutely HCV infected chimpanzees (144). Recently, Lanford et 
al reported a lack of response to exogenous IFNα in chimpanzees chronically infected with 
HCV (145). Data obtained from uninfected chimpanzees revealed remarkable tissue-
specificity of the transcriptional response to IFNα when comparing liver and peripheral blood 
mononuclear cells (PBMCs) (146). 
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1.3 Viral sensory pathways 
 
 
1.3.1 Pattern recognition receptors (PRRs) 
 
Pattern recognition receptors (PRRs) are part of the innate immune response. They recognize 
distinct components of microorganisms, the so-called pathogen-associated molecular patterns 
(PAMPs), and transmit signals through a variety of pathways finally leading to the activation 
of immune cells and various anti-microbial effector systems. These include type I interferon 
responses or the production of proinflammatory cytokines (reviewed in (147, 148)). Different 
classes of PRRs have been described to date, including the membrane-bound Toll-like 
receptors (TLRs) and cytoplasmic receptors comprising retinoic-acid-inducible gene-I (RIG-
I)-like helicases (RLHs) and nucleotide-oligomerization domain leucine-rich repeat (NOD-
LRR) proteins. The different PRRs recognize specific PAMPs and, as a consequence, activate 
distinct anti-pathogenic responses. PRRs are highly conserved among species, they are germ-
line encoded and constitutively expressed in host cells. The current knowledge on PRRs 
indicates that the innate immune response has specific features arguing against the earlier 
concept of innate immunity being entirely unspecific. 
 
 
1.3.2 Cytoplasmic PRRs 
 
Cytoplasmic receptors like the RLHs and NOD-LRR proteins recognize microorganisms that 
have invaded the cytoplasm of host cells. NOD-LRR proteins comprise a C-terminal LRR, a 
central nucleotide binding domain and a N-terminal signaling domain (149). NOD1 and 
NOD2 are members of the NOD-LRR family and involved in intracellular sensing of 
bacterial products. RLHs consist of a C-terminal DexD/H box helicase domain (responsible 
for dsRNA binding) and of N-terminal caspase-recruitment domains (CARDs) (150). RLH-
mediated signaling is triggered by dsRNA and results in transcriptional induction of IFNα 
and IFNβ, which are crucial for mounting the defense against viral infection. RIG-I (also 
known as Ddx58) and Melanoma differentiation associated gene-5 (Mda5, also known as 
Ifih1 or helicard), representing two RLH family members, were shown to respond differently 
to RNA viruses (151). This can be illustrated by the response to influenza virus, which was 
highly pronounced in Mda5 deficient mice, while absent in RIG-I deficient cells. It was 
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recently shown, that the RIG-I pathway is also stimulated by 5’-triphosphate ssRNA (152, 
153). 
 In 2005 an important adapter protein for RLH signaling, Cardif/IPS-1/VISA/MAVS 
(154-157), was identified by 4 independent research groups. Cardif deficient mice fail to 
produce type I IFNs in response to infection with RNA viruses (158, 159). Cardif is 
associated to the outer mitochondrial membrane and contains a protein-binding CARD-
domain through which it associates with RIG-I. This interaction ultimately, upon activation 
of a kinase complex, results in the phosphorylation of the interferon-regulatory factors (IRF)-
3 and IRF-7 (Scheme 8).  
 
  
 
Scheme 8. Sensing of viral dsRNA by cytoplasmic RIG-I-like helicases (RLHs) 
Retinoic-acid-inducible gene-I (RIG-I) senses viral dsRNA and interacts with the adaptor protein 
Cardif. This results in the activation of two kinase complexes: (i) TRAF3 adaptor protein and 
TBK1/IKK-ε kinases with resulting activation of IRF-3 and IRF-7 and transcriptional induction of 
type I IFNs; (ii) NEMO adaptor and IKK-α/IKK-β kinases with resulting activation of nuclear factor 
kappa B (NF-κB) and transcription of proinflammatory cytokines. 
 
 
 IRF-3 and IRF-7, normally present in the cytoplasm, dimerize upon phosphorylation 
and translocate to the nucleus where they induce the transcription of type I IFNs. Cells 
lacking IRF-3 therefore have a severely impaired IFNα and IFNβ production (160). Using 
mice deficient in the IRF-7 gene, IRF-7 was also shown to be crucial for type I IFN induction 
via the virus-activated RLH pathway (161). In the past years, further molecules involved in 
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IRF activation have been described: TANK-binding kinase 1 (TBK-1) and IKK-ε, both 
members of the inhibitor of NF-κB kinase (IKK) family (162, 163). Moreover, TNF-receptor 
associated factor (TRAF) 3 has been shown to associate to Cardif (164, 165) and to recruit 
and activate TBK-1/IKK-ε. RLHs also activate the transcription factor nuclear factor-kappa 
B (NF-κB) through the adaptor NEMO and the kinases IKK-α and IKK-β. Interestingly, 
NEMO was recently reported to also be required for IRF-3 activation and thus functions as 
adaptor protein allowing RIG-I mediated activation of both the NF-κB and IRF signaling 
pathways (166). 
 
 
1.3.3 Toll-like receptors (TLRs) 
 
TLRs were first discovered in 1988 in studies on fruit fly development (167). In murine 
studies it was later demonstrated that injection of endotoxin into mice with a defective TLR4 
was not lethal in contrast to wildtype mice (168), indicating the involvement of TLRs in 
responses to pathogens. There are at least 10 human TLRs. TLRs are comprised of leucine-
rich repeats (LRRs), a transmembrane domain, and a TIR (Toll/IL-1 receptor homology) 
domain. Bacterial components including lipoproteins and lipopolysaccharides are being 
recognized by TLR1, TLR2, TLR4, TLR5 and TLR6. In contrast, TLR3, TLR7 and TLR9, 
all localized on endosomes, are able to detect viral nucleic acids. TLR3 recognizes dsRNA 
(e.g. HCV-RNA), whereas TLR7 detects ssRNA (169, 170) and TLR9 interacts with 
unmethylated DNA with CpG motifs (171). TLR activation induces signaling cascades that 
mainly involve the key transcription factors NF-κB and various IRFs.  
 As an example, the HCV-induced TLR3 signaling cascade is shown in Scheme 9. 
TLR3 is present in endosomes of DCs where it senses dsRNA and induces signaling via the 
adaptor protein TRIF (TIR domain containing adaptor inducing IFNβ, also known as 
TICAM-1) (172). Further downstream, TRAF3 is responsible for the activation of the TBK-
1/IKK-ε kinases and phosphorylation of IRF-3 (164, 165). Of note, the TLR3 and the RIG-I 
signaling pathways converge at this level. TLR3 also activates the transcription factor NF-κB 
through TRAF6, the adaptors RIP-1 and NEMO and the kinases IKKα and IKKβ. The role of 
TLR3 is controversial as TLR3 deficient mice were shown to be more resistant to infections 
with West Nile Virus (173).  
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Scheme 9. TLR3 signaling pathway. 
Toll-like receptor 3 (TLR3), localized on endosomes, recognizes viral dsRNA and activates adaptor 
proteins TRIF, TRAF, RIP-1 and NEMO. The kinases TBK1 and IKK-ε phosphorylate IFN 
regulatory factor (IRF)-3, whereas the IKK-α/IKK-β complex activates transcription factor NF-κB. 
 
 
 TLR7 and TLR9 are important for virus-induced type I IFN production in 
plasmocytoid DCs. Their signaling depends on MyD88 (a TIR domain containing adaptor 
protein). MyD88 recruits a complex consisting of IL-1 receptor-associated kinases (IRAK)-1 
and IRAK-4, TRAF3, TRAF6, IKK-α and IRF-7 ultimately resulting in IRF-7 activation and 
IFN production. 
 
 
1.3.4 HCV interference with viral sensory pathways 
 
Many viruses, including influenza virus, have developed strategies to inhibit early signaling 
events that lead to IFN production in infected host cells (174). Similarly, HCV has not only 
evolved mechanisms that interfere with the downstream signaling pathway of IFNα, but also 
was shown to disrupt pathways leading to type I IFN production (Scheme 10).  
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Scheme 10. HCV NS3-4A interference with viral sensory pathways 
The HCV NS3-4A protease cleaves the adaptor proteins Cardif and TRIF and thereby inactivates both 
the RIG-I and the TLR3 induced signaling pathways. 
 
The HCV NS3-4A protease was reported to block phosphorylation and downstream 
effects of IRF-3 by an unknown mechanism (175). Importantly, Meylan et al. could show that 
the NS3-4A protease targets and inactivates Cardif (154). The cleavage site is located within 
the C-terminus of the Cardif protein. A cysteine to alanine mutation at position 508 (C508A) 
of Cardif resulted in complete resistance to cleavage by the viral protease. It remains 
unknown whether Cardif cleavage can be detected in patients infected with HCV and whether 
there exist HCV genotype-specific differences in the ability to cleave Cardif. Moreover, it 
remains unclear whether the ISG activation status of chronic HCV patients (with future non-
responders to treatment showing a pre-activated endogenous IFN system in the liver) is 
dependent on the viral sensory pathways and therefore also on Cardif function.  
  The NS3-4A protease of HCV also counteracts TLR3 dependent pathways by 
targeting the adaptor protein TRIF for proteolytic cleavage (176). The site for this in vitro 
TRIF cleavage is cysteine 372. Of note, restoring Cardif and TRIF functions could explain 
antiviral efficacy of therapeutic compounds targeting the HCV NS3-4A protease through 
other mechanisms than only suppression of viral replication. 
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2. Aims of the PhD-thesis project 
 
 
The current standard therapy for chronic hepatitis C (CHC) consists of a combination of a 
long-acting pegylated form of IFNα (pegIFNα) and ribavirin, both given for 6 to 12 months. 
It achieves a cure from HCV infection in only about half of the patients. The underlying 
mechanisms of failure of pegIFNα based therapy are unknown, mainly because the effects of 
IFNα in human liver have not been investigated due to difficulties in obtaining liver tissue 
from patients undergoing treatment. It is also not known how hepatocytes respond to the 
continuously high IFNα concentrations obtained with pegIFNα. 
 
 
The aims of this PhD-thesis project were: 
 
I. To investigate IFN induced effects in the liver of CHC patients.  
 
II. To investigate the behavior of IFN signal transduction pathways in the liver 
during repeated or prolonged exposure to IFNα using mouse models.  
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3. Materials and methods 
 
 
For main materials and methods, see the respective sections in the incorporated manuscripts 
(Sarasin-Filipowicz et al, PNAS in press, “IFN alpha signaling and the treatment outcome of 
chronic hepatitis C” and Sarasin-Filipowicz et al, manuscript in preparation, “Interferon alpha 
induces long-lasting refractoriness of Jak-STAT signaling in the mouse liver through 
induction of USP18/UBP43”). For additional materials and methods concerning results 
described in paragraph 4.2, see legends of the respective figures (Figures 4.2.A-D). 
 
Described below is a summary of the methodological approaches used in the projects: 
 
In a first approach, we collected paired liver biopsies from 16 patients with the aim to 
correlate the hepato-cellular response to pegIFNα with the clinical outcome of HCV 
treatment. The samples were obtained before treatment and 4 hours after the first injection of 
pegIFNα and IFN-induced gene expression with a special emphasis on Jak-STAT signaling 
was analyzed by Western blot, immunohistochemistry, Electrophoretic mobility shift assays 
(EMSAs) and Affymetrix microarrays. We also investigated IFN responsiveness of PBMCs 
obtained from the same patients in order to compare these findings with the effects induced in 
the HCV infected liver. 
 
A second approach was used to investigate why certain HCV patients present an 
unexplained pre-activation of the endogenous IFN system in their liver. To elucidate the 
cause of this phenomenon, we analyzed a possible impact of different HCV genotypes on the 
pre-activation of ISGs (quantified by real-time RT-qPCR), using a collection of 112 pre-
treatment liver biopsy samples from CHC patients. Moreover, we aimed at establishing a 
correlation of the observed ISG induction with the nuclear translocation of activated STAT1, 
as assessed by immunohistochemistry. Further, we investigated whether the ISG activation 
status of CHC patients is dependent on the viral sensory pathways in the liver. Towards this 
aim we used the pre-treatment liver biopsy samples to assess whether Cardif, an adaptor 
molecule known as a target of the NS3-4A HCV protease, is cleaved in patients infected with 
HCV and whether genotype-specific differences in Cardif cleavage exist.  We assessed 
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Cardif protein and mRNA levels and correlated our findings with the clinical data of the 
patients. 
 
 In a third approach we established a mouse model with the aim to investigate whether 
a continuous presence of IFNα results in a permanent stimulation or, opposite, in a 
refractoriness of the IFN signaling pathway in vivo. We repeatedly injected wildtype mice 
with mouse IFNα and measured serum levels by ELISA. We assessed IFNα signaling in the 
mouse liver by Western blot for activated STATs, by EMSAs and by measuring target gene 
induction by Northern blot and RT-qPCR. A possible involvement of known negative 
regulators of IFNα-induced Jak-STAT signaling, including SOCS and UBP43, was 
investigated in knockout mice deficient in these molecules. 
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4. Results 
 
4.1 Interferon signaling and treatment outcome in chronic hepatitis C  
 
Sarasin-Filipowicz M. et al. 
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Hepatitis C virus (HCV) infection is a major cause of chronic liver
disease worldwide. The current standard therapy for chronic hep-
atitis C (CHC) consists of a combination of pegylated IFN alpha
(pegIFN!) and ribavirin. It achieves a sustained viral clearance in
only 50–60% of patients. To learn more about molecular mecha-
nisms underlying treatment failure, we investigated IFN-induced
signaling in paired liver biopsies collected from CHC patients
before and after administration of pegIFN!. In patients with a
rapid virological response to treatment, pegIFN! induced a strong
up-regulation of IFN-stimulated genes (ISGs). As shown previously,
nonresponders had high expression levels of ISGs before therapy.
Analysis of posttreatment biopsies of these patients revealed that
pegIFN! did not induce expression of ISGs above the pretreatment
levels. In accordance with ISG expression data, phosphorylation,
DNA binding, and nuclear localization of STAT1 indicated that the
IFN signaling pathway in nonresponsive patients is preactivated
and refractory to further stimulation. Some features characteristic
of nonrespondersweremore accentuated in patients infectedwith
HCV genotypes 1 and 4 compared with genotypes 2 and 3,
providing a possible explanation for the poor response of the
former group to therapy. Taken together with previous findings,
our data support the concept that activation of the endogenous IFN
system in CHC not only is ineffective in clearing the infection but
also may impede the response to therapy, most likely by inducing
a refractory state of the IFN signaling pathway.
Jak-STAT signaling ! liver ! viral hepatitis
Hepatitis C virus (HCV) infection is a major cause of chronicliver disease worldwide. An important and striking feature
of hepatitis C is its tendency toward chronicity. In !70% of
infected individuals, HCV establishes a persistent infection over
decades that may lead to cirrhosis and hepatocellular carcinoma.
An interesting hypothesis in HCV biology proposes that the viral
NS3-4A protease not only processes the viral proteins but also
cleaves and inactivates components of the intracellular sensory
pathways, TRIF and Cardif, that detect viral infection and
induce the transcriptional activation of type I IFN. Two RNA
helicases, RIG-I and MDA5, identified as intracellular sensors
of dsRNA, act through Cardif to induce IFN! production (1).
The ability of HCV to inhibit the activation of the endogenous
type I IFN system could underlie its success in establishing a
chronic infection (2).
Type I IFNs not only are crucial factors in the innate immune
system but also are the most important components of current
therapies against CHC. The current standard therapy consists of
pegylated IFN" (pegIFN") and the antiviral agent ribavirin (3).
The treatment achieves a sustained virological response (SVR)
in "55% of patients, with significant differences between ge-
notypes (4). An SVR is defined as the loss of detectable HCV
RNA during treatment and its continued absence for at least 6
months after stopping therapy. Studies of long-term followup on
SVR patients demonstrate that this response is durable in!95%
of patients. The probability of an SVR strongly depends on the
early response to treatment. Patients who do not show an early
virological response (EVR), defined as a decline of the viral load
by !2 log10 after 12 weeks of therapy, are highly unlikely to
develop an SVR (5–7). Patients with an EVR have a good chance
of being cured, with 65% of them achieving SVR (5, 7). The
prognosis is even better for patients who have a rapid virological
response (RVR), defined as serum HCV RNA undetectable
after 4 weeks of treatment. Over 85% of them will achieve SVR
(6, 8). Unfortunately, #20% of patients with genotype 1 and
"60% of patients with genotypes 2 or 3 show an RVR (6, 8). The
host factors that are important for an early response to therapy
are currently unknown.
Type I IFNs achieve their potent antiviral effects through the
regulation of hundreds of IFN-stimulated genes (ISGs). ISG-
encoded proteins establish a general antiviral state within the
cell (9). IFNs induce ISG transcription by activating the Jak-
STAT pathway (10). Type I IFNs bind to the same cell surface
receptor (IFNAR) and activate the receptor-associated tyrosine
kinases Jak1 and Tyk2. The kinases then phosphorylate and
activate STAT1 and STAT2. The activated STATs translocate to
the nucleus, where they bind specific DNA elements in promot-
ers of ISGs. Many ISGs have antiviral activity, but some are
involved in other processes such as lipid metabolism, apoptosis,
protein degradation, and inflammatory cell responses (11). HCV
interferes with the IFN system probably at multiple levels.
IFN-induced Jak-STAT signaling is inhibited in cells and trans-
genic mice that express HCV proteins (12, 13) and in liver
biopsies of patients with CHC (14). In vitro, HCV proteins NS5A
and E2 bind and inactivate protein kinase R, an important
antiviral protein (15). However, the molecular mechanisms that
are important for the response to pegIFN" in patients with CHC
remain unknown.
The capacity of HCV to interfere with the IFN pathway at
many different levels is a likely mechanism underlying HCV
success to establish a chronic infection (2). However, quite
paradoxically, in chimpanzees acutely or chronically infected
with HCV, hundreds of ISGs are induced in the liver (16, 17).
Nevertheless, despite the activation of the endogenous IFN
system, the virus is not cleared from chronically infected animals
(18). The results obtained with chimpanzees are difficult to
extrapolate to humans, because there are important differences
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in the pathobiology of HCV infection between these species.
Whereas most chimpanzees acutely infected with HCV clear the
virus spontaneously, infections in humans mostly become
chronic. However, chronically infected chimpanzees can rarely
be cured with IFN, whereas more than half of patients with CHC
are successfully treated (19).
Induction of ISGs was also found in pretreatment liver biop-
sies of many patients with CHC, again demonstrating that HCV
infection can lead to activation of the endogenous IFN system
(20). Notably, patients with preelevated expression of ISGs
tended to respond poorly to therapy when compared with
patients with low initial expression (20). The cause of this
differential response to therapy is not understood. Are patients
with elevated initial expression refractory to further stimulation
of ISGs by exogenous IFN? Does the administration of IFN to
patients with low initial ISG values lead to ISG expression levels
exceeding those found in the other group, possibly explaining a
success of therapy in low-ISG patients? Are there specific ISGs
important for viral clearance that are not activated in nonre-
sponders? To circumvent limitations in the procurement of liver
biopsies, several groups have assessed whether peripheral blood
mononuclear cells (PBMCs) could serve as a surrogate tissue to
evaluate the response to IFN" (21–23). However, no conclusive
data are available for humans, because a direct comparison of
IFN-induced ISGs between liver and PBMCs has not been done.
To approach focal questions related to the pathophysiology of
HCV infection, we investigated IFN-induced signaling and ISG
expression in paired liver biopsies and PBMCs collected from
patients with CHC before and after the first injection of peg-
IFN". We correlated the biochemical and molecular data with
the response to treatment, and we compared the response to
IFN" in liver and PBMCs.
Results
Patients and Response to Treatment. Sixteen patients included in
this study, 6 women and 10 men, were treated with a weight-
adjusted combination of s.c.-injected pegIFN"2b once weekly
and oral ribavirin twice daily. All had two liver biopsies, the
pretreatment biopsy (B-1) and the second biopsy (B-2), obtained
4 h after the first injection of pegIFN"2b. We have chosen to
analyze gene expression 4 h after pegIFN"2b injection, because
kinetics of the induction of ISGs by pegIFN" in liver of
chimpanzees was maximal at this time and was followed by rapid
down-regulation of many genes (22).We realize that we probably
missed the up-regulation of some late-induced ISGs, but because
of rapid down-regulation, we would have missed more ISGs
when using later time points.
Seven of the patients were infected with HCV genotype (GT)
1, two with GT 4, four with GT 3, and three with GT 2. Eight
patients who had negative serum HCV RNA after 4 weeks of
treatment (RVR) and two patients with !3 log10 drop of viral
titer within the first 4 weeks were classified as rapid responders
(RRs), whereas six patients showed a viral load reduction of#1.5
log10 and were classified as non-RRs (Table 1).
Serum IFN" concentrations were below the limit of detection
in all patients before treatment and, in accordance with previ-
ously published pharmacokinetic data (24), between 34 and 360
pg/ml in samples obtained at 4 h after the pegIFN"2b injection
(data not shown). There was no significant correlation between
the virological response at week 4 and the serum IFN" concen-
tration at 4 h postinjection.
IFN-Induced Regulation of Target Genes. Gene expression was
analyzed with Affymetrix U133plus2.0 arrays in B-1 and B-2
samples and also in PBMCs isolated from blood obtained before
(PBMC-1) and 4 h after the first pegIFN"2b injection (PBMC-
2). We identified 252 genes significantly [paired t test, P # 0.05,
see supporting information (SI)Materials and Methods] changed
!2-fold between B-1 and B-2 in !50% of the 10 RR biopsy
samples, whereas only 36 genes passed the same criteria when
analyzing the 6 non-RR patients (Fig. 1A). To compare the
number of significantly regulated genes between RR and
non-RR patients in groups with an equal number of patients, 15
groups of 6 patients randomly selected from the 10 RR patients
were generated. In each group, the genes significantly (P # 0.05
or P # 0.01, paired t test) changed in !50% of patients were
identified and counted. In liver biopsies of the 15 RR groups, the
mean number ($SD) of regulated genes was 178.6 ($58.8) and
225.9 ($61.5) at significance levels P # 0.01 and P # 0.05,
respectively. In the non-RR group, there were 23 and 36 genes
significantly regulated at P# 0.01 and P# 0.05, respectively. The
Table 1. Study patient characteristics
Patient no. 4-week response Sex Age HCV GT
Viral load,
log10 international
units/ml
12-week response Follow-up Metavir Weight, kgBaseline
4
weeks
12
weeks
1 RR M 52 3a 7.14 Neg. Neg. EVR SVR A2/F2 75
2 RR M 37 3a 4.90 Neg. Neg. EVR SVR A1/F2 73
3 RR M 38 1a 6.91 Neg. Neg. EVR EoTR A2/F1 85
4 RR M 33 2b 6.27 Neg. Neg. EVR EoTR A1/F2 57
5 RR M 48 2b 6.67 Neg. Neg. EVR SVR A3/F4 110
6 RR F 53 2a/c 4.95 Neg. Neg. EVR SVR A3/F3 74
7 RR M 56 3 5.25 Neg. Neg. EVR EoTR A3/F4 61
8 RR M 38 4 4.08 Neg. Neg. EVR Ongoing A2/F2 69
9 RR F 50 1b 7.22 3.52 Neg. EVR Ongoing A1/F2 47
10 RR F 48 1 6.49 3.31 Neg. EVR Ongoing A3/F4 60
11 Non-RR F 54 3a 4.52 4.08 1.3 EVR No EoTR A3/F4 69
12 Non-RR M 64 1b 6.24 4.83 3.46 EVR No EoTR A3/F4 74
13 Non-RR M 49 4 6.91 5.87 5.22 PNR - A3/F4 102
14 Non-RR M 56 1b 6.89 6.76 6.01 PNR - A2/F3 60
15 Non-RR F 50 1a 7.11 6.58 6.35 PNR - A1/F2 77
16 Non-RR F 47 1a 6.16 5.99 5.52 PNR - A2/F2 81
M, male; F, female; GT, genotype.
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differences between the RR and non-RR samples were statis-
tically significant (Fig. 1C).
Not surprisingly, many of the regulated genes represent known
ISGs. However, contrary to our expectations, expression levels
of most of these ISGs were not higher in post-pegIFN"2b
treatment biopsies from RR patients compared with non-RRs.
Only 7.5% of the 252 genes significantly regulated in !50% of
10 RR patients were higher in the B-2 samples of RRs (see Table
S1). Rather, non-RR patient samples had a higher level of ISG
expression already in B-1, and the fold change in the B-2 samples
was therefore only minor. This is illustrated in Fig. 2A at the
example of four ISGs. The genes show a very low expression in
biopsies from individuals without hepatitis C (controls) and in
B-1s of RR patients. The six non-RR patients had a high
expression of these genes before treatment, and pegIFN"2b
administration did not increase or only minimally increased their
expression. There were very few exceptions to this rule (an
example is shown in Fig. 2B). These genes had low expression in
the pretreatment biopsies, and pegIFN"2b induced them in all
patients. Nevertheless, the predominant pattern of gene expres-
sion resembled this shown in Fig. 2A. A complete list and a heat
map of the expression of 252 genes significantly (P # 0.05)
changed !2-fold between B-1 and B-2 in the RR group are
shown for all biopsy samples in Table S1 and Fig. S1.
There was a considerable overlap of pegIFN"2b-regulated
genes in liver and PBMCs (Fig. 1B). Interestingly, in all patients,
pegIFN"2b regulated more genes in PBMCs than in liver.
However, the difference in the up-regulation of ISGs was more
pronounced in biopsies compared with the PBMCs (Fig. 1C). In
PBMCs, no preactivation of ISGs was found, and pegIFN"2b
treatment induced ISGs in both RR and non-RR patients (Fig.
1C and Fig. S2). This indicates that chronic HCV infection has
strong local effects on the IFN system in liver but little effect in
PBMCs.
A Subset of Genes That Predicts Response to Treatment. Supervised
classifier analysis of array data allows the identification of a
subset of genes that best predicts the outcome, in our case rapid
response vs. nonresponse at week 4. All liver biopsy and PBMC
datasets were subjected to supervised classifier prediction using
the response at 4 weeks of treatment as grouping criteria. For
PBMC samples, the analysis did not identify a subset of genes
that could predict the treatment outcome (Fig. S3 C and D). In
contrast, a subset of 16 genes was identified in the liver B-2
samples that predicted response to treatment with an error rate
of 16.1% using the K Nearest Neighbors test (Fig. S3B). An even
better prediction was possible with a subset of 29 genes in the
pretreatment biopsies B-1, where the error rate was 4.3% (Fig.
S3A). In this set, there were 22 genes up-regulated by pegIFN"2b
(Table S2). Therefore, 76% best predictor genes represent ISGs.
Contrary to the predominance of ISGs in the best predictor set
from pretreatment biopsies, only 3 (19%) of the 16 best predictor
genes derived from an analysis of the B-2 biopsies were ISGs
(Table S3). These results support the findings shown in Fig. 2 that
expression levels of most ISGs in B-2 do not differ between RR
and non-RR samples and therefore are not suited for the
discrimination of responders from nonresponders. Among the
non-ISGs present in the B-1 and B-2 liver biopsy lists discussed
above are genes having functions in signal transduction, cell cycle
regulation, apoptosis, and amino acid metabolism.
RT-qPCR Analysis of ISG Expression in Liver Biopsies. Array analysis
of the paired liver biopsies emphasized the importance of ISG
expression in B-1 biopsies for the outcome of therapy. To
confirm these data, we measured by real-time quantitative PCR
Fig. 1. PegIFN"2b induced regulation of gene expression in liver and PBMCs.
(A) Venn diagram of genes significantly (paired t test, P # 0.05) up- or
down-regulated!2-fold in response to pegIFN-"2b in!50%of the 10 RR and
6non-RRbiopsy samples. (B) Venndiagramofgenes significantly (paired t test,
P# 0.05) up- or down-regulated!2-fold in response to pegIFN-"2b in biopsy
and PBMC samples of !50% of RR patients. (C) RR up- or down-regulate
significantly more genes in the liver in response to pegIFN-"2b than non-RR
patients. Shown are the mean (%SEM) number of genes changed !2-fold at
significance levels P# 0.01 (lanes 1, 2, 5, and 6) and P# 0.05 (lanes 3, 4, 7, and
8) in!50%ofpatientswithineach responsegroup in liverbiopsies andPBMCs.
Fig. 2. PegIFN"2b induced gene regulation in HCV-infected patients shows
major differences between livers of RR and non-RR patients. (A) Four ISGs
(Viperin, Mda5/helicard, OAS1, USP18) were chosen from the list of genes
significantly regulated!2-fold betweenB-1 andB-2 in RRpatients. In the liver
ofnon-RRpatients, expressionof thesegenes is alreadyhighbefore treatment
(lanes 25–30) and does not further increase after pegIFN" (lanes 31–36). In RR
patients, pretreatment expression (lanes 5–14) is similar to controls (lanes
1–4), and pegIFN" induces a strong up-regulation (lanes 15–24). The y axes
display absolute expression values. (B) An example of a gene (CCL8) up-
regulated in liver in response to pegIFN-"2b in both RR and non-RR patients.
The x axis represents individual biopsy samples. Lanes 5–14 (B-1) and 15–24
(B-2) correspond to RR patients number 1–10 in Table 1 (in the same order),
and lanes 25–30 (B-1) and 31–36 (B-2) correspond to non-RR patients numbers
11–16.
7036 ! www.pnas.org"cgi"doi"10.1073"pnas.0707882105 Sarasin-Filipowicz et al.
(RT-qPCR) the expression of selected ISGs in 16 patients with
B-1 and B-2 biopsies and in pretreatment biopsies of 96 addi-
tional patients with CHC (Tables S4 and S5). In the 16 patients
with paired biopsies, the RT-qPCR values matched well the array
expression, validating the quality of the array data (Fig. S4A and
data not shown). The expression of all four ISGs in pretherapy
biopsies was significantly different between the RR and non-RR
groups (Fig. 3A), further supporting the conclusion that there is
an inverse correlation between the pretreatment expression of
ISGs in liver and the response to IFN" therapy. A significant
up-regulation of ISGs correlated also with nonresponse at week
12 and with final treatment outcome (Fig. S4 B–D).
Pretreatment ISG Expression Levels Correlatewith HCV Genotype.We
also analyzed the expression of ISGs with regard to the HCV
genotype (GT) (Fig. 3B). Interestingly, the investigated ISGs
showed significantly higher expression in patients infected with
the ‘‘difficult-to-treat’’ GTs 1 and 4 than with GTs 2 and 3, which
can be successfully treated in!80% of patients. Importantly, the
expression levels of ISGs were higher in non-RR than RR
patients independently from the HCV GT (Fig. 3C). Therefore,
the increased ISG expression level in non-RR patients (Fig. 3A)
cannot simply be explained by the fact that GT 1 is overrepre-
sented in the non-RR group. Rather, that patients with HCVGT
1 and 4 more frequently have an increased expression of ISGs in
their liver provides a plausible explanation for the poor response
of these patients to IFN therapy.
IFN-Induced Jak-STAT Signaling. The injected pegIFN"2b binds to
IFN receptors and activates the Jak-STAT pathway. A central
event in this activation is the phosphorylation of STAT1 on
tyrosine 701 (25). We analyzed extracts from all B-1 and B-2
biopsies by Western blot using a phospho-specific STAT1 anti-
body (Fig. 4A). A semiquantitative analysis of the phospho-
STAT1 bands revealed a median induction of 3.6-fold in RR
patients and 1.6-fold in non-RR patients (P & 0.03).
Phosphorylated STAT1 translocates into the nucleus and
binds as a dimer to specific response elements of ISG promoters
(25). Immunohistochemical analysis of phospho-STAT1 local-
ization in paired biopsies of RR patients revealed a minimal
nuclear staining in B-1 samples and a strong staining in most
hepatocyte nuclei in B-2 samples (Fig. 4B and Fig. S5A). In
contrast, all but one (number 11) non-RR patients showed a
remarkably different staining pattern. In the pretreatment bi-
opsies, a large proportion of hepatocytes already had an appre-
ciable nuclear staining, which did not increase in B-2 samples.
Interestingly, there was a visible increase of phospho-STAT1
staining in nuclei of Kupffer cells (liver macrophages) in B-2
samples of non-RR patients (Fig. 4B).
STAT1 DNA binding was assessed in extracts of B-1 and B-2
Fig. 3. RT-qPCR analysis of selected ISGs. (A) The expression level of selected
ISGs in pretreatment biopsies is lower in RR than in non-RR patients. (B)
Expression levels of USP18 and IFI27 in pretreatment biopsies are significantly
higher in patients infected with genotype 1 (GT1) compared with GT 3. (C)
Expression levels of USP18 and IFI27 are higher in non-RR patients also after
stratification of the patients in a GT1/4 (‘‘difficult-to-treat’’) and a GT2/3
group. In A–C, the y axis shows expression relative to that of GAPDH. The P
valueswere obtainedwith theMann–Whitney test.N&number of patients in
each group.
Fig. 4. Analysis of Jak-STAT signaling in liver biopsies. (A) STAT1 phosphorylation in extracts of liver biopsies collected before (B-1) and after (B-2) pegIFN-"2b
injection. Extracts were analyzed by Western blot analysis by using antibodies specific for PY (701)-STAT1. Signals were quantified by using Odyssey Imaging
Software to calculate the integrated intensity (kilo counts'mm2). The values represent the fold increase of phosphorylation in B-2 samples. RR patient numbers
are shown in blue, non-RR patients in red. Blotswere stripped and reprobed for total STAT1 used as a loading control for each pair of samples. (B) Representative
examples of B-1 and B-2 of RR and non-RR patients. No nuclear staining is evident in pretreatment biopsies of RR patients (Pat. 4). The light-blue color of the
nuclei originates from the counterstainingwith hematoxylin. Four hours after pegIFN", most hepatocytes show strong nuclear staining. In non-RR patients (Pat.
12), weak nuclear staining is already present in pretreatment biopsies, and pegIFN" induces little change in hepatocytes. The visible increased nuclear staining
is confined to Kupffer cells.
Sarasin-Filipowicz et al. PNAS ! May 13, 2008 ! vol. 105 ! no. 19 ! 7037
M
ED
IC
A
L
SC
IE
N
CE
S
biopsies by EMSAs. All RRs showed a marked increase in
STAT1 DNA binding in the B-2 samples. In contrast, most
non-RR patients showed aminimal or no increase of the gel-shift
signal upon pegIFN" application (Fig. S5B). Taken together, the
data demonstrate substantial differences in the IFN-induced
Jak-STAT signaling between RR and non-RR patients.
Discussion
To learn more about possible mechanisms underlying differen-
tial response of HCV-infected patients to IFN therapy, we
investigated the IFN-induced signaling and ISG induction in
paired liver biopsies collected from patients with CHC before
and during therapy with pegIFN". Comparison of IFN signaling
in two liver samples obtained from the same patient and
comparison with the ISG induction in matching PBMC samples
originating from the same patient allowed us to obtain unequiv-
ocal evidence that patients who respond poorly to therapy show
preactivation of their IFN system, and that the preactivation is
confined to the liver and is not evident in PBMCs. Importantly,
in patients with low initial ISG expression, representing future
responders to therapy, expression of ISGs in response to pe-
gIFN" did not exceed that seen in nonresponders, either before
or after therapy. This could suggest that patients with the initial
preactivation of the IFN system, future nonresponders, have
some defects at steps downstream of ISG expression, making
them refractory to both endogenous IFN and IFN therapy.
These findings in human patients are in accordance with obser-
vations in chimpanzees chronically infected with HCV (19). A
human study reported a blunted response to IFN" in PBMCs of
patients with a relative lack of viral response to treatment (26).
In our group of 16 patients, we also detected a difference in the
number of genes significantly changed at P # 0.05 in PBMCs
between RR and non-RR patients (Fig. 1C), but this difference
was less pronounced compared to the liver biopsies.
IFN"-induced STAT1 phosphorylation was stronger in RR
than in non-RR patients, but there was still a clear activation of
STAT1 in four of the six non-RR patients (Fig. 4A). The
immunohistochemical analysis revealed a more pronounced
difference. In non-RR samples, pegIFN" strongly induced nu-
clear STAT1 translocation in Kupffer cells, contrary to RR
samples, where nuclear STAT1 accumulation was induced pre-
dominantly in hepatocytes. Interestingly, most non-RR patients
had nuclear phospho-STAT1 already present in pretreatment
biopsies. This is consistent with the observation that ISG tran-
scripts are up-regulated in pretreatment biopsies of later non-
responders. How this preactivation of the Jak-STAT pathway is
connected to the refractoriness of the IFN system in non-RR
patients requires further investigation.
Over the last few years, important insights into the interfer-
ence of HCV with the innate immune system revealed the ability
of HCV to inhibit both TLR3-TRIF-IRF3 and the RIG-I/
MDA5-Cardif signaling pathways of IFN! induction (27, 28).
This capacity of HCV could help explain why the virus often
establishes a chronic infection. However, our data and previously
published results (20) demonstrate that the endogenous IFN
system is constantly activated in many patients. Moreover,
patients with a preactivated IFN system seem to respond poorly
to IFN therapy. This finding is counterintuitive (one would
expect that an active innate immune system would help eliminate
the virus during IFN" therapy), but it is largely supported by
other published data from chimpanzees and human patients (16,
17, 20). From the analyses of ISG expression in liver biopsies, it
is apparent that in some patients, HCV induces (or at least does
not block) the endogenous IFN system, whereas in others it
successfully represses it, possibly by cleaving TRIF and/or
Cardif. Paradoxically, this difference has no apparent impact on
the ability of HCV to maintain a chronic infection.
In patients without a preactivated IFN system, pegIFN"2b
induced a robust up-regulation of many ISGs in the liver within
4 h. Similar high ISG expression was already present in the
pretreatment biopsies of patients who later did not show a RR
at week 4. It is somewhat perplexing why the latter patients do
not resolve the chronic HCV infection spontaneously despite the
strong activation of the IFN system. One possibility is that ISG
proteins that are up-regulated in both cases possess different
posttranscriptional modifications. In an alternative scenario,
nonresponse to both endogenous and exogenous IFN" may be
caused by the lack of induction of a few critical ISGs that are
specifically required for the elimination of HCV. We cannot
exclude this possibility, but an array analysis performed on
paired liver samples did not reveal ISGs that were specifically
up-regulated in RRs. Furthermore, this model cannot explain
why preactivation of the endogenous IFN system is so closely
linked to later nonresponse to treatment.
Alternatively, the kinetics of induction of the IFN response
could be decisive. In patients without a preactivated IFN system,
the injection of exogenous IFN" during treatment should induce
an antiviral state very rapidly in most liver cells, and HCV would
not have ‘‘enough’’ time to escape from the IFN-induced de-
fense. However, the buildup of the antiviral state could be slow
in the other group of patients, which would give HCV enough
time to adapt to and evade the intracellular antiviral defense
system, making it also resistant to the subsequent IFN therapy.
How could the induction of the endogenous IFN system
compromise the success of IFN" therapy? Clearly, the activation
of negative feedback loops that inhibit IFN signaling could play
a role. Prominent candidates among the negative regulators are
suppressors of cytokine signaling 1 (SOCS1) and SOCS3 (29),
two IFN-induced proteins that bind to the IFN receptor and
inhibit the activity of Jak1 and Tyk2, and the more recently
described regulator Ubp43 (protein of the USP18 gene), an
IFN-stimulated protein that binds to IFN" receptor 2 (IFNAR2)
and blocks the access of Jak1 to it (30). However, we could not
find a significant difference in the expression levels of these
negative regulators in the pegIFN"2b-stimulated liver biopsies
of RR compared with non-RR patients (data not shown).
Moreover, a general up-regulation of negative regulators such as
SOCSs and Ubp43 is not compatible with the observed strong
constitutive expression of a large number of ISGs in the subset
of patients that poorly respond to IFN therapy. If IFN" signaling
were indeed inhibited by the induction of SOCSs and Ubp43 in
the majority of liver cells, then one should not observe such a
pronounced preactivation of ISGs in pretreatment livers.
Notably, although the preactivation of tested ISGs occurred
more frequently in liver biopsies of patients infected with HCV
GT 1 and 4 than with GT 2 or 3, it did occur in both groups.
Preactivation of ISGs was found in non-RR patients with GT 2/3,
whereas RR patients with GT 1/4 had no induction in pretreat-
ment biopsies (Fig. 3C). Therefore, preactivation of the endog-
enous IFN system is strongly linked to the later response to
treatment independent of the HCV GT. Our finding that the
frequency and degree of preactivation of the endogenous IFN
system depend on the HCVGT could provide an explanation for
the observation that GT 2 and 3 infections can be cured in!80%
of patients, compared with #50% of infections with GT 1 (4).
Perhaps HCV GTs 2 and 3 are more successful in preventing the
activation of innate immunity in the liver. The success of the
virus in preventing the induction of the endogenous IFN system
would, however, come at the cost of being more susceptible to
IFN" therapies. Of note, a single chimpanzee infected with GT
3 has been shown to have lower ISG expression levels than
animals infected with GT 1 (17).
We have shown that HCV inhibits the IFN"-induced signaling
via the Jak-STAT pathway by up-regulating a protein phospha-
tase PP2A (12, 14, 31, 32). Inhibition of IFN" signaling by HCV
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by this or other mechanisms could explain why the strong
preactivation of the endogenous IFN system does not lead to a
spontaneous elimination of HCV. If one assumes that not all
hepatocytes are infected by HCV, but rather a minority, then the
induction of ISGs observed in pretreatment biopsies of non-RR
patients could occur predominantly in noninfected hepatocytes.
In infected cells, IFN would be ineffective because of the
inhibition of the Jak-STAT signaling pathway. The IFN respon-
sible for the preactivation of the system would be secreted by
hepatocytes infected with a virus that is not successful in
preventing IFN production. Because of the HCV-induced inhi-
bition of the Jak-STAT pathway, the secreted IFN! would not
induce an antiviral state in the infected hepatocytes but rather
in noninfected neighbor cells. To gain further insights into the
pathobiology of CHC, future studies should focus on analysis at
the single-cell level. Unfortunately, the detection of HCV-
infected hepatocytes in liver biopsies is still unsatisfactory,
making such studies difficult.
Although the precise mechanism of the HCV escape from the
immune defense system still remains to be elucidated, the
impairment of hepatitis C therapy by preactivation of the
endogenous IFN system is now well established. It would be
interesting to investigate whether this preactivation is a revers-
ible process. The injection of neutralizing anti-IFN"/! antibod-
ies or other factors blocking the IFN response before treatment
could return the endogenous IFN system to a ‘‘naive’’ state and
potentially enhance the response to IFN"-based therapies.
Materials and Methods
Patient Samples and Treatment. From January 2006 toApril 2007, patientswith
CHC referred to the outpatient liver clinic of University Hospital Basel were
asked for permission to use part of their diagnostic liver biopsy (B-1) for
research purposes. Patients who then were treated with pegylated-IFN"2b
(PegIntron) and ribavirin (Rebetol, both from Essex Chemie) were asked to
participate in this study. Sixteen patients agreed to undergo a second liver
biopsy (B-2) 4 h after the first injection of 1.5 #g/kg body weight pegIFN"2b
(PegIntron). AllwereCaucasians. Thefirst doseof ribavirinwas given after this
second biopsy to avoid further confounding factors. The protocol was ap-
proved by the Ethics Committee of the University Hospital Basel. Written
informed consent was obtained from all patients. Blood for PBMC isolation
was collected before treatment and 4 h after the first pegIFN"2b injection.
Patients were treated with pegIFN"2b (1.5 #g/kg body weight) and ribavirin
(weight-based dosing: #65 kg: 800 mg/d; 65–85 kg: 1 g/d; !85 kg: 1.2 g/d).
HCV RNAwas quantified before treatment initiation and atweeks 4 and 12 of
the treatment (Table 1). Treatment duration was 24 weeks for patients with
genotypes 2/3 and 48 weeks for genotypes 1/4. As non-CHC controls, four
patientswhounderwentultrasound-guided liverbiopsiesof focal lesionsgave
informed consent for abiopsy fromnormal liver tissueoutside the focal lesion.
Pretreatment liver biopsies from 96 additional patients (all but one were
Caucasians) with CHC were used for RT-qPCR for selected ISGs (patient data
shown in Table S4).
Measurement of IFN! in Serum. Pretreatment IFN" levels and the concentra-
tion of pegIFN"2b 4 h after the first injection were measured in serum using
the human IFN" ELISA kit from PBL Biomedical Laboratories according to the
manufacturer’s instructions. This kit has been shown to recognize both un-
pegylated and pegylated human IFN" (22).
RNA Isolation, Western Blots, EMSA, Immunohistochemistry, andMicroarray and
RT-qPCR Analyses. The procedures are described in detail in SI Materials and
Methods. All original arraydataarebeingdeposited in theNational Center for
Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database.
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SI Materials and Methods
Western Blots and EMSA. Whole cell, cytoplasmic and nuclear
extracts were prepared as described (1, 2). 10 !g of total protein
from human liver lysates was loaded for SDS/PAGE and trans-
ferred onto a nitrocellulose membrane (Schleicher & Schuell,
Switzerland). The membranes were blocked in 3% BSA/milk
(1:1)-0.1% Triton X-100 for 1 h, washed with Tris-buffered
saline Tween-20 (TBST), and incubated with the primary anti-
body overnight at 4°C.
Proteins were detected with primary antibodies specific to
phosphorylated STAT1 (PY (701)-STAT1; #9171; Cell Signal-
ing) and STAT1 (carboxy-terminus; Transduction Laboratories,
BD Biosciences, PharMingen). After 3 washes with TBST,
membranes were incubated with infrared fluorescent secondary
goat anti-mouse (IRDye 680) or anti-rabbit (IRDye 800) anti-
bodies (both from LI-COR Biosciences) for 1 h at room tem-
perature. Blots were analyzed by Odyssey Infrared Imaging
System from LI-COR. The infrared image was obtained in a
single scan and the signal was quantified using the integrated
intensity.
EMSAs were performed using 2 !g of nuclear extracts and
32P-radiolabeled DNA-oligonucleotide duplex of the serum in-
ducible element (SIE)-m67, corresponding to STAT response
element sequences (3).
Immunohistochemistry. Standard indirect immunoperoxidase pro-
cedures were used for immunohistochemistry (ABC-Elite, Vec-
tra Laboratories). 4-mm-thick sections were cut from paraffin
blocks, rehydrated, pretreated (20! in ER2 solution) incubated
with a monoclonal rabbit antibody against phospho-STAT1
(dilution 1:200, #9167 Cell Signaling) and counterstained with
haematoxilin. The whole staining procedure (dehydration, pre-
treatment, incubation, counterstaining and mounting) was per-
formed with an automated stainer (Bond, Vision BioSystems
Europe, Newcastle-upon-Thyne, U.K.). For quantification of
nuclear phospho-STAT1 staining, 5 times 200 hepatocytes were
counted for each B-1 and B-2 sample of each patient. In SI Fig.
S5A, the mean values with the standard deviations are shown.
RNA Isolation and Microarray Analysis. Total RNA was extracted
from liver and PBMC samples using the RNeasy Mini Kit
(Qiagen) according to manufacturer’s instructions. RNA was
aliquoted and stored at - 80°C. Gene expression was assessed in
liver and PBMCs by microarray analysis using Affymetrix Hu-
man Genome U133 Plus 2.0 arrays representing over 56,000
transcripts and variants with 11 perfect-match/mis-match probe
pairs per transcript. The microarray hybridizations were per-
formed at the functional genomics facility of the Friedrich
Miescher Institute for Biomedical Research in Basel. Total RNA
(1–2 !g) from each sample was reverse transcribed and biotin-
ylated using the Affymetrix 1-cycle amplification kit as per
manufacturer’s instructions. Biotinylated cRNA (20 !g) was
fragmented by heating with magnesium (as per Affymetrix’s
instructions) and 15 !g of fragmented cRNA was hybridized to
Human U133 Plus 2.0 GeneChips according to the manufactur-
er’s instructions. Quality control and background normalization
was performed using Refiner 4.1 from Genedata AG (Basel,
Switzerland). Expression value estimates were obtained using
the GC-RMA implementation in Refiner 4.1. Quantile-
normalization and median scaling of the genes called present
(detection P value "0.04) to a value of 500 was performed in
Genedata’s Analyst 4.1 package. These data will subsequently be
referred to as ‘‘absolute’’ expression values in the text.
Data analysis was performed using Expressionist Analyst 4.1
from Genedata AG.
Genes were required to pass a paired t test with a P " 0.05 or
P " 0.01 and have a fold change of 2 or greater between the
paired patient samples in #50% of patients within each group.
More precisely, for each patient, genes up- or down-regulated
#2-fold in posttreatment samples (compared with pretreatment)
were identified and saved in gene lists. The gene lists of all RR
patients and those of all non-RR patients were combined to
generate two extended lists. The genes of these lists were
analyzed with a paired t test using the B-1 and B-2 samples of the
patients in each response group. Genes had to pass the paired t
test with a significance level of P " 0.05 or P " 0.01. Finally,
genes up- or down-regulated #2-fold with P " 0.05 or P " 0.01
in #50% of patients within each of the response groups were
selected.
A fold change of 2 was selected to provide a list of genes that
were changing greatly within the samples. The false discovery
rate (FDR) of the t test was estimated by setting the universe size
to the number of genes that were detected with an Affymetrix
detection P value "0.04 (often called ‘‘present’’) in at least one
of the conditions ($32000 genes). The FDR analysis was made
using a permutation based false discovery estimate (4). In
addition we performed Storey-Tibshirani (5) FDR estimates,
maximal FDR values for which were 0.25 for P " 0.05 and 0.12
for P " 0.01.
The probability for the intersections in the Venn diagrams in
Fig. 1 A and B occurring by chance was calculated using the
hypergeometric test and was very low for both cases (4.91%40 and
6.03%192). Both hypergeometric probabilities were calculated
using the p hyper function in the R statistical package and
Bonferroni corrections were applied.
To compare the number of significantly regulated genes
between RR and non-RR patients in groups with equal number
of patients, 15 groups of 6 out of 10 patients were selected using
computer-generated pseudorandom numbers. In each group, the
genes changed #2-fold with a significance level of P " 0.05 or
P " 0.01 (paired t test) in #50% of patients were identified and
counted. We then calculated the probability of the Non-RR
derived result (i.e., 36 genes for P " 0.05) being part of the
expected Normal sampling distribution of the results obtained
from the 15 random RR samples using the ‘‘pnormal’’ function
from the statistical package R. This gave p-values of 0.004 and
0.001 for the biopsy samples when considering the data from the
t test at either the "0.01 or "0.05 level respectively (Fig. 1C).
To compare the mean ISG expression levels in B-2 samples of
RRs and non-RRs, a Welch t test was performed using the list
of 252 genes significantly regulated #2-fold in #50% of RR
patients. Only 19 genes (7.5%) passed the test (P " 0.05) with
a minimum of a 2-fold difference between RR and non-RR.
The heat map in Fig. S1 was generated by hierarchical
clustering of the 252 genes significantly regulated #2-fold in
#50% of RR patients.
For the supervised classifier prediction of liver biopsy samples
and PBMCs using the response at week 4 as a grouping criterion,
4 supervised clustering algorithms were used (Support Vector
Machine, Sparse Linear Discriminant Analysis, Fisher Linear
Discriminant Analysis, K Nearest Neighbors). The misclassifi-
cation rates could be determined for every algorithm used and
K Nearest Neighbors (KNN) was selected to generate the list of
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genes best predicting treatment response at week 4 in biopsy
samples (B-1 and B-2). In the case of Fig. S3A, Support Vector
Machine rendered an even lower misclassification rate of 1.9%
if compared with the 4.3% from KNN, but the lists of best
predictors in B-1 were identical for both tests.
RNA Isolation, Reverse Transcription, and SYBR-PCR. The array data
were validated by quantitative real-time RT-PCR analysis of
several IFN regulated genes including STAT1, IP10, USP18 and
IFI27. Total RNA was extracted as described above. The RNA
was reverse transcribed by Moloney murine leukemia virus
reverse transcriptase (Promega Biosciences, Inc.) in the presence
of random hexamers (Promega) and deoxynucleoside triphos-
phate. The reaction mixture was incubated for 5 min at 70°C and
then for 1 h at 37°C. The reaction was stopped by heating at 95°C
for 5 min. SYBR-PCR was performed based on SYBR green
fluorescence (SYBR green PCR master mix; Applied Biosys-
tems, Foster City, CA). Primers for GAPDH (glyceraldehyde-
3-phosphate dehydrogenase), STAT1, IP10, USP18 and IFI27
were designed across exon-intron junctions (Table S5). The
difference in the cycle threshold (&CT) value was derived by
subtracting the CT value for GAPDH, which served as an
internal control, from the CT value for transcripts of interest. All
reactions were run in duplicate by using an ABI 7000 sequence
detection system (Applied Biosystems). mRNA expression levels
of the transcripts were calculated relative to GAPDH from the
&CT values using the formula 2-&CT. The change of expression
in paired liver biopsy samples was calculated as a fold change
according to the formula 2ˆ(&CT B-1–&CT B-2).
Box plot diagrams and Mann–Whitney tests were performed
using GraphPad Prism version 4.00 for Macintosh, GraphPad
Software, www.graphpad.com.
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Fig. S1. Thepredominant pattern of gene expression in all patient biopsy samples is shownas a heatmap. Themapwas generatedwith a hierarchical clustering
analysis using a list of 252 genes that are altered#2 fold in#50% of all RRs with a p value of"0.05. The color coding of the absolute expression values is shown
on the left.Many genes have a lowexpression level in the control patients and the pretreatment biopsies of the RRpatients (B-1). In RR patients, pegIFN" induces
an up-regulation (B-2). In non-RR patients, many of the genes are already strongly induced in the pretreatment biopsy samples (B-1), and no further induction
is then found after pegIFN" (B-2).
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Fig. S2. PegIFN-"2b induced gene regulation in HCV-infected patients shows major differences between RR and non-RR patients in the liver but not in PBMCs. (A)
Five ISGs (Mx1, viperin,Mda5/helicard, OAS1, USP18)were chosen from the list of genes significantly (P" 0.05) regulated#2-fold between B-1 and B-2 in RR patients.
In the liver of non-RR patients, expression of these genes is already high before treatment (lanes 25–30), and does not further increase after pegIFN" (lanes 31–36). In
RRpatients, pretreatment expression (lanes 5–14) is similar to controls (lanes 1–4), andpegIFN" induces a strongup-regulation (lanes 15–24). Nopreactivation is found
in PBMCs (lanes 37–46 and 57–62), and pegIFN" strongly induces these genes in both RR and non-RR patients (lanes 47–56 and 63–68). The y-axes display absolute
expression values. (B) An example of a gene (CCL8) up-regulated in liver in response to pegIFN-"2b in both RR and non-RR patients. The expression values in PBMCs
are shown in lanes 37–68).
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Fig. S3. Supervised classifier prediction in liver biopsy samples and PBMCs with response to treatment at week 4 as grouping criterion. (A) Supervised classifier
prediction using the B-1 biopsies of the two response groups resulted in a list of 29 genes (33 transcripts) as best predictors of treatment outcome with a
misclassification rate of 4.3% when using the K Nearest Neighbors test. (B) Supervised classifier prediction using the B-2 biopsies of the two response groups
revealed a list of 16 genes (16 transcripts) as best predictors of treatment outcomewith amisclassification rate of 16.1%. (C andD) Supervised classifier prediction
of PBMC-1 and PBMC-2 samples did not generate a useful list of predictive genes with any of the 4 statistical tests used (Support Vector Machine, Sparse Linear
Discriminant Analysis, Fisher Linear Discriminant Analysis, K Nearest Neighbors). The misclassification rates were 38.5% for PBMC-1 and 42.6% for PBMC-2.
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Fig. S4. RT-qPCR analysis of selected ISGs. (A) RT-qPCR analysis of the USP18mRNA corroborates the array data. Depicted is the fold induction of USP18mRNA
betweenB-1 andB-2 in individual patients. The correlation coefficient between theRT-qPCRandmicroarray data is r'0.9861. (B) The expression level of selected
ISGs inpretreatmentbiopsies is lower inpatientswithearly virological response (EVR'more than2 logdropof viral loadatweek12) than inpatientswithprimary
non-response (PNR ' less than 2 log drop of viral load at week 12). (C) Both within the group of patients with genotype 1 and 4 (‘‘difficult’’-to-treat) and the
group with genotype 2 and 3 (‘‘easy’’-to-treat) the PNR patients have higher pretreatment expression levels of USP18 and IFI27. In B and C, the y axis shows
expression relative to that of GAPDH. Statistical significance was tested with the Mann-Whitney test. n ' number of patients in each group. (D) Patients with
sustained virological response (SVR ' undetectable HCV RNA 6 months after end of treatment) or end-of-treatment response (EoTR) show significantly lower
expression of USP18 and IFI27 than patients with PNR or no EoTR.
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Fig. S5. (A) Semiquantitative assessment of immunohistochemical staining of phospho-STAT1 in liver biopsies. Nuclear staining of hepatocytes was quantified
by repeated counting (5 times) in 200 hepatocytes in B-1 (blue) and B-2 (red) samples of the indicated patients (patient numbers correspond to the numbers in
table 1). In five out of six non-RR patients, a considerable proportion of hepatocytes had a weak but clear nuclear staining already in the pretreatment biopsies.
All of the RRpatients hadnophospho-STAT1 signals in the nuclei before treatment, but showeda strong induction after pegIFN". (B) The induction of STAT-DNA
binding in response to pegIFN"2b is impaired in most of the non-RR patients. Nuclear extracts from B-1 and B-2 samples were analyzed with EMSAs using the
radiolabeled SIE-m67 oligonucleotide probe. The asterisk (*) depicts the signal of the activated STAT1 dimers that have bound the oligonucleotide sequence.
The numbers above the gel shift panels represent the patient numbers as already used in table 1. The upper panel shows the 10 patients with a rapid response
at week 4 (numbers 1–10). The lower panel shows the 6 non-RR patients (numbers 11–16).
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Table S1. List of 252 genes changed >2-fold from B-1 to B-2 in >50% of 10 RR patients with a significance of P < 0.05 (paired t test)
Name Description Gene Symbol RR Mean B2/B1 non-RR Mean B2/B1
214038!at chemokine (C-C motif) ligand 8 CCL8 55.42 29.45
217502!at interferon-induced protein with tetratricopeptide
repeats 2
IFIT2 31.50 2.75
213797!at radical S-adenosyl methionine domain containing
2
RSAD2 28.47 1.93
214059!at Interferon-induced protein 44 IFI44 14.02 2.84
227458!at CD274 antigen CD274 13.79 3.82
226757!at interferon-induced protein with tetratricopeptide
repeats 2
IFIT2 12.84 2.45
204994!at myxovirus (influenza virus) resistance 2 (mouse) MX2 12.06 3.16
210302!s!at mab-21-like 2 (C. elegans) MAB21L2 11.76 1.37
204747!at interferon-induced protein with tetratricopeptide
repeats 3
IFIT3 11.67 1.97
210001!s!at suppressor of cytokine signaling 1 SOCS1 11.34 2.21
239979!at Epithelial stromal interaction 1 (breast) EPSTI1 9.60 2.69
230036!at sterile alpha motif domain containing 9-like SAMD9L 9.29 2.47
222793!at DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 DDX58 8.97 1.86
203153!at interferon-induced protein with tetratricopeptide
repeats 1, interferon-induced protein with
tetratricopeptide repeats 1
IFIT1 8.51 1.63
202086!at myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse),
myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse)
MX1 8.33 1.44
209999!x!at suppressor of cytokine signaling 1 SOCS1 8.28 1.37
218943!s!at DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 DDX58 8.03 1.86
226702!at hypothetical protein LOC129607 LOC129607 7.98 1.42
219691!at sterile alpha motif domain containing 9 SAMD9 7.96 1.87
1557078!at likely ortholog of mouse schlafen 5 MGC19764 7.83 1.97
243271!at Sterile alpha motif domain containing 9-like SAMD9L 7.80 4.93
219352!at hect domain and RLD 6 HERC6 7.75 1.42
204439!at interferon-induced protein 44-like IFI44L 7.12 1.31
223298!s!at 5’-nucleotidase, cytosolic III NT5C3 7.05 1.76
230314!at Similar to hypothetical protein 628 LOC440424 6.89 1.89
1553055!a!at likely ortholog of mouse schlafen 5 MGC19764 6.83 1.76
1555464!at interferon induced with helicase C domain 1 IFIH1 6.71 2.42
229450!at Interferon-induced protein with tetratricopeptide
repeats 3
IFIT3 6.56 1.59
228230!at peroxisomal proliferator-activated receptor A
interacting complex 285
PRIC285 6.49 1.64
219211!at ubiquitin specific peptidase 18 USP18 6.46 1.51
210873!x!at apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like 3A
APOBEC3A 6.38 3.10
205483!s!at interferon, alpha-inducible protein (clone IFI-15K) G1P2 6.31 1.22
231956!at KIAA1618 KIAA1618 6.13 1.72
228439!at hypothetical protein BC012330 MGC20410 6.11 2.24
204972!at 2’-5’-oligoadenylate synthetase 2, 69/71kDa OAS2 6.00 1.36
242234!at XIAP associated factor-1 BIRC4BP 5.95 1.68
219684!at 28kD interferon responsive protein IFRG28 5.78 1.39
242961!x!at DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 DDX58 5.77 1.75
243999!at likely ortholog of mouse schlafen 5 MGC19764 5.72 1.74
1552309!a!at nexilin (F actin binding protein) NEXN 5.58 1.76
202869!at 2’,5’-oligoadenylate synthetase 1, 40/46kDa OAS1 5.48 1.18
219863!at hect domain and RLD 5 HERC5 5.39 1.34
205569!at lysosomal-associated membrane protein 3 LAMP3 5.31 1.59
218400!at 2’-5’-oligoadenylate synthetase 3, 100kDa OAS3 5.27 1.38
210797!s!at 2’-5’-oligoadenylate synthetase-like OASL 5.23 1.26
232375!at Signal transducer and activator of transcription 1,
91kDa
STAT1 5.22 1.59
211122!s!at chemokine (C-X-C motif) ligand 11 CXCL11 5.19 1.59
241916!at Phospholipid scramblase 1 PLSCR1 5.16 2.30
205660!at 2’-5’-oligoadenylate synthetase-like OASL 5.04 1.26
202672!s!at activating transcription factor 3 ATF3 4.91 3.21
230000!at chromosome 17 open reading frame 27 C17orf27 4.89 1.20
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Table 1 (continued)
Name Description Gene Symbol RR Mean B2/B1 non-RR Mean B2/B1
238439!at ankyrin repeat domain 22 ANKRD22 4.84 3.23
204804!at tripartite motif-containing 21 TRIM21 4.80 1.81
208392!x!at SP110 nuclear body protein SP110 4.79 1.52
225076!s!at KIAA1404 protein KIAA1404 4.76 1.68
223834!at CD274 antigen CD274 4.74 1.82
220059!at BCR downstream signaling 1 BRDG1 4.72 2.19
223980!s!at SP110 nuclear body protein SP110 4.45 1.51
211267!at homeo box (expressed in ES cells) 1 HESX1 4.43 3.10
228468!at microtubule associated serine/threonine
kinase-like
MASTL 4.43 1.51
33304!at interferon stimulated exonuclease gene 20kDa ISG20 4.39 1.62
202988!s!at regulator of G-protein signalling 1 RGS1 4.37 4.66
235276!at gb:AA781795 /DB XREF ' gi:2841126 /DB XREF
' ai51d05.s1 /CLONE ' 1360521 /FEA ' EST
/CNT ' 14 /TID ' Hs.122587.0 /TIER ' ConsEnd
/STK ' 1 /UG ' Hs.122587 /UG TITLE ' ESTs
4.27 1.43
219209!at interferon induced with helicase C domain 1 IFIH1 4.24 1.44
209762!x!at SP110 nuclear body protein SP110 4.24 1.77
236156!at lipase A, lysosomal acid, cholesterol esterase
(Wolman disease)
LIPA 4.19 2.42
226103!at nexilin (F actin binding protein) NEXN 4.16 1.64
203805!s!at Fanconi anemia, complementation group A,
Fanconi anemia, complementation group A
FANCA 4.15 1.17
227609!at epithelial stromal interaction 1 (breast) EPSTI1 4.14 1.22
208436!s!at interferon regulatory factor 7 IRF7 4.11 1.37
239196!at ankyrin repeat domain 22 ANKRD22 4.06 2.08
1556314!a!at CDNA FLJ33375 fis, clone BRACE2006137 3.99 2.34
228152!s!at hypothetical protein FLJ31033 FLJ31033 3.94 1.42
225557!at AXIN1 up-regulated 1 AXUD1 3.93 1.72
211012!s!at promyelocytic leukemia, hypothetical protein
LOC161527
LOC161527, PML 3.93 1.79
210163!at chemokine (C-X-C motif) ligand 11 CXCL11 3.88 1.69
226725!at Transcribed locus 3.83 1.52
222881!at heparanase HPSE 3.71 1.95
235157!at Poly (ADP-ribose) polymerase family, member 14 PARP14 3.69 1.44
221680!s!at ets variant gene 7 (TEL2 oncogene) ETV7 3.62 1.27
1554519!at CD80 antigen (CD28 antigen ligand 1, B7–1
antigen)
CD80 3.61 2.23
206715!at transcription factor EC TFEC 3.60 2.38
206513!at absent in melanoma 2 AIM2 3.56 1.96
218543!s!at poly (ADP-ribose) polymerase family, member 12 PARP12 3.55 1.34
204187!at guanosine monophosphate reductase, guanosine
monophosphate reductase
GMPR 3.55 1.42
216020!at Interferon induced with helicase C domain 1 IFIH1 3.54 1.50
209824!s!at aryl hydrocarbon receptor nuclear
translocator-like
ARNTL 3.54 1.42
209457!at dual specificity phosphatase 5 DUSP5 3.45 2.46
213038!at IBR domain containing 3 IBRDC3 3.44 1.38
224225!s!at ets variant gene 7 (TEL2 oncogene) ETV7 3.44 1.36
229625!at Guanylate binding protein 5 GBP5 3.42 2.02
203595!s!at interferon-induced protein with tetratricopeptide
repeats 5
IFIT5 3.39 1.39
225344!at nuclear receptor coactivator 7 NCOA7 3.38 1.57
213361!at tudor domain containing 7 TDRD7 3.36 1.37
220104!at zinc finger CCCH-type, antiviral 1 ZC3HAV1 3.33 1.79
208965!s!at interferon, gamma-inducible protein 16 IFI16 3.33 1.66
238025!at mixed lineage kinase domain-like MLKL 3.31 1.51
205875!s!at three prime repair exonuclease 1 TREX1 3.30 1.36
225291!at polyribonucleotide nucleotidyltransferase 1 PNPT1 3.25 1.49
210029!at indoleamine-pyrrole 2,3 dioxygenase INDO 3.20 1.00
206553!at 2’-5’-oligoadenylate synthetase 2, 69/71kDa OAS2 3.18 1.37
228362!s!at Hypothetical protein LOC441168 RP1–93H18.5 3.17 1.70
204286!s!at phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 3.15 3.03
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Table S1. (continued)
Name Description Gene Symbol RR Mean B2/B1 non-RR Mean B2/B1
214586!at G protein-coupled receptor 37 (endothelin
receptor type B-like)
GPR37 3.14 0.85
238581!at Guanylate binding protein 5 GBP5 3.13 1.74
228304!at Transcribed locus 3.11 1.63
238743!at Coiled-coil domain containing 75 CCDC75 3.10 1.42
209795!at CD69 antigen (p60, early T-cell activation antigen) CD69 3.10 3.82
209892!at fucosyltransferase 4 (alpha (1,3)
fucosyltransferase, myeloid-specific)
FUT4 3.09 2.22
235175!at guanylate binding protein 4 GBP4 3.08 1.61
206332!s!at interferon, gamma-inducible protein 16 IFI16 3.08 1.52
36564!at IBR domain containing 3 IBRDC3 3.06 1.53
216834!at regulator of G-protein signalling 1 RGS1 3.06 2.51
221766!s!at family with sequence similarity 46, member A FAM46A 3.04 1.48
212657!s!at interleukin 1 receptor antagonist IL1RN 3.03 1.49
1559051!s!at chromosome 6 open reading frame 150 C6orf150 3.03 3.24
208966!x!at interferon, gamma-inducible protein 16 IFI16 3.01 1.57
203610!s!at tripartite motif-containing 38 TRIM38 3.01 1.32
218625!at neuritin 1 NRN1 3.01 1.67
202912!at adrenomedullin ADM 2.97 1.32
216243!s!at interleukin 1 receptor antagonist IL1RN 2.95 1.31
238725!at Interferon regulatory factor 1 IRF1 2.94 1.19
203596!s!at interferon-induced protein with tetratricopeptide
repeats 5
IFIT5 2.94 1.46
224973!at Family with sequence similarity 46, member A FAM46A 2.94 1.40
219011!at pleckstrin homology domain containing, family A
(phosphoinositide binding specific) member 4
PLEKHA4 2.92 1.32
219885!at likely ortholog of mouse schlafen 3 FLJ10260 2.92 1.58
204285!s!at phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 2.91 3.12
211013!x!at promyelocytic leukemia PML 2.87 1.26
223501!at tumor necrosis factor (ligand) superfamily,
member 13b
TNFSF13B 2.87 2.00
35254!at TRAF-type zinc finger domain containing 1 TRAFD1 2.86 1.61
1563075!s!at Clone IMAGE:110987 mRNA sequence 2.81 1.68
213294!at Coiled-coil domain containing 75 CCDC75 2.80 1.28
232517!s!at peroxisomal proliferator-activated receptor A
interacting complex 285
PRIC285 2.79 1.53
214933!at calcium channel, voltage-dependent, P/Q type,
alpha 1A subunit
CACNA1A 2.79 1.89
238430!x!at likely ortholog of mouse schlafen 5 MGC19764 2.79 1.36
209417!s!at interferon-induced protein 35 IFI35 2.79 1.24
238039!at CDNA FLJ26339 fis, clone HRT02975 2.77 1.23
219403!s!at heparanase HPSE 2.77 1.28
230383!x!at Transcribed locus, moderately similar to
NP 060190.1 signal-transducing adaptor
protein-2; brk kinase substrate (Homo sapiens)
2.76 1.45
207375!s!at interleukin 15 receptor, alpha IL15RA 2.75 1.27
225443!at DCP1 decapping enzyme homolog A (S. cerevisiae) DCP1A 2.71 1.16
205739!x!at zinc finger protein 588 ZNF588 2.70 1.66
223502!s!at tumor necrosis factor (ligand) superfamily,
member 13b
TNFSF13B 2.70 1.99
214995!s!at apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like 3G, apolipoprotein B mRNA
editing enzyme, catalytic polypeptide-like 3F
APOBEC3F, APOBEC3G 2.68 1.61
218501!at Rho guanine nucleotide exchange factor (GEF) 3 ARHGEF3 2.67 1.87
222816!s!at zinc finger, CCHC domain containing 2 ZCCHC2 2.66 1.17
243296!at Pre-B-cell colony enhancing factor 1 PBEF1 2.66 1.05
230405!at hypothetical gene supported by AL713721 LOC441109 2.65 1.40
210218!s!at nuclear antigen Sp100 SP100 2.64 1.10
204533!at chemokine (C-X-C motif) ligand 10 CXCL10/IP-10 2.63 1.42
34689!at three prime repair exonuclease 1 TREX1 2.63 1.29
202446!s!at phospholipid scramblase 1 PLSCR1 2.62 1.37
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Table S1. (continued)
Name Description Gene Symbol RR Mean B2/B1 non-RR Mean B2/B1
209969!s!at signal transducer and activator of transcription 1,
91kDa
STAT1 2.60 1.14
203567!s!at tripartite motif-containing 38 TRIM38 2.58 1.32
202307!s!at transporter 1, ATP-binding cassette, sub-family B
(MDR/TAP)
TAP1 2.57 1.43
209631!s!at G protein-coupled receptor 37 (endothelin
receptor type B-like)
GPR37 2.57 0.94
213982!s!at RAB GTPase activating protein 1-like RABGAP1L 2.56 1.46
202269!x!at guanylate binding protein 1, interferon-inducible,
67kDa, guanylate binding protein 1,
interferon-inducible, 67kDa
GBP1 2.56 1.44
202531!at interferon regulatory factor 1 IRF1 2.56 1.26
226773!at MRNA (clone ICRFp507I1077) 2.56 1.37
229391!s!at hypothetical protein LOC441168 LOC441168 2.55 2.15
216202!s!at serine palmitoyltransferase, long chain base
subunit 2
SPTLC2 2.55 1.64
204211!x!at eukaryotic translation initiation factor 2-alpha
kinase 2
EIF2AK2 2.54 1.28
212659!s!at interleukin 1 receptor antagonist IL1RN 2.54 1.34
221432!s!at solute carrier family 25, member 28, solute carrier
family 25, member 28
SLC25A28 2.53 1.39
219062!s!at zinc finger, CCHC domain containing 2 ZCCHC2 2.53 1.29
229543!at gb:AV734646 /DB XREF ' gi:10852191
/DB XREF ' AV734646 /CLONE ' cdAAGE02
/FEA ' EST /CNT ' 18 /TID ' Hs.54277.2 /TIER '
ConsEnd /STK ' 0 /UG ' Hs.54277 /LL ' 9130
/UG GENE ' DXS9928E /UG TITLE ' DNA
segment on chromosome . . .
2.52 1.73
1557236!at Apolipoprotein L, 6 APOL6 2.52 1.09
216598!s!at chemokine (C-C motif) ligand 2 CCL2 2.51 2.52
223192!at solute carrier family 25, member 28 SLC25A28 2.50 1.41
235543!at gb:AI928184 /DB XREF ' gi:5664148 /DB XREF
' wo95b05.x1 /CLONE ' IMAGE:2463057 /FEA
' EST /CNT ' 12 /TID ' Hs.122011.0 /TIER '
ConsEnd /STK ' 2 /UG ' Hs.122011 /UG TITLE
' ESTs
2.48 1.23
206133!at XIAP associated factor-1 BIRC4BP 2.46 1.13
219364!at likely ortholog of mouse D11lgp2 LGP2 2.45 1.32
224806!at tripartite motif-containing 25 TRIM25 2.45 1.23
202688!at tumor necrosis factor (ligand) superfamily,
member 10, tumor necrosis factor (ligand)
superfamily, member 10
TNFSF10 2.44 1.44
204415!at interferon, alpha-inducible protein (clone IFI-6–16) G1P3 2.44 1.08
227807!at poly (ADP-ribose) polymerase family, member 9 PARP9 2.43 1.55
212420!at E74-like factor 1 (ets domain transcription factor) ELF1 2.42 1.28
221865!at chromosome 9 open reading frame 91 C9orf91 2.39 2.07
214329!x!at tumor necrosis factor (ligand) superfamily,
member 10, tumor necrosis factor (ligand)
superfamily, member 10
TNFSF10 2.39 1.38
210971!s!at aryl hydrocarbon receptor nuclear
translocator-like
ARNTL 2.39 1.21
213051!at zinc finger CCCH-type, antiviral 1 ZC3HAV1 2.37 1.31
219716!at apolipoprotein L, 6 APOL6 2.37 1.29
220146!at toll-like receptor 7 TLR7 2.35 2.24
218986!s!at hypothetical protein FLJ20035 FLJ20035 2.35 1.14
209893!s!at fucosyltransferase 4 (alpha (1,3)
fucosyltransferase, myeloid-specific)
FUT4 2.34 1.77
225634!at zinc finger CCCH-type, antiviral 1 ZC3HAV1 2.33 1.20
219357!at GTP binding protein 1 GTPBP1 2.32 1.34
205932!s!at msh homeo box homolog 1 (Drosophila) MSX1 2.32 1.42
206247!at MHC class I polypeptide-related sequence B MICB 2.31 1.59
38269!at protein kinase D2 PRKD2 2.30 1.40
235737!at thymic stromal lymphopoietin TSLP 2.30 1.09
208912!s!at 2’,3’-cyclic nucleotide 3’ phosphodiesterase CNP 2.29 1.17
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Table S1. (continued)
Name Description Gene Symbol RR Mean B2/B1 non-RR Mean B2/B1
232383!at transcription factor EC TFEC 2.29 1.60
226474!at nucleotide-binding oligomerization domains 27 NOD27 2.27 1.45
232150!at Chromosome 20 open reading frame 18 C20orf18 2.25 1.53
203127!s!at serine palmitoyltransferase, long chain base
subunit 2
SPTLC2 2.24 1.76
231577!s!at guanylate binding protein 1, interferon-inducible,
67kDa
GBP1 2.24 1.38
217497!at endothelial cell growth factor 1 (platelet-derived) ECGF1 2.24 1.54
209282!at protein kinase D2 PRKD2 2.23 1.42
205151!s!at gb:NM 014817.1 /DB XREF ' gi:7662219 /GEN
' KIAA0644 /FEA ' FLmRNA /CNT ' 48 /TID '
Hs.21572.0 /TIER ' FL * Stack /STK ' 11 /UG '
Hs.21572 /LL ' 9865 /DEF ' Homo sapiens
KIAA0644 gene product (KIAA0644), mRNA.
/PROD ' KI . . .
2.22 1.43
230110!at mucolipin 2 MCOLN2 2.22 1.27
204961!s!at neutrophil cytosolic factor 1 (47kDa, chronic
granulomatous disease, autosomal 1)
NCF1 2.21 1.35
214511!x!at Fc fragment of IgG, high affinity Ia, receptor
(CD64), Fc-gamma receptor I B2
FCGR1A, LOC440607 2.19 1.82
206503!x!at promyelocytic leukemia PML 2.19 1.40
204205!at apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like 3G
APOBEC3G 2.19 1.46
216950!s!at Fc fragment of IgG, high affinity Ia, receptor
(CD64)
FCGR1A 2.17 1.82
212660!at PHD finger protein 15 PHF15 2.17 1.64
227877!at similar to annexin II receptor LOC389289 2.17 1.42
213716!s!at secreted and transmembrane 1 SECTM1 2.16 1.27
221044!s!at tripartite motif-containing 34, tripartite
motif-containing 6 and tripartite
motif-containing 34
TRIM34, TRIM6-TRIM34 2.16 1.40
203236!s!at lectin, galactoside-binding, soluble, 9 (galectin 9) LGALS9 2.16 1.57
231876!at tripartite motif-containing 56 TRIM56 2.15 1.15
1568592!at hypothetical gene supported by BC031266 LOC400368 2.15 1.27
229390!at hypothetical protein LOC441168 LOC441168 2.15 1.78
203964!at N-myc (and STAT) interactor NMI 2.15 1.32
212577!at structural maintenance of chromosomes flexible
hinge domain containing 1
SMCHD1 2.11 1.37
209732!at C-type lectin domain family 2, member B CLEC2B 2.10 1.59
224175!s!at tripartite motif-containing 34, tripartite
motif-containing 6 and tripartite
motif-containing 34
TRIM34, TRIM6-TRIM34 2.10 1.37
202864!s!at nuclear antigen Sp100 SP100 2.09 1.11
241869!at apolipoprotein L, 6 APOL6 2.08 1.47
229723!at T-cell activation GTPase activating protein TAGAP 2.08 1.70
206271!at toll-like receptor 3 TLR3 2.08 1.15
218999!at hypothetical protein FLJ11000 FLJ11000 2.07 1.20
205692!s!at CD38 antigen (p45) CD38 2.05 1.12
217546!at metallothionein 1M MT1M 2.03 1.01
202430!s!at phospholipid scramblase 1 PLSCR1 1.97 1.11
239587!at Transcribed locus 1.94 1.13
223220!s!at poly (ADP-ribose) polymerase family, member 9 PARP9 1.90 1.18
208960!s!at Kruppel-like factor 6 KLF6 1.87 1.66
225973!at transporter 2, ATP-binding cassette, sub-family B
(MDR/TAP)
TAP2 1.72 1.21
230252!at G protein-coupled receptor 92 GPR92 0.57 0.51
44790!s!at chromosome 13 open reading frame 18 C13orf18 0.56 0.67
227410!at family with sequence similarity 43, member A FAM43A 0.56 0.64
206765!at potassium inwardly-rectifying channel, subfamily
J, member 2
KCNJ2 0.53 0.51
209218!at squalene epoxidase SQLE 0.53 1.42
202887!s!at DNA-damage-inducible transcript 4 DDIT4 0.52 0.89
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Name Description Gene Symbol RR Mean B2/B1 non-RR Mean B2/B1
209782!s!at D site of albumin promoter (albumin D-box)
binding protein
DBP 0.47 0.61
227285!at chromosome 1 open reading frame 51 C1orf51 0.46 0.61
202861!at period homolog 1 (Drosophila) PER1 0.46 0.56
228854!at Transcribed locus 0.42 0.33
205883!at zinc finger and BTB domain containing 16 ZBTB16 0.33 0.38
Shownare the average fold changes fromB-1 to B-2 in RR andnon-RRpatients. Nineteengenes (shown in italic) had significantly (P" 0.05,Welch t test) higher
mean expression values in B-2 samples from RR vs. non-RR patients.
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Table S2a. Analysis of gene expresson in pretreatment biopsies (B-1)
Gene
symbol Description Affy-ID 
Mean 
(SEM)
expression 
in 10 RRs 
Mean (SEM) 
expression in 6 
non-RRs 
Non-
RR/
RR
Function 
IFI44L interferon-induced protein 44-like 204439_at 306 (50) 3392 (903) 11.10 cell cycle 
RSAD2
radical S-adenosyl 
methionine domain 
containing 2 
242625_at 272 (41) 2405 (425) 8.83
innate
immune
response
G1P2
interferon, alpha-
inducible protein 
(clone IFI-15K) 
205483_s_at 2238 (397) 17375 (2762) 7.76
innate
immune
response
IFI27 interferon, alpha-inducible protein 27 202411_at 3320 (714) 24927 (2441) 7.51
innate
immune
response
LAMP3 lysosomal-associated membrane protein 3 205569_at 96 (22) 665 (108) 6.97
cell 
proliferation 
OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa 218400_at 319 (46) 1842 (296) 5.77
innate
immune
response
HERC6 hect domain and RLD 6 219352_at 144 (32) 795 (93) 5.53
immune
response
HIST1H2BD Histone 1, H2bd 235456_at 40 (4) 202 (33) 5.02 DNApackaging 
IFIT1
interferon-induced 
protein with 
tetratricopeptide 
repeats 1 
203153_at 2209 (165) 9995 (1706) 4.53
innate
immune
response
LOC129607 hypothetical protein LOC129607 226702_at 970 (143) 4135 (520) 4.26
amino acid 
metabolism 
IFI44 interferon-induced protein 44 214453_s_at 1101 (153) 4183 (405) 3.80
innate
immune
response
HERC5 hect domain and RLD 5 219863_at 963 (93) 3144 (552) 3.26
protein 
ubiquitination 
LGALS3BP
lectin, galactoside-
binding, soluble, 3 
binding protein 
200923_at 1537 (238) 4960 (475) 3.23 response to stress 
SAMD9 sterile alpha motif domain containing 9 228531_at 323 (32) 997 (166) 3.08 unknown
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Table S2b. Analysis of gene expresson in pretreatment biopsies (B-1)
IFIT2
interferon-induced 
protein with 
tetratricopeptide 
repeats 2 
226757_at 951 (63) 2744 (510) 2.89
innate
immune
response
LOC286208 hypothetical protein LOC286208 1560089_at 39 (3) 110 (18) 2.86 -
IRF7 interferon regulatory factor 7 208436_s_at 240 (16) 679 (107) 2.82
innate
immune
response
FLJ20035 hypothetical protein FLJ20035 218986_s_at 1191 (84) 3341 (378) 2.80 Helicase
IFIT3
Interferon-induced 
protein with 
tetratricopeptide 
repeats 3 
229450_at 2760 (213) 7703 (1327) 2.79
innate
immune
response
RALGPS1 
Ral GEF with PH 
domain and SH3 
binding motif 1 
204199_at 22 (2) 61 (8) 2.70 signaltransduction
PARP12
poly (ADP-ribose) 
polymerase family, 
member 12 
218543_s_at 437 (36) 1158 (60) 2.65
poly (ADP-
ribose)
polymerase 
family 
HIST1H2BG histone 1, H2bg 210387_at 13 (1) 29 (3) 2.13 DNApackaging 
PARP9
poly (ADP-ribose) 
polymerase family, 
member 9 
223220_s_at 1386 (111) 2868 (263) 2.07
poly (ADP-
ribose)
polymerase 
family 
PNPT1 
polyribonucleotide 
nucleotidyltransferase 
1
225291_at 518 (23) 971 (105) 1.88 RNAcatabolism 
CCDC75 Coiled-coil domain containing 75 213294_at 776 (40) 1382 (105) 1.78 -
CNP 2',3'-cyclic nucleotide 3' phosphodiesterase 208912_s_at 682 (24) 1054 (70) 1.55
nucleotide 
metabolism 
HTATIP2 HIV-1 Tat interactive protein 2, 30kDa 209448_at 3317 (130) 4451 (74) 1.34 Apoptosis
RPLP0
ribosomal protein, 
large, P0, ribosomal 
protein, large, P0 
211720_x_at 16980(404) 13294 (439) 0.78
protein 
biosynthesis 
LOC402560 Hypothetical LOC401384 227554_at 562 (95) 90 (20) 0.16 -
List of 29 genes best predicting treatment outcome at week 4 (IFN stimulated genes shaded in grey; genes that differ between RR and non-RR but are not
regulated by IFN are not shaded).
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Table S3. Analysis of gene expression in biopsies obtained 4 h after pegIFN! (B-2)
Gene symbol Description Affy-ID 
Mean 
(SEM)
expression 
in 10 RRs 
Mean 
(SEM)
expression 
in 6 non-
RRs
Non-
RR
/RR
Function 
IFI27 interferon, alpha-inducible protein 27 202411_at 4540 (735)
25501
(2372) 5.62
innate immune 
response
LGALS3BP
lectin, galactoside-
binding, soluble, 3 
binding protein 
200923_at 1728 (282) 5223 (386) 3.02 response to stress 
ZFP3 zinc finger protein 3 homolog (mouse) 235728_at 33 (4) 75 (7) 2.28 ion binding 
MYH14 myosin, heavy polypeptide 14 234290_x_at 33 (2) 64 (5) 1.98
cell 
morphogenesis
PARP6
poly (ADP-ribose) 
polymerase family, 
member 6 
219639_x_at 149 (8) 285 (23) 1.92
poly (ADP-
ribose)
polymerase 
family 
GPR143 G protein-coupled receptor 143 206696_at 18 (1) 28 (2) 1.54
signal
transduction
BRUNOL5
bruno-like 5, RNA 
binding protein 
(Drosophila)
232416_at 13 (0.3) 19 (1) 1.43 RNA binding 
ATP5A1
ATP synthase, H+ 
transporting, 
mitochondrial F1 
complex, alpha 
subunit, isoform 1, 
cardiac muscle 
213738_s_at 14472(290)
17712
(487) 1.22
cellular 
metabolism 
CHMP4A
chromatin 
modifying protein 
4A
228764_s_at 348 (11) 234 (6) 0.67 protein localization 
IDS
iduronate 2-
sulfatase (Hunter 
syndrome) 
206342_x_at 185 (7) 122 (5) 0.66 carbohydrate metabolism 
gb:AI341383
/DB_XREF=gi:407
8310
/DB_XREF=qx91a
06.x1
/CLONE=IMAGE:
2009842
/FEA=EST
/CNT=52
/TID=Hs.112751.2 
/TIER=Stack 
/STK=42
/UG=Hs.112751
/LL=23383 
/UG_GENE=KIAA
0892
/UG_TITLE=KIAA
0892 protein 
227092_at 475 (24) 254 (17) 0.54   
VISA Virus-inducedsignaling adapter 229741_at 167 (7) 77 (4) 0.46
innate immune 
response
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Table S3b. Analysis of gene expression in biopsies obtained 4 h after pegIFN! (B-2)
PCOLCE 
procollagen C-
endopeptidase
enhancer
202465_at 1297 (135) 539 (56) 0.42 development
IRF1 Interferon regulatory factor 1 238725_at 1106 (109) 449 (30) 0.41
innate immune 
response
PSMAL 
prostate-specific
membrane antigen-
like
211303_x_at 793 (76) 278 (68) 0.35 Unknown
LOC402560 Hypothetical LOC401384 227554_at 578 (85) 83 (17) 0.14 -
List of 16 genes best predicting treatment outcome at week 4 (IFN stimulated genes shaded in grey; genes that differ between RR and non-RR but are not
regulated by IFN are not shaded).
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Table S4a. Study patients’ characteristics
Biopsy 
number Sex Age
HCV
genotype 
Baseline 
VL IU/ml Metavir 
4 week 
response
12 week 
response Follow-up 
A 810 m 53 3 6112502 A3/F4 - - EoTR,Relapse 
A 643 f 52 2a/c 72157 A2/F4 - - EoTR,Relapse 
A 441 m 45 1b 2910319 A1/F4 Non-RVR EVR
EoTR,
Relapse 
A 502.b m 67 1b 2137002 A1/F2 Non-RVR EVR No EoTR 
A 626 m 63 1 1752158 A3/F4 Non-RVR EVR No EoTR 
A 517 f 53 3a 204455 A2/F4 Non-RVR EVR No EoTR 
A 454 m 45 1 684000 A1/F4 Non-RVR PNR PNR
A 478 m 45 1 5632925 A2/F3 Non-RVR PNR PNR
A 606 m 41 1 12328724 A2/F3 Non-RVR PNR PNR
A 795 m 54 1 222053 A3/F4 Non-RVR PNR PNR
A 603 f 38 2 5780000 A2/F3 Non-RVR PNR PNR
A 733 f 58 2 5262008 A2/F4 Non-RVR PNR PNR
A 770 m 49 4 8048807 A3/F4 Non-RVR PNR PNR
A 535 f 49 1a >700'000 A1/F2 Non-RVR PNR PNR
A 558.c f 47 1a 1444062 A2/F2 Non-RVR PNR PNR
A 578 f 43 1a 1300504 A1/F2 Non-RVR PNR PNR
A 595 f 52 1a 4458717 A2/F2 Non-RVR PNR PNR
A 745 f 37 1a 953556 A3/F3 Non-RVR PNR PNR
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Table S4b. Study patients’ characteristics
A 756 m 61 1a 5545733 A2/F4 Non-RVR PNR PNR
A 759 m 62 1a 5624281 A3/F4 Non-RVR PNR PNR
A 521.b f 44 1b 248000 A2/F2 Non-RVR PNR PNR
A 555.b m 60 1b 7636130 A2/F3 Non-RVR PNR PNR
A 563 m 48 1b 713046 A3/F4 Non-RVR PNR PNR
A 615 m 59 1b 191299 A3/F3 Non-RVR PNR PNR
A 664 m 56 1b 7790643 A2/F3 Non-RVR PNR PNR
A 709 m 48 1b 2949376 A2/F4 Non-RVR PNR PNR
A 518 m 48 4 45523 A1/F4 Non-RVR EVR
treatment 
interrupted 
A 685 m 40 3a 2531993 A3/F3 Non-RVR EVR ongoing 
A 673 f 38 1b 8002763 A2/F3 Non-RVR EVR ongoing 
A 570.b f 54 3 6655260 A1/F2 Non-RVR EVR EoTR
A 704 m 41 3a 15538256 A1/F1 Non-RVR EVR EoTR
A 536 m 49 3a 2283557 A1/F2 Non-RVR EVR SVR
A 376 m 42 3a 352000 A1/F1 - EVR SVR
A 502.c m 37 3a 247290 A2/F2 - EVR SVR
A 558.b f 45 3a 6409813 A1/F2 - EVR EoTR
A 475 f 45 4c/d 1718991 A3/F3 - EVR SVR
A 764 m 38 4 12000 A2/F2 RR   ongoing 
A 590 f 48 1a 3107291 A3/F4 RR   ongoing 
A 720 f 50 1b 16639113 A1/F2 RR   ongoing 
A 706 m 56 3 178919 A3/F4 RR   ongoing 
A 542 f 28 3 423000 A2/F1 RVR EVR SVR
A 601 f 63 2a/c 3306636 A2/F3 RVR EVR SVR
A 609 f 53 2a/c 1196303 A3/F3 RVR EVR EoTR
A 614 m 33 2b 1867778 A1/F2 RVR EVR EoTR
A 623 m 47 2b 4663883 A3/F4 RVR EVR EoTR
A 426 m 26 3a 87458 A1/F1 RVR EVR EoTR
A 534 m 52 3a 13773866 A2/F2 RVR EVR SVR
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Table S4c. Study patients’ characteristics
A 584 m 37 3a 78684 A1/F2 RVR EVR EoTR
A 594 m 38 1a 9638894 A2/F1 RVR EVR ongoing 
A 792 f 16 1a 3378 A3/F1 RVR EVR ongoing 
A 662 m 49 3a 12381160 A2/F2 RVR EVR ongoing 
A 688 f 48 3a 13538256 A2/F3 RVR EVR ongoing 
A 748 m 29 3a 11879263 A2/F2 RVR EVR ongoing 
A 707 f 24 1b 440 A2/F2 RVR   ongoing 
A 740 f 24 3a 805551 A2/F3 RVR   ongoing 
A 767 m 31 3a 282100 A3/F3 RVR   ongoing 
A 789 m  34 4 173000 A2/F2 ongoing 
A 809 f 41 1a 4652760 A2/F1 ongoing 
A 515 f 54 3a 75644 A2/F4 ongoing 
A 642 m 33 3a 1683442 A2/F1 ongoing 
A 774 m 43 3a 51326 A3/F4 ongoing 
A 658 m 57 1 10327448 A1/F1 - - No treatment 
A 675 f 53 1 - A3/F4 - - No treatment 
A 701 m 27 1 13157175 A2/F2 - - No treatment 
A 726 f 28 1 340000 A2/F2 - - No treatment 
A 727 f 56 1 895473 A2/F2 - - No treatment 
A 514 f 32 1a 460169 A2/F2 - - No treatment 
A 531 m 39 1a 3427262 A1/F2 - - No treatment 
A 532 m 55 1a 788024 A1/F1 - - No treatment 
A 544.b m 46 1a 1218968 A1/F1 - - No treatment 
A 566 m 42 1a 3556921 A1/F1 - - No treatment 
A 574 m 43 1a 792776 A1/F1 - - No treatment 
A 586 m 46 1a 761368 A2/F2 - - No treatment 
A 619 f 41 1a 4519497 A2/F1 - - No treatment 
A 667 f 32 1a 259633 A1/F1 - - No treatment 
A 698 m 35 1a 3378710 A1/F1 - - No treatment 
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Table S4d. Study patients’ characteristics
A 725 m 48 1a 36108528 A1/F2 - - No treatment 
A 735 m 35 1a 222771 A1/F1 - - No treatment 
A 753 m 49 1a - A3/F4 - - No treatment 
A 765 f 37 1a 2351514 A1/F1 - - No treatment 
A 799 f 41 1a 14028196 A2/F2 - - No treatment 
A 525 m 63 1b 117458 A1/F1 - - No treatment 
A 549 m 69 1b 1810000 A2/F2 - - No treatment 
A 551 m 46 1b 69000000 A1/F2 - - No treatment 
A 559.b f 39 1b 1350000000 A1/F1 - - No treatment 
A 567 m 29 1b 384525 A2/F2 - - No treatment 
A 577 f 40 1b 300359 A1/F1 - - No treatment 
A 582 m 35 1b 17594 A1/F2 - - No treatment 
A 687 f 69 1b 1686605 A1/F2 - - No treatment 
A 694 m 68 1b 5652771 A3/F4 - - No treatment 
A 705 m 44 1b 67587 A2/F4 - - No treatment 
A 641 m 58 2b 4853209 A2/F3 - - No treatment 
A 732 m 32 2 1144075 A2/F2 - - No treatment 
A 564 m 31 3 759000 A2/F2 - - No treatment 
A 469 m 26 3a 24626114 A1/F0 - - No treatment 
A 500 m 36 3a 1480000 A1/F1 - - No treatment 
A 524 m 47 3a 337115 A2/F4 - - No treatment 
A 539 m 35 3a 1152145 A2/F2 - - No treatment 
A 541 f 31 3a 961000 A1/F1 - - No treatment 
A 548 m 60 3a 951896 A3/F4 - - No treatment 
A 621 m 45 3a 134785 A2/F1 - - No treatment 
A 638 m 50 3a 1274215 A1/F2 - - No treatment 
A 650 f 44 3a 319000 A2/F2 - - No treatment 
A 689 f 67 3a 265382 A3/F4 - - No treatment 
A 768 m 36 3a 1140000 A3/F3 - - No treatment 
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Table S4e. Study patients’ characteristics
A 485.b m 42 4 191686 A1/F2 - - No treatment 
A 622 f 48 4 88216 A1/F1 - - No treatment 
A 734 m 34 4 521210 A2/F2 - - No treatment 
A 744 m  52 4 585000 A3/F4 - - No treatment 
A 757 m 39 4 104945 A1/F2 - - No treatment 
A 804 m 45 4 321000 A2/F2 - - No treatment 
A 656 m 51 4e 864372 A3/F4 - - No treatment 
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Table S5. Primer sequences used for real-time RT-PCR analysis
Gene Primer 1 sequence Primer 2 sequence
GAPDH 5’ GCTCCTCCTGTTCGACAGTCA 3’ 5’ ACCTTCCCCATGGTG TCTGA 3’
STAT1 5’ TCCCCA GGCCCTTGTTG 3’ 5’ CAAGCTGCTGAAGTTGGTACCA 3’
IP10 5’ CGATTCTGATTTGCTGCCTTAT 3’ 5’ GCAGGTACAGCGTACGGTTCT 3’
USP18 5’ CTC AGTCCCGACGTGGAACT 3’ 5’ ATCTCTCAAGCGCCATGCA 3’
IFI27 5’ CCTCGGGCAGCCTTGTG 3’ 5’ AATCCGGAGAGTCCAGTTGCT 3’
Sarasin-Filipowicz et al. www.pnas.org/cgi/content/short/0707882105 23 of 23
 67 
4.2 Cardif cleavage in CHC and correlation with ISG induction 
 
4.2.1 Cardif is cleaved in human HCV infected liver and cleavage occurs more often in 
patients infected with genotypes 2 and 3  
 
The NS3-4A protease has been reported to target and inactivate Cardif in vitro (154). We 
assessed whether Cardif cleavage can be detected in the livers of patients infected with HCV. 
Liver whole cell extracts from 40 chronically infected HCV patients, 10 HBV patients and 
two controls (healthy liver tissue) were subjected to Western blot analysis. Representative 
examples for detection of full-length (FL) and cleaved Cardif are shown in Figure 4.2.A. The 
two bands correspond to Cardif FL (aa 1-540) and Cardif in the cleaved form (aa 1-508). As a 
control for Cardif FL, lysates from Huh7.5 cells that only contain uncleaved Cardif, and as a 
control for cleaved Cardif, lysates from the replicon cell line HCVrepBB7 (B-7; ref.(177)) 
were loaded on each gel. The 40 HCV samples showed a variable degree of Cardif cleavage: 
some samples had only FL, some samples only cleaved Cardif, and most samples had partial 
cleavage of Cardif. None of the 10 HBV patients and 2 controls showed Cardif cleavage 
(Figure 4.2.A and data not shown). 
 
 
 
Figure 4.2.A. Levels of Cardif full-length and cleaved Cardif in human liver biopsies 
Proteins from cells and liver biopsies were extracted using RIPA buffer (50mM Tris pH 8.0, 150mM 
NaCl, 1% NP40, 0.5 % DOC, 0.1% SDS, 1 mM sodium orthovanadate, 10 mM NaF and a cocktail of 
protease inhibitors). Cardif protein was assessed by Western blot. For Cardif detection, monoclonal 
antibody Adri-1 or polyclonal antibody AT107 (both gifts from Olivier Donzé, Apotech Corporation, 
Lausanne) were used at a 1:2500 dilution. As control, actin was detected using a monoclonal antibody 
AC15 from Sigma. Detection of the proteins was revealed by chemiluminescence using the ECL 
Advance Western Blotting Detection kit (Amersham Biosciences). 
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We then analyzed whether the different HCV genotypes have different abilities to cleave 
Cardif. As the cleaved form of Cardif often seems to be degraded and quantification of the 
cleaved form therefore is difficult, we assessed the amount of Cardif FL in the 40 HCV 
biopsy lysates and stratified the results into the “difficult-to-treat” GTs 1 and 4 versus the 
more treatment susceptible GTs 2 and 3. Interestingly, the amount of Cardif FL is higher in 
biopsies from patients with GTs 1 and 4 than GTs 2 and 3 (Figure 4.2.B, left panel). It is 
therefore very likely, that HCV GTs 2 and 3 are more successful in cleaving Cardif. As 
expected, there was also a statistically significant difference in the protein amount of Cardif 
FL between HCV and HBV samples. Importanty, Cardif mRNA amounts are not different 
between HCV GTs 1/4 and 2/3 (Figure 4.2.B, right panel). Moreover, healthy control 
samples had similar amounts of Cardif mRNA in the liver as HCV samples. 
 
 
 
Figure 4.2.B. Quantification of Cardif full-length (FL) and Cardif mRNA according to HCV 
genotype 
Left panel: Cardif FL protein was assessed by Western blot. Densitometric scanning was 
performed using an ImageScanner (Amersham Pharmacia Biotech). The bands corresponding to 
Cardif FL and actin were quantified with the ImageMaster TotalLab software (Amersham 
Pharmacia Biotech). Data expressed as Cardif FL correspond to densitometric value of the Cardif 
FL band divided by the densitometric value of actin. Depicted is the amount of FL Cardif in HCV 
(stratified into genotypes 1/4 versus 2/3) and HBV patients. Statistical analysis was performed 
using Mann-Whitney t-tests. The horizontal line in the box plot represents the median of the 
sample values. The lower and upper quartile is shown within the box below and above the line 
that represents the median. The lower whisker depicts the smallest observation, the upper 
whisker ends at the largest observation. 
Right panel: Cardif mRNA expression in the liver was assessed in 69 HCV and 6 healthy control 
samples by RT-qPCR using the primers C212fd ACTTCATTGCGGCACTGAGG and C522rev 
TCTGGATTCCTTGGGATGGC. Statistical analysis was performed using Mann-Whitney t-test 
and revealed no significance (ns) between controls and HCV samples. 
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4.2.2 Expression of full-length Cardif correlates with ISG pre-activation in the liver 
 
It is unknown whether the ISG activation status of chronic HCV patients (with future non-
responders to treatment showing a pre-activated endogenous IFN system in the liver) is 
dependent on the viral sensory pathways and therefore also on Cardif function. We aimed to 
investigate whether there is a correlation between protein expression of Cardif FL in the 
HCV infected liver and the mRNA levels of known ISGs. Indeed, we observed that high 
protein levels of Cardif FL are often associated with high expression of ISG transcripts. An 
example of an ISG (IFI27) is shown in Figure 4.2.C. Some patients with high Cardif FL 
protein expression showed, however, no pre-activation of the endogenous IFN system, 
arguing that in these patients viral sensory pathways are affected at other levels, either 
upstream or downstream of Cardif. 
 
 
 
 
Figure 4.2.C. Correlation of Cardif FL protein with IFI27 mRNA expression in the liver 
Cardif FL protein in 40 HCV liver biopsies was assessed by Western blot. Densitometric scanning 
was performed using an ImageScanner (Amersham Pharmacia Biotech). The bands corresponding 
to Cardif FL and actin were quantified with the ImageMaster TotalLab software (Amersham 
Pharmacia Biotech). IFI27 mRNA expression in the liver was assessed in the same 40 HCV liver 
biopsies by RT-qPCR. Nonparametric correlation analysis was performed and the Spearman 
correlation coefficient is r=0.3348. 
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4.2.3 Activation of STAT1 in hepatocytes correlates with levels of ISG mRNAs in the 
liver of patients with CHC 
 
To elucidate whether the increase in ISG transcripts observed in HCV infected livers results 
from an activated Jak-STAT signaling pathway in hepatocytes, we assessed the levels of 
phosphorylated STAT1 (p-STAT1) by immunohistochemistry in a cohort of 80 HCV patients 
and 8 controls (healthy liver tissue). Nuclear p-STAT1 signal was quantified in hepatocytes 
and each biopsy sample was assigned to one of four categories (-, +, ++, +++; see Figure 
4.2.D for details). There was a correlation of nuclear p-STAT1 staining in hepatocytes with 
the expression of ISGs in the liver (Figure 4.2.D).  
 
 
Figure 4.2.D. Quantification of p-STAT1 nuclear staining in hepatocytes of HCV patients and 
correlation to mRNA levels of four different ISGs (STAT1, IP-10/CXCL10, USP18, IFI27) 
Standard indirect immunoperoxidase procedures were used for immunohistochemistry (ABC-Elite, 
Vectra Laboratories). 4-mm-thick sections were cut from paraffin blocks, rehydrated, pretreated 
(20’ in ER2 solution) incubated with a monoclonal rabbit antibody against phospho-STAT1 
(dilution 1:200, #9167 Cell Signaling) and counterstained with haematoxilin. The whole staining 
procedure (dehydration, pre-treatment, incubation, counterstaining and mounting) was performed 
with an automated stainer (Bond®, Vision BioSystems Europe, Newcastle-upon-Thyne, UK). The 
p-STAT1 signal  
ISG mRNA expression in the liver was assessed in 80 HCV liver biopsies by RT-qPCR. The ISG 
expression levels were calculated relative to the expression of GAPDH as internal control. 
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4.3. Interferon alpha induces long-lasting refractoriness of Jak-STAT 
signaling in the mouse liver through induction of USP18/UBP43 
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Abstract. 
 
Recombinant interferon-α (IFNα) is used for the treatment of chronic viral hepatitis and 
some forms of cancer. During these therapies recombinant IFNα is injected once daily or 
every second day for several months. Recently, a long-acting form of IFNα, pegylated IFNα 
(pegIFNα) has replaced the standard IFNα in therapies of chronic hepatitis C because it is 
more effective, supposedly due to inducing a long-lasting activation of IFN signaling 
pathways. IFN signaling in cultured cells, however, becomes refractory within hours, and 
little is known about the pharmacodynamic effects of continuously high IFNα serum 
concentrations. To investigate the behaviour of the IFN system in vivo, we repeatedly 
injected mice with IFNα and analyzed its effects in the liver. Within hours after the first 
injection, IFN signaling became refractory to further stimulation for up to two days. An 
analysis of the negative regulators of IFNα signaling revealed that suppressor of cytokine 
signaling 1 (SOCS1) is rapidly upregulated after IFNα administration and is likely 
responsible for the early termination of IFNα signaling. For the longlasting refractoriness, 
neither SOCS1 nor SOCS3 appear to be instrumental. Rather, USP18/UBP43, an inhibitor of 
Jak1 that was recently found to be involved in the control of hepatitis C virus (HCV) and the 
responsiveness to pegIFNα treatment is the key mediator. Our  results indicate that the 
current therapeutic practice using the long-lasting pegIFNα is not well adapted to the intrinsic 
properties of the IFN system and is not exploiting the full therapeutic potential of 
recombinant IFNα. 
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Introduction 
 
Since their discovery in 1957, type I interferons (IFNs) have become valuable and widely 
used clinical drugs [1, 2]. IFNα is used in the treatment of chronic hepatitis B and hepatitis C 
and of some forms of cancer, whereas IFNβ is effective for treating multiple sclerosis. With 
an estimated 3% of the global population affected, chronic hepatitis C (CHC) represents a 
major health concern since it can lead to liver cirrhosis and hepatocellular carcinoma [3]. 
Treatment of CHC with recombinant IFNα2 injected 3 times a week achieved sustained 
virological responses (SVR) in 15-20% of patients. A major improvement of the SVR to 35-
40% was observed by the addition of the broad-spectrum antiviral agent ribavirin [4]. The 
introduction of a pegylated, long-acting form of IFNα2 (pegIFNα2) further increased the 
SVR to 50-55% of patients [5, 6]. The reasons for the improved efficacy of pegIFNα are not 
known, but it is assumed that the constant high serum concentrations achieved with pegIFNα 
provide for un-interrupted anti-viral activity through a permanent stimulation of the IFN 
signaling pathways, whereas the serum concentrations of standard IFNα (with a elimination 
half-life of 4 to 10 h) decline below pharmacologically active levels in the second half of 
each 48 hour dosing interval [7, 8]. There is, however, no experimental evidence for the 
hypothesis that continuously high IFNα concentrations achieve a better activation of the 
IFNα induced antiviral effector systems. In fact, there is evidence against this hypothesis 
provided by cell culture experiments. 
 
It has been known for many years that cultured cells become refractory to IFN within 
hours and remain unresponsive for up to 3 days [9]. Maximal activation of the IFN signaling 
pathways is observed within the first two hours of IFN treatment. Continuous exposure to 
IFN results in a “desensitization” characterized by a return to pretreatment levels of 
interferon stimulated gene (ISG) transcription. Moreover, during the 48 to 72 h following the 
initial IFNα stimulation of the cells, any further IFN treatment fails to reinduce the 
transcription of ISGs. Currently it is not known, whether refractoriness also occurs during 
IFN therapies in patients. Such knowledge would be important for a rational design of IFN 
therapies. Dosing intervals shorter than the period of refractoriness would strongly reduce the 
efficacy of the injected IFN. Likewise, use of modified IFNα with a prolonged serum half-
life such as pegIFNα with the aim to achieve constant (peg)IFNα serum concentrations 
would not increase efficacy either, if the target cells remain unresponsive during most of the 
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dosing interval. Admittedly, the clinical experience showing an improved therapeutic 
response rate with pegIFNα argues against the occurrence of desensitization in patients. To 
investigate if the liver becomes refractory to IFNα in vivo, we investigated IFNα signaling in 
mice injected repeatedly with IFNα. 
 
Type I IFNs (IFNαs and IFNβ) exert their effects through the Jak-STAT signaling 
pathway [10]. Upon binding of IFNα to its cell surface receptor (IFNAR), the receptor-
associated tyrosine kinases Jak1 and Tyk2 become activated and phosphorylate tyrosines on 
the cytoplasmic tails of IFNAR chains 1 and 2. The phosphorylated receptors provide 
specific docking sites for signal transducers and activators of transcription (STAT) 1, 2 and 3. 
STATs are activated at the receptor-kinase complex by tyrosine phosphorylation [11, 12]. 
Activated STATs dissociate from the receptor and translocate to the nucleus where they act 
as transcription factors binding to specific regions in the promoters of IFN regulated genes 
(IRGs) [13]. In response to IFNα, STAT1-STAT2 heterodimers combine with IRF9 to form 
the transcription complex ISGF3, which binds to IFN stimulated response elements (ISREs) 
within the promoters of IRGs [14]. IFNα also activates homo- and heterodimers of STAT1 
and STAT3, which bind to gamma-activated sequence (GAS) response elements [15]. 
 
The activation of the Jak-STAT pathway is tightly controlled by several negative 
regulatory mechanisms. Suppressors of Cytokine Signaling (SOCS) 1 and 3 prevent STAT 
activation by inhibiting Jaks [16]. Further downstream, the protein inhibitor of activated 
STAT (PIAS) 1 binds to hypomethylated STAT dimers and inhibits STAT-DNA interaction 
[17-19]. STATs are deactivated by the nuclear phosphatase TC-PTP, followed by nuclear 
export [20]. Recently, ubiquitin specific peptidase 18 (USP18/UBP43) has been described as 
negative regulator in type I IFN signaling. USP18/UBP43 was originally identified as a 
protease cleaving ubiquitin-like modifier ISG15 from target proteins, but recently found to 
play a negative regulatory role independently of its ISG-deconjugating ability [21, 22]. 
UBP43 was reported to inhibit the activation of Jak1 by interfering with its interaction with 
IFNAR2 [23]. UBP43 deficient mice show a severe phenotype characterized by brain cell 
injury, poly-I:C hypersensitivity, and premature death [24, 25]. Interestingly, they are 
resistant to otherwise fatal cerebral infections with lymphocytic choriomeningitis virus and 
vesicular stomatitis virus [26]. USP18/UBP43 is elevated in livers of future non-responders 
to pegIFNα therapy [27]. Moreover, USP18/UBP43 silencing in cells with a replicating 
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chimeric HCV genome results in deregulation of STAT1 signaling and potentiation of IFNs 
ability to inhibit HCV-RNA replication [28]. 
 
To investigate the sensitivity of the liver during prolonged exposure to therapeutic 
concentrations of IFNα, we treated mice repeatedly with subcutaneous injections of IFNα 
and prepared extracts from their livers at various time points. IFNα signaling was 
investigated by phospho-STAT Western blots, gel shifts and quantification of IFNα target 
gene induction. In this manuscript we report that liver cells in vivo become refractory within 
hours after the first injection of IFNα and remain so for at least 2 days. A systematic analysis 
of the negative regulators of IFNα signaling surprisingly revealed that SOCS are responsible 
for the early inhibition of STAT phosphorylation within the first 2-4 h, but not for the 
observed long-term refractoriness. Rather, a long lasting upregulation of USP18/UBP43 was 
found to be responsible for the observed unresponsiveness of liver cells to prolonged IFNα 
exposure. Strikingly, in the absence of USP18/UBP43, even a strong upregulation of SOCS1 
did not prevent activation of STAT1 and STAT2, suggesting that SOCS1 inhibitory effects 
on IFNα signaling depend on USP18/UBP43. 
 
Taken together, our results demonstrate a refractoriness of IFNα signaling in vivo, 
and indicate that USP18/UBP43 plays a crucial role in the observed long-term desensitization 
of this signal transduction pathway in the mouse liver. Our findings have implications for the 
treatment of patients with chronic hepatitis C. Strategies aimed at restoring sensitivity to 
IFNα, for example targeting the upregulation of USP18/UBP43 in liver cells, could increase 
the efficacy of IFNα therapies. 
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Materials and Methods 
 
Animals.  
C57/BL6 mice were obtained from BRL (Biological Research Laboratories, Füllinsdorf, 
Switzerland), IL-10 deficient mice and Alb-Cre (strain name: B6.Cg-Tg(Alb-cre)21Mgn/J) 
transgenic mice were obtained from Jackson Laboratory, Bar Harbor, Maine 04609 USA. 
STAT3lox/lox mice and SOCS3lox/lox mice were described previously [29, 30]. STAT3lox/lox and 
SOCS3lox/lox mice were crossed to Alb-Cre transgenic mice to generate AlbCre+STAT3lox/lox 
and AlbCre+SOCS3lox/lox conditional knockout mice, respectively. All transgenic mice were 
viable and fertile. AlbCre-STAT3lox/lox and AlbCre-SOCS3lox/lox littermates were used as 
negative controls in the experiments. The generation of UBP43-/- mice on a FVB background 
was described previously [24, 31]. Genotyping for the Cre transgene was performed by PCR 
using the following nucleotides: Cre-1, 5’-CACCATTGCCCCTGTTTCACTATC-3’; Cre-2, 
5’-GCCAGGCGTTTTCTGAGCATAC-3’. Genotyping for the IL-10 deficient mice: IL10-1, 
5’GCCTTCAGTATAAAAGGGGGA CC-3’; IL10-2, 5’-GTGGGTGCAGTTATTGTCTTC 
CCG-3’; IL10-Neo, 5’-AATCCA TCTTGTTCAATGGCCGATC-3’. STAT3lox/lox genotyping 
was performed using the following primers: APRF 11 Up, 5’-CACCAACACATGCTA 
TTTGTAGG-3’; APRF 11 Down, 5’-CCTGTCTCTGACAGGCCATC-3’; APRF14 Down, 
5’-GCAGCAGAATACTCTACA GCTC-3’. SOCS3lox/lox genotyping was performed with: 
SR221, 5’-GAGTTTTCTCTGGGCGTCCTCCTAG-3’ and SR222, 5’-TGGTACTCGCTT 
TTGGAGCTGAA-3’. The animals were maintained on a 12 h day and 12 h night schedule 
with ad libitum access to food and drinking water. Mice were bred in a specific pathogen-free 
environment. Procedures with the animals were conducted with the approval of the animal 
care committee of the Kanton Basel, Switzerland. All UBP43-/- animals used in the studies 
were handled in accordance with guidelines of The Scripps Research Institute and procedures 
were approved by the Institutional Animal Care and Use Committee of the institute.  
6 to 8 weeks old male animals were used for all experiments. 
Animals were anaesthetized with isofluorane before blood drawing from tail vessels. The 
animals were euthanized by CO-narcosis. The resected liver lobes were immediately frozen 
in liquid nitrogen and kept at -70°C until further processing; one lobe of liver was frozen in 
Trizol for RNA isolation. The subcutaneous injections with PBS or mouse Interferon-alpha 
(mIFNα) were performed between 8.00 am and 5.00 pm. Recombinant mIFNα was 
purchased from CalBiochem (Juro Supply GmbH, Switzerland). PBS was from the 
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University Hospital Basel. Mouse IL-10 MAb was from Pierce (Perbio Science Switzerland 
SA, Lausanne) and was injected intraperitoneally at a dose of 100 μg 30 min prior to mIFNα 
injections. 
 
ELISA.  
To isolate serum from mIFNα or PBS injected C57/BL6 mice, 20 to 30 μl of blood from 
mouse tail was collected at different timepoints, kept 10 min at RT, 30 min at 4°C, then 
centrifuged at 2500 g for 20 min at 4°C. The supernatant was again spun at 1500 g for 10 
minutes at 4°C. For measurement of mIFNα, the serum was diluted 1:100 in dilution buffer 
and ELISA was performed using Mouse Interferon ELISA Kit (PIERCE, Perbio Science 
Switzerland SA, Lausanne) according to manufacturer’s instructions.  
For Measurement of mIL-10, the serum was diluted 1:4 in dilution buffer and ELISA was 
performed using the Quantakine Mouse IL-10 Immunoassay from R&D Systems Inc., 14 
McKinley Place NE, Minneapolis, MN 55413 according to manufacturer’s instructions. 
 
Protein preparation and Western Blot Analysis.  
30 to 50 mg of liver tissue were homogenized in a buffer containing 100 mM NaCl, 50 mM 
Tris pH 7.5, 1 mM EDTA, 0.1 % TX-100, 10 mM NaF, 1 mM PMSF, 1 mM Vanadate and 
1x Protease inhibitor cocktail tablets (Roche Diagnostics GmbH, Mannheim, Germany). 
Samples were kept at 4°C for 30 and centrifuged for 5 min at 15000 rpm at 4°C. Protein 
concentration was determined using Lowry (BioRad Protein Assay, Bio-Rad Laboratories 
AG, Reinach, Switzerland). 
10-20 µg of total protein from mouse liver lysates was loaded for SDS-PAGE and transferred 
onto a nitrocellulose membrane (Schleicher & Schuell, Switzerland). The membranes were 
blocked in 3% BSA/milk-0.1% Triton X-100 for 1 h, washed with Tris-buffered saline 
Tween-20 (TBST), and incubated with the primary antibody overnight at 4°C.  
Proteins were detected with primary antibodies specific to phospho–Stat1 (Tyr 701) (#9171), 
phospho–Stat3 (Tyr 705) (#9131, Cell Signalling, Bioconcept, Allschwil, Switzerland) and 
phospho–Stat2 (Tyr 689) (#07-224, Upstate, Lake Placid, NY). Stat1 p84/p91 (sc-346), Stat2 
(sc-950) and Stat3 (sc-482) were purchased from Santa Cruz (LabForce AG, Nunningen, 
Switzerland). Mouse monoclonal STAT1-ab (carboxy-terminus; #610186) was from 
Transduction Laboratories, BD Biosciences, Pharmingen. Anti-SOCS-1 (ab3691) was 
purchased from Abcam, Cambridge, UK. Anti-β-Actin was from Sigma, Sigma-Aldrich 
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Chemie GmbH, Steinheim, Germany. Blot-FastStain was obtained from Geno Technology, 
Inc. (Cell Concepts GmbH, Umkirch, Germany).  
After 3 washes with TBST, membranes were incubated with Anti-rabbit antibody-HRP and 
anti-mouse antibody-HRP obtained from Cell Signaling (Bioconcept, Allschwil, Switzerland) 
and signals were detected with SuperSignal West Pico Chemiluminescent Substrate 
(PIERCE, Perbio Science Switzerland SA, Lausanne, Switzerland). Alternatively, signals 
were detected using the Odyssey Infrared Imaging System from LI-COR after incubation 
with infrared fluorescent secondary goat anti-mouse (IRDye 680) or anti-rabbit (IRDye 800) 
antibodies (both from LI-COR Biosciences) for 1 h at room temperature. The infrared image 
was obtained in a single scan and the signal was quantified using the integrated intensity. 
 
EMSA.  
Nuclear extracts from 150 - 200 mg liver tissue were prepared as previously described [32]. 2 
μl of nuclear extract (= 5 to 10 ng protein sample) aliquots were incubated with a 32P- 
radiolabeled mutated serum-inducible element oligonucleotide designated m67-hSIE with the 
sequence 5'-CATTTCCCGTAATCAT-3' for STAT1 and STAT3 or the interferon stimulated 
response element (ISRE) probe derived from the interferon stimulated gene 15 promoter 
(ISRE-015) with the sequence 5'- GAAAGGGAAACCGAACTGAAGC-3' [33]. For 
supershift experiments, 1μl of antibody specific for STAT1, STAT2 or STAT3 was added to 
the gel shift incubation reactions.  
The samples were loaded on a 5% non-denaturing polyacrylamide gel and electrophoresis 
was performed for 4 h at 400 V at 4°C. The gel was dried and visualized by autoradiography.  
 
RNA Isolation and Northern Blot Analysis. 
RNA was purified using Trizol (Tri Reagent) provided by Molecular Research Center, Inc, 
(Lucerna Chem AG, Lucerne, Switzerland). RNA was aliquoted and stored at -75°C. The 
denatured RNA was separated on a 1.2% Agarose Formaldehyde MOPS gel and transferred 
to a Hybond-N+ Nylon membrane (Amersham Pharmacia Biotech Europe GmbH, 
Dübendorf, Switzerland) by capillary diffusion using 20x SSC buffer. The membranes were 
hybridized to 32P labeled SOCS1 and SOCS3 probes at 65°C for overnight in the Quickhyb 
oven (Stratagene Europe, Switzerland) and washed twice with 2x SSC, 0.2% SDS at 42°C for 
15 min, then twice with 0.2x SSC, 0.1% SDS at 42°C for 10 min. Results were visualized by 
autoradiography.  
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Real-time RT-qPCR.  
RNA was purified from frozen liver tissue (< 20 mg) with Nucleo Spin RNA II kit 
(Macherey-Nagel, Düren, Germany) according to manufacturer's instructions. RNA was 
stored at -75°C. RNA was reverse transcribed by Moloney murine leukemia virus reverse 
transcriptase (Promega Biosciences, Inc., Wallisellen, Switzerland) in the presence of random 
hexamers (Promega) and deoxynucleoside triphosphate. The reaction mixture was incubated 
for 5 min at 70°C and then for 1 h at 37°C. The reaction was stopped by heating at 95°C. 
SYBR-PCR was performed based on SYBR green fluorescence (SYBR green PCR master 
mix; Applied Biosystems, Foster City, CA). The ΔCT value was derived by subtracting the 
threshold cycle (CT) value for mouse ribosomal protein L19 (mRPL19), which served as 
internal control, from the CT values for SOCS1, SOCS3, and USP18. Primers were designed 
across exon-intron junctions to prevent influence from genomic DNA amplification. Primers 
for mRPL19 were ATCCGCAAGCCT GTGACTGT and TCGGGCCAGGGTGTTTTT, for 
mSOCS1 GTGGTTGTGGAGGGTGAG ATG and GGGATGAGGTCTCCAGCCA, for 
mSOCS3 were CCTTTCTTATCCGCGACAGC and CGCTCAACGTGAAGAAGTGG, for 
USP18 were CGTGCTTGAGAGGGTCATTTG and GGTCCGGAGTCCACAACTTC. All 
reactions were run in duplicate using the ABI 7000 Sequence Detection System (Applied 
Biosystems). mRNA expression level between T0 and Tn was expressed as a fold increase 
according to the formula 2ΔCT(T0)-ΔCT(Tn). mRNA expression levels of transcripts were 
calculated relative to GAPDH from the ΔCT values using the formula 2-ΔCT. 
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Results. 
 
Pharmacokinetics of mouse IFNα 
We first studied the pharmacokinetics of subcutaneously administred mIFNα by measuring 
the serum concentration in mice at different time points after injection. A single dose of 1000 
IU/g body weight resulted in a fast increase to 10000 to 12000 pg/ml in 60 min followed by a 
decline to pretreatment levels 8 h after the injection (Figure 1A). The serum concentration 
half-life was 4-5 h. To achieve constantly elevated serum concentrations as obtained by 
pegylated human IFNα, we then used a priming dose of 1000 IU/g body weight mIFNα 
followed by repeated injections of 300 IU/g body weight to obtain IFNα serum 
concentrations between 6000 and 10000 pg/ml for up to 16 h (Figure 1B). 
 
IFNα signaling in the mouse liver 
To study the IFNα induced activation of the Jak-STAT pathway and its termination by 
negative regulators we sacrified mice at different time points after mIFNα injections and 
analyzed the activation of pathway components in liver extracts. To simulate the clinical 
setting of treatment of patients with chronic hepatitis C with standard IFNα, where IFNα 
serum concentrations decline below pharmacologically active levels in the second half of 
each 48 h dosing interval [7, 8], mice were given a second injection of mIFNα 8 h after the 
first injection, when serum concentrations were again at baseline levels (Figure 2A). After the 
first injection, a strong phosphorylation of STAT1 was observed within 30 minutes. STAT1 
activation reached its maximum after 1 to 2 h, and then declined within 4 h after the initial 
injection (Figure 3A). Surprisingly, the second injection at time point 8 h induced very little 
STAT1 phosphorylation, although the amount of STAT1 in the liver was strongly induced by 
the first IFNα injection (Figure 3A). Moreover, in a long-term experiment with 7 injections 
given every 8 h, we did not observe restoration of IFNα sensitivity for up to 48 h (data not 
shown). To control for circadian variations and stress, a number of mice were injected at the 
same time points with PBS (left panel of Figure 3A). Indeed, there was a variation of STAT1 
expression during the 16 h of the experiment, but mIFNα induced much higher expression 
levels. As expected, no STAT1 phosphorylation was induced by PBS. 
 Treatment with mIFNα also resulted in STAT3 phosphorylation in liver cells. The 
maximal activation occurred at 2 h and, contrary to STAT1, the activation pattern was similar 
after the second injection. There was no upregulation of STAT3 expression after mIFNα 
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treatment (Fig 3A).  
 These results were confirmed by electrophoretic mobility shift assay (EMSA). 
Phosphorylated STATs form dimers that can translocate into the nucleus and bind specific 
response elements such as the GAS element. The first injection of mIFNα induced a strong 
STAT1 homodimer gel shift using the m67-SIE oligonucleotide (a GAS element), whereas 
the second injection had little effect (Figure 3B). On the other hand, STAT3 homodimers 
were strongly induced after both the first and the second injection. IFNα also induces ISGF3, 
a heterotrimeric transcription factor composed of activated STAT1 and STAT2, and IRF9. 
ISGF3 activity was also induced only after the first, but not after the second injection of 
mIFNα (Figure 3C). 
 Taken together, these data indicate that IFNα induced Jak-STAT signaling in the mouse 
liver is transient and furthermore refractory to a second IFNα dose applied 8 h later, at a time 
point when serum concentrations of IFNα have returned to pretreatment levels. 
 We hypothesized that this surprisingly long-lasting refractoriness of the signal 
transduction pathway could be a reason why anti-HCV therapies with standard IFNα had 
limited success, because the IFNα injected 48 h after the previous dose could encounter a still 
refractory signal transduction system. Since pegylated IFNαs with their long half-life are 
more potent, we next analyzed if the continuous presence of high serum concentrations of 
IFNα could prevent the induction of refractoriness. 
 Since pegylated mouse IFNα is not available, mice were injected with 1000 IU/g of 
mIFNα as a priming dose, followed by four injections of 300 IU/g of mIFNα as maintenance 
doses. With this regimen, steady concentrations of 6000-10000 pg/ml were maintained for up 
to 16 h mimicking the pharmacokinetics of pegIFNα in patients (Figure 1B). Again, mice 
were sacrificed at different time points (Figure 2B) and IFNα signaling was analyzed with 
Western blots and EMSAs. There was strong but transient phosphorylation of STAT1 and 
STAT2 in the first 2 h after initial injection of mIFNα, but subsequent injections failed to 
induce further STAT1 phosphorylation, although STAT1 expression was highly upregulated 
(Figure 4A). Accordingly, the ISGF3 gel shift signal was only detectable at time point 1 hour 
after the initial injection (Figure 4B). Contrary to STAT1 and STAT2, activation of STAT3 
was prolonged in continuous presence of mIFNα (Figure 4A).  
 In conclusion, IFNα treatment of mice induces a strong initial activation of signaling in 
the liver followed by a rapid inhibition of STAT1 and STAT2 activation and a persistent 
refractoriness even in the continuous presence of IFNα. 
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Negative regulation of IFNα signaling by SOCS1 and SOCS3 in the mouse 
liver 
Within hours, IFNα induces the transcriptional upregulation of SOCS1 and SOCS3, two 
negative regulators of the Jak-STAT pathway that are instrumental for the termination of 
STAT phosphorylation at the receptor-kinase complex [16]. We therefore tested if the long-
term refractoriness of the IFN signal transduction system in mouse liver would be due to a 
continuous high-level expression of SOCS proteins. SOCS1 mRNA was detectable after 1 h 
until 3 h, but not during the later time points despite the continuously high serum 
concentrations of mIFNα (Figure 4C). SOCS1 protein was upregulated after 3 h, but was 
barely detectable at later time points (Figure 4D). Induction of SOCS3 showed a different 
pattern. In continuous presence of high mIFNα levels, SOCS3 mRNA expression was 
induced after 1 hour and remained high during the entire 16 h (Figure 4C). The observed 
SOCS3 upregulation could be caused by the prolonged STAT3 activation, because STAT3 is 
a transcriptional inducer of the SOCS3 gene [34]. And since SOCS3 is known to inhibit 
IFNα induced STAT1 phosphorylation [35], the prolonged in vivo refractoriness of the IFN 
system could indeed be due to the observed SOCS3 induction. 
 
The role of IL-10, STAT3 and SOCS3 in long-term refractoriness of IFNα 
signal transduction 
Because the IFNα receptor-kinase complex is inhibited by SOCS3, the signals that maintain 
high SOCS3 expression cannot be transmitted through the IFN receptor, but have to be 
derived from a cytokine receptor that is not inhibited by SOCS3. IL-10 was an attractive 
candidate, because it is a strong activator of STAT3 and inducer of SOCS3, and, importantly, 
the IL-10 receptor is not inhibited by SOCS3 [36]. We therefore measured mIL-10 serum 
levels upon a single injection of mIFNα (Figure 5A, upper panel) or in response to multiple 
injections of mIFNα (Figure 5A, lower panel) and indeed found strong induction of IL-10. 
After a single mIFNα injection, the IL-10 serum concentrations were transiently elevated, but 
in the setting of multiple injections with the resulting constantly elevated serum IFNα 
concentration, IL-10 levels remained high. Apparently, the IFNα induced pathways that 
stimulate IL-10 expression do not become refractory.  
To clarify the role of IL-10 in the observed refractoriness of IFNα signaling, we used 
IL-10 deficient mice and injected them with two doses of mIFNα given 8 h apart. STAT1 
activation in these mice was assessed one hour after the first (time 1h) and one hour after the 
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second injection (time 9h) (Figure 5B). Contrary to our expectations, the IFNα signal 
transduction became refractory in the IL-10 deficient mice as well. While the first mIFNα 
injection induced a strong phospho-STAT1 signal after one hour, the second injection 8 h 
later had little effect on STAT1 phosphorylation (time point 9h) both in the wildtype and the 
IL-10 deficient mice (Figure 5B). The same results were observed when wildtype mice were 
injected with neutralizing IL-10 antibodies 30 minutes before the mIFNα injections (data not 
shown). Of note, there was no decrease of STAT3 phosphorylation in the IL-10 deficient 
mice. We conclude that the elevated serum IL-10 concentrations induced by mIFNα 
injections are not necessary for the prolonged activation of STAT3 and the induction of a 
refractory state. 
We then used hepatocyte specific STAT3 and SOCS3 deficient mice to test if the 
activation of STAT3 or the upregulation of SOCS3 is required for the induction of the 
refractory state. To that aim, we crossed STAT3lox/lox mice [29] and SOCS3lox/lox mice [30] 
with albumin-Cre transgenic mice [37]. The refractoriness of the IFNα signal transduction 
pathway was then assessed in these mice during repeated mIFNα injections. Neither the 
deletion of STAT3 nor SOCS3 could restore responsiveness to the second injection of 
mIFNα (Figure 5C), disproving the hypothesis that STAT3 and SOCS3 are mediators of 
IFNα refractoriness.  
 
Prolonged upregulation of USP18/UBP43 is responsible for IFNα 
refractoriness 
Recently USP18/UBP43 emerged as an important negative regulator in type I IFN signaling 
[21-23, 28]. We therefore measured USP18 mRNA levels in the liver of wildtype, IL-10 
deficient, and hepatocyte specific STAT3 and SOCS3 deficient mice after injections of 
mIFNα. In all these mice, USP18 mRNA was strongly induced one hour after the first 
injection, and also 1 hour after the second injection (time point 9h) (Figure 6A). In the setting 
of repeated injections (Figure 2B) with constantly elevated serum IFNα concentrations, 
USP18 mRNA was upregulated one hour after the first injection, and then stayed more than 5 
fold induced at all later time points for up to 16 h (data not shown). This expression profile 
would be consistent with an important role of USP18/UBP43 for the induction and 
maintenance of a refractory state of the IFNα signaling pathway in the liver. 
We therefore assessed IFNα signaling in UBP43 deficient mice [24, 25]. After the 
first injection of mIFNα, UBP43-/- mice showed an even stronger STAT1 phosphorylation in 
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the liver than the wildtype controls (Figure 6B and 6C). More importantly, UBP43-/- mice 
were responsive to the second injection of mIFNα. At time point 9h, one hour after the 
second injection, the phospho-STAT1 and phospho-STAT2 signals were as strong as those 
found in wildtype mice one hour after the first injection (Figure 6B and 6C). Moreover, the 
phospho-STAT1 signals at 9h were stronger than those found at time points 4h and 8h after 
the first injection, demonstrating a stimulatory effect of the second mINFα dose. We 
conclude that USP18/UBP43 is required for the induction of IFNα refractoriness in the liver 
of mice.  
 Finally, we assessed SOCS1 expression in wildtype and UBP43 deficient mice. 
Compared to wildtype mice, SOCS1 mRNA was hyper-induced in UBP43-/- mice one hour 
after the first mIFNα injection, and at time point 9h, when SOCS1 mRNA was no longer 
induced in wildtype mice, it was even further induced in UBP43-/- mice (Figure 6D). This 
finding is important, because at time point 9h all IFNα stimulated STATs showed a strong 
phosphorylation (Figure 6B). We therefore conclude that in the absence of USP18/UBP43, 
SOCS1 cannot inhibit IFNα induced phosphorylation and activation of STAT1, STAT2 and 
STAT3. 
 
 
 
 87 
Discussion 
 
Desensitization of the IFN signal transduction pathways during prolonged exposure of 
cultured cells to IFNα has been described more than 20 years ago [9], but very little was 
known if and to what extent IFN refractoriness occurs in animals and humans. Infections that 
activate the endogenous type I IFN system usually last for several days and weeks, and even 
years, as for example chronic viral hepatitis. Intuitively, one would assume that the IFN 
system remains sensitive and effective in at least all those situations where the infection is 
finally cleared. In the present work, however, we present strong evidence that the IFNα 
signaling pathways in mouse liver become unresponsive within hours after the first 
application of mIFNα and remain so for at least two days. Refractoriness was observed in 
mice that received multiple injections and had sustained IFNα serum concentrations between 
6000 and 10000 pg/ml, i.e. concentrations that induce a strong STAT1 activation before the 
initiation of the refractory state (see 30 minutes time points in Figures 1A and 3A). 
Refractoriness was also observed in mice that received a second injection after 8 h, thus at a 
time when IFNα serum concentrations were again at pretreatment levels. The refractory state 
was characterized by an almost complete inhibition of tyrosine phosphorylation of STAT1 
and STAT2. The residual STAT1 and STAT2 activation documented by the faint phospho-
STAT1 and –STAT2 signals detected in Western blots did not induce target genes such as 
SOCS1, possibly also because the IFNα induced increase of total STAT1 and, to a lesser 
extent, also STAT2 protein amount further reduced the ratio of phosphorylated to 
unphosphorylated STATs. The induction pattern of SOCS1 is consistent with its well-known 
role in the early negative feedback regulation of IFNα signaling. Since SOCS1 is not 
expressed to any detectable degree at later timepoints (Figure 4C and 4D), SOCS1 clearly can 
not be responsible for the long-lasting inhibition of STAT1 and STAT2 phosphorylation. 
 STAT3 can be activated by IFNα to form transcriptionally active homodimers or 
STAT1-STAT3 heterodimers [38]. Interestingly, STAT3 showed an activation pattern that 
differed from STAT1 and STAT2. STAT3 was maximally phosphorylated after 1 hour, and 
remained activated during the entire time course of the multiple injection experiment (Figure 
4A). Accordingly, SOCS3, a known target gene of STAT3, was also upregulated during the 
entire experiment (Figure 4C). However, if we assume that SOCS3 inhibits IFNα signaling in 
the mouse liver in the same way as has been reported in cells [35], then the continuous 
activation of STAT3 could not be due to IFNα signals. Instead, additional cytokine signals 
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would have to stimulate STAT3 activation. Interleukin-10 was an attractive candidate, 
because it is a strong activator of STAT3 but its receptor-kinase complex is not inhibited by 
SOCS3 [36]. Furthermore, IL-10 inhibits expression of IFNα induced genes in monocytes by 
suppressing STAT1 phosphorylation [39] and attenuates IFNα induced STAT1 
phosphorylation in the mouse liver [40]. However, the induction of a refractory state in IL-10 
deficient mice proves that IL-10 is not necessary for IFNα refractoriness (Figure 5B). 
Likewise, liver specific STAT3 and SOCS3 deficient mice were still refractory to prolonged 
IFNα stimulation (Figure 5C), a finding that further disproves an important role of the 
STAT3-SOCS3 axis for the induction of IFNα refractoriness. 
 USP18/UBP43 blocks Jak1 phosphorylation through a specific interaction with the 
IFNAR2 subunit of the receptor and thereby attenuates IFN signaling [23]. USP18/UBP43 is 
induced by IFNα [41, 42] and provides a negative feedback loop that restricts IFNα signals. 
In the liver, USP18/UBP43 shows a low constitutive expression [21], but we found a strong 
upregulation after treating mice with subcutaneous injections of mIFNα (Figure 6A). 
Contrary to SOCS1 with its transient upregulation after the first injection of mIFNα (Figure 
4C), USP18/UBP43 was still highly induced 1 hour after a second injection of mIFNα 
(Figure 6A). Since the apparent half-life of USP18 mRNA is 3-4 h [43], this prolonged up-
regulation of USP18 was probably caused by the weak STAT1 activity observed after the 
second injection of mIFNα. Whatever the mechanism that maintains its prolonged up-
regulation, USP18/UBP43 is clearly important for the induction of IFN refractoriness, 
because no such desensitization to mIFNα was observed in USP18/UBP43 deficient mice 
(Figure 6B). 
 USP18/UBP43 restricts the IFNβ induced upregulation of more than 700 genes, 
amongst them SOCS1 [44]. Indeed, SOCS1 was highly expressed in the liver of UBP43-/- 
mice injected with mIFNα (Figure 6D). Interestingly, in UBP43-/- mice SOCS1 expression 
was further increased after the second injection of mIFNα. Despite the very high expression 
of SOCS1 at the time point 9 h, the second injection of mIFNα induced a strong 
phosphorylation of STAT1 in UBP43-/- mice. This surprising result provides strong genetic 
evidence that the inhibitory activity of SOCS1 requires the presence of USP18/UBP43. 
 Our results have potentially important consequences for the treatment of patients with 
chronic viral hepatitis with recombinant IFNα. If we assume that the human liver also 
becomes refractory to IFNα within hours after the first injection of recombinant IFNα and 
that the liver cells remain unresponsive to further IFNα stimulation, then the current practice 
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of injecting pegylated IFNα (pegIFNα) with its very long half-life would lack a 
pharmacodynamic rational, because during most of the dosing interval pegIFNα would not 
have any effect on its prime target cells, the HCV infected hepatocytes, but could still have 
unwanted secondary effects in other organ systems such as the central nervous system, the 
skin, the muscles and the joints. Clearly, the mechanisms underlying the increased efficacy of 
pegIFNα compared to standard IFNα remain unsolved. The results presented here should 
therefore motivate an in-depth analysis of the pharmacodynamic effects of the current 
pegIFNα treatments in the livers of patients with chronic hepatitis C. 
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Figures 
 
 
 
Figure 1. Pharmacokinetics of subcutaneous mIFNα injection into mice. 
 
(A) Serum concentrations of mIFNα after subcutaneous injection of a single dose of 1000 
IU/g. 
The profile was obtained from two C57BL6 mice receiving mIFNα by subcutaneous (s.c.) 
injection. The peak of serum concentration was reached one hour after the injection. After 8 
h, the concentration of mIFNα was back to pretreatment levels. The error bars represent the 
standard error of the mean.  
(B) mIFNα serum concentration after multiple mIFNα injections. Two C57BL6 mice were 
injected s.c. with 1000 IU/g body weight of mIFNα as a priming dose, and four times with 
300 IU/g body weight as maintenance doses every three hours. Sera were collected 
immediately before each injection and one hour after each injection. The black arrows 
indicate time points of mIFNα injections.  
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Figure 2. Schematic representation of the experimental outline for the analysis of IFNα 
signaling in mouse liver. 
 
(A) Schematic diagram showing the time course of the experiment with two injections of 
mIFNα. The interval between the injections is 8 h and the vertical bars in the diagram 
indicate the time points of animal sacrifice and liver resection. 
(B) Schematic diagram showing the time course of the multiple injection experiment. Mice 
were injected with 1000 IU/g of mIFNα as a priming dose, followed by four injections of 300 
IU/g of mIFNα as maintenance doses. The vertical bars in the diagram indicate the time 
points of animal sacrifice and liver resection. 
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Figure 3. Activation of Jak/STAT signaling in response to two injections of mIFNα. 
 
(A) C57BL6 mice were treated with two injections of mIFNα (1000 IU/ml, right panel) or 
PBS (left panel) as indicated in the time course in Figure 2A. IFN-α-induced tyrosine 
phosphorylation of STAT1 and STAT3 was assessed by immunoblotting of liver whole cell 
extracts. Blots were stripped and reprobed for total STAT1 and STAT3 and for actin as a 
loading control. 
(B) DNA binding of STAT1 and STAT3 homo- and heterodimers upon stimulation with 
mIFNα. Nuclear extracts of liver cells obtained at different time points from two times 
mIFNα injected mice were analyzed in electrophoretic mobility shift assays with the SIE-
m67 oligonucleotide probe. Extract from mouse liver 1 hour after mIFNα stimulation was 
used as positive control (lane A). Antisera specific to STAT1 (lane B) and STAT3 (lane C) 
were used to shift STAT1 homodimers, STAT3 homodimers and STAT1:STAT3 
heterodimers (marked with arrows).  
(C) DNA binding of ISGF3 in liver cells after two times mIFNα treatment. Liver Nuclear 
extracts of C57/BL6 mice were analyzed in EMSAs using ISRE oligonucleotide probes. 
Extract from mouse liver 1 hour after mIFNα stimulation was used as a positive control (lane 
A) and the ISGF3 band was shifted using antiserum specific for STAT1 (lane B) and STAT2 
(lane C). 
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Figure 4. Activation of Jak/STAT signaling in response to continuous mIFNα treatment. 
 
(A) Phosphorylation of STAT1, STAT2 and STAT3 was assessed by Western Blot using 
whole cell extracts of mouse liver after mIFNα treatment. Blots were stripped and reblotted 
for total STAT1/STAT2/STAT3 and stained with Blot-FastStain as loading control. 
(B) DNA binding of ISGF3 in liver cells after continuous mIFNα treatment. Liver Nuclear 
extracts of C57/BL6 mice were analyzed in EMSAs using ISRE oligonucleotide probes. 
Nuclear extract from mouse liver 1 hour after mIFNα stimulation was used as a positive 
control (lane A) and shifts of the ISGF3 band were performed by using antiserum specific for 
STAT1 (lane B) and STAT2 (lane C). 
(C) SOCS1 and SOCS3 mRNA expression level in the continuous presence of mIFNα. 
Total RNA from mIFNα injected mice was prepared and subjected to Northern Blot analysis 
for SOCS1 and SOCS3 mRNA expression. Equal loading of the gel was verified by ethidium 
bromide staining and comparing the intensities of the 28S rRNA and 18S rRNA bands. 
(D) SOCS1 protein expression was determined by Western blot using whole cell extracts of 
mouse liver after mIFNα treatment. 
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Figure 5. IL-10 serum concentrations and Jak-STAT signaling in mice deficient of IL-10, 
STAT3 or SOCS3. 
 
(A) Upper panel: Injection of a single subcutaneous dose of mIFNα (1000 IU/g body weight) 
induces a transient increase in IL-10 serum concentrations. The level of mIL-10 as 
determined by ELISA is shown in the graph. 
Lower panel: Repeated injections of 300 IU/g body weight of mIFNα every 4 h after an 
initial priming dose of 1000 IU/g body weight induces constantly high mIL-10 serum 
concentrations. During mIFNα maintenance doses, the concentration of mIL-10 stays at 
levels around 40 pg/ml (see graph with black triangles). As negative control, the level of 
serum mIL-10 was determined in a mouse multiply injected with PBS (see graph with black 
squares). 
(B) Two times mIFNα injection experiment in IL-10 deficient mice. 
Upper panel: Schematic representation of the experimental design with two mIFNα injections 
performed 8 h apart. Animals were sacrificed at time point 0 h (control), 1 hour and 9 hour (1 
hour after the second injection). Immunoblotting for pSTAT1/STAT1 and pSTAT3/STAT3 is 
shown for C57/BL6 wild-type (wt) mice and for IL-10-/- animals.  
(C) Two times mIFNα injection experiment in mice with liver specific knockout of STAT3 
and SOCS3. Immunoblotting for pSTAT1/STAT1, pSTAT3/STAT3 and actin is shown for 
wt C57/BL6 mice and for SOCS3lox/loxCre+ and STAT3lox/loxCre+ animals.  
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Figure 6. Role of USP18/UBP43 in IFNα refractoriness. 
 
(A) Real time rt-qPCR analysis of USP18 mRNA expression in response to the first and the 
second injection of mIFNα. Total RNA was isolated from the livers of wt, IL10-/-, 
SOCS3lox/loxCre+ and STAT3lox/loxCre+ animals at the timepoints 0, 1h, 9h (1h after the second 
injection). Data are plotted as the amount of USP18 mRNA relative to mRPL19 and are the 
means (+/- SEM) of two animals per timepoint for the knockout mice and 4 animals per 
timepoint for the wt mice. 
(B) Activation of the Jak/STAT signaling pathway in response to the first and the second 
injection of mIFNα in wildtype and USP18/UBP43 deficient mice. Phosphorylation of 
STAT1, STAT2 and STAT3 was assessed by Western Blot using whole cell extracts of 
mouse liver from wt and USP18/UBP43-/- mice. Blots were stripped and reblotted for total 
STAT1/STAT2/STAT3 and for actin as loading control. 
(C) Bar diagram of phospho-STAT1 signals in wild-type and USP18/UBP43 deficient mice. 
Phospho-STAT1 and actin signals from figure 6B were quantified using the Odyssey Infrared 
Imaging System. The integrated intensities of phospho-STAT1 signals were divided by the 
actin values. The y-axis displays arbitrary units. 
(D) Real time rt-qPCR analysis of SOCS1 mRNA expression in response to the first and the 
second injection of mIFNα in 2 wildtype and in 2 USP18/UBP43 deficient mice. Shown are 
mean values (with SEM) of the ratio of SOCS1 mRNA over mRLP19. 
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5. Discussion  
 
5.1. Interferon regulated gene expression in the liver determines 
response to treatment in chronic hepatitis C 
 
Response patterns to pegIFNα/ribavirin treatment in patients with CHC range from a 
complete non-response to a very rapid virological response (RVR) with undetectable 
HCV-RNA in the serum as soon as 4 weeks after treatment initiation. It is well known 
that 50-60% of patients infected with HCV genotype (GT) 1 and 20% of GT 2/3 
patients are not cured by current standard treatment. To learn more about possible 
mechanisms underlying differential response of HCV infected patients to IFN 
therapy, we investigated IFN-induced signaling and ISG induction in paired liver 
biopsies collected from patients with CHC before (B-1) and during (B-2) therapy with 
pegIFNα. In addition to the liver samples, blood for PBMC isolation was collected 
before (PBMC-1) treatment and 4 hours after (PBMC-2) the first pegIFNα injection. 
Virological response early in the course of treatment is an excellent predictor of later 
sustained virological response (SVR), with the RVR being followed by an SVR in 
85% of cases. Therefore, we divided the 16 patients from which paired liver biopsy 
samples were obtained into rapid responders (RRs) and non-RRs according to their 
response at week 4 of treatment.  
 
Besides infecting human patients, HCV can also infect chimpanzees making 
them the only available animal model for in vivo studies. It is known that 
chimpanzees chronically infected with HCV have hundreds of ISGs induced in the 
liver (143). Interestingly however, all chimpanzees are non-responders to IFN based 
treatment (145) and therefore not suitable for studying the molecular basis underlying 
the treatment failure. Injection of pegIFNα into HCV infected chimpanzees does not 
result in an increase of ISG expression in liver, unlike in PBMCs, which respond to 
IFN normally. This finding and the fact that IFN responsive genes in PBMCs are 
known to differ from ISGs in liver tissue (146) underline the importance of tissue-
specific differences when studying HCV infection in humans. Data obtained from 
human HCV patients demonstrated that future non-responders present with pre-
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activation of the endogenous IFN system in the liver (131). In contrast to the 
observation that PBMCs in chimpanzees normally respond to IFN, a human study 
reported a blunted response to IFNα in PBMCs of patients with a relative absence of 
viral response to treatment (178). 
 
In our analysis of the 16 paired liver biopsy samples, collected before and 4 
hours after the first pegIFNα injection, pegIFNα induced STAT1 phosphorylation 
was stronger in RR than in non-RR patients when analyzed by Western blot.  There 
was a considerable overlap between the two response groups, possibly due to 
heterogeneity of cells in the liver protein extract. Three out of six non-RR patients 
showed a 2-fold increase in the p-STAT1 signal in the B-2 sample if compared to B-1 
(Figure 4A, see PNAS manuscript). A more prominent difference between the two 
response groups was evident from the immunohistochemical analysis of liver tissue 
(Figure 4B, see PNAS manuscript). In RR patients, there was no initial staining for 
phosphorylated STAT1 in hepatocyte nuclei, whereas administration of pegIFNα 
induced STAT1 nuclear translocation. In non-RR samples, pegIFNα strongly induced 
nuclear STAT1 translocation in Kupffer cells, whereas no increase in hepatocytes 
could be observed. Interestingly, most non-RR patients had nuclear phospho-STAT1 
already present in pre-treatment B-1 biopsies. This is consistent with the observation 
that ISG transcripts are upregulated in pre-treatment biopsies of later non-responders 
(131). The analysis of IFN-regulated gene expression using Affymetrix U133 2.0 Plus 
microarrays revealed a pronounced difference in the number of genes regulated in the 
two response groups. 252 transcripts were significantly up- or down-regulated by >2-
fold in the livers of RRs, whereas only a very low number of transcripts were induced 
in response to pegIFNα in the liver of non-RR patients in response to pegIFNα 
(Figure 1A, see PNAS manuscript). In contrast, many more genes were regulated in 
PBMCs in both patient groups and the difference between the two response groups 
was far less pronounced than in the liver, arguing for strong local defects of IFNα 
signaling in the liver (Figure 1C, see PNAS manuscript). To allow the identification 
of a subset of genes that best predicts the outcome, which we defined as rapid 
response versus non-response at week 4, we performed a supervised classifier 
analysis of the array data. For PBMC samples the analysis did not identify a subset of 
genes that could predict the treatment outcome, further corroborating that PBMCs are 
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not a good surrogate marker for the differences between RRs and non-RRs taking 
place in the liver (Figure S3, see PNAS manuscript). In contrast, a subset of 16 genes 
was identified in the liver B-2 samples that predicted response to treatment and an 
even better prediction was possible in the pre-treatment biopsies B-1. Remarkably, 22 
of the 29 genes were ISGs. Taken together, clinical response to pegIFNα/ribavirin 
therapy was found exclusively in patients who have no pre-activation of the 
endogenous IFN system in the B-1 sample. The findings in non-responders support 
the interesting concept that activation of the endogenous IFN system in CHC not only 
is ineffective in spontaneously clearing the infection, but may also impede the 
response to therapy, most likely by inducing a refractory state of the IFN signaling 
pathway.  Evidently, measures aiming at preventing or reversing pre-activation of 
ISGs in the HCV infected liver, if applied before IFN treatment initiation, could 
restore IFN responsiveness and effectiveness in all HCV infected patients.  
 
 
5.2. Correlation of HCV genotype with ISG pre-activation in the liver 
and involvement of viral sensory pathways in inducing type I IFNs 
 
Signaling through the Jak-STAT pathway is crucial for most of the known effects of 
IFNs, therefore inhibition of this pathway might well be a central effect target of 
HCV. Indeed, our laboratory has previously reported an inhibition of IFN induced 
binding of activated STATs to their cognate response elements by HCV proteins in 
cell lines and transgenic mice. Interestingly, this inhibition was not associated with 
induction of well-known Jak-STAT signaling inhibitors, but with an HCV induced 
upregulation of the catalytic subunit of PP2A finally resulting in STAT1 
hypomethylation (118). HCV has a striking capability to establish a chronic infection, 
and attenuation of IFN signaling might be an important advantage of the virus early in 
the course of infection. Epidemiological studies suggest that 20-30% of patients 
resolve acute HCV infection without treatment suggesting that innate and/or adaptive 
immune responses are indeed capable of controlling the outcome of the infection. 
Evidently, HCV cannot block IFN signaling completely as demonstrated by the 
success of therapies based on the application of pharmacological doses of 
recombinant IFNα in some but not all patients with CHC. It is not well understood, 
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which host factors determine the response to IFN therapy. Likewise, the mechanisms 
leading to pre-activation of the Jak-STAT pathway in later non-responders and how 
the observed pre-activation is connected to the refractoriness of the IFN system 
requires further investigations. Why does the high level of ISG induction in the non-
RR patient group not result in a spontaneous clearance of the virus? Is it because of 
defective IFN signaling or IFN effector systems in virus infected cells? Furthermore, 
it remains to be elucidated why therapeutic IFN is ineffective in patients with a pre-
activation of the endogenous IFN system. Is their IFN system already maximally 
induced (all receptors saturated) and effector mechanisms are inhibited by the virus or 
does perhaps the upregulation of negative regulators of IFN signaling (SOCS, 
USP18/UBP43 etc.) prevent any further stimulation of the Jak-STAT signaling 
pathway? The negative effect of a pre-activation of the IFN system could be the result 
of a relative desensitization and refractoriness of the IFNα signal transduction 
pathways. 
 
Interestingly, patients infected with HCV GT2 and GT3 very often show a 
favorable response to IFN-based treatment. Our finding that patients infected with 
HCV GT1/4 more often have an induced endogenous IFN system might therefore 
provide a plausible reason for the worse treatment prognosis of this patient group. Of 
note, a single chimpanzee infected with the GT3 has been shown to have lower ISG 
expression levels than animals infected with GT1 (143). Why the endogenous IFN 
system is activated in a (large) group of patients, but not in all of them, could be due 
to differences between viruses (genotypes, quasispecies) in their capacity to prevent 
IFN induction and/or to genetically determined variation in virus sensory pathways 
(involving RIG-I, Cardif, IRF3 and other molecules). We have analyzed the 
possibility that different HCV genotypes are differentially affecting the induction of 
type I IFN through the RIG-I/Cardif pathways. As the HCV NS3-4A protease has 
been described to cleave the adaptor protein Cardif in vitro (154), we assessed Cardif 
mRNA and protein expression and the presence of Cardif cleavage products in pre-
treatment liver biopsies of HCV patients. Cardif cleavage was more often seen in 
livers of GT 2/3 patients. Moreover the expression of full-length Cardif correlated 
well with STAT1 hepatocyte nuclear staining in immunohistochemistry and the 
expression of ISGs in the liver of the same patient. This makes an intact RIG-
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mediated signaling pathway a good candidate for inducing type I IFNs, STAT1 
nuclear translocation and transcriptional induction of ISGs. Further studies will be 
needed to corroborate our findings. Especially, it would be of great interest to assess 
IRF-3 phosphorylation in liver biopsies and to find a correlation of IRF3 and STAT1 
activation. Our finding that the frequency and degree of pre-activation of the 
endogenous IFN system depends on the HCV GT and that HCV GTs 2 and 3 show 
more frequent Cardif cleavage indicate that GT 2/3 are more successful in preventing 
the activation of innate immunity in the liver. The success of the virus in preventing 
the induction of the endogenous IFN system would however come at the cost of being 
more susceptible to IFNα-based therapies.  
 
 
5.3 Refractoriness of IFNα signaling in the mouse liver 
 
The clinical efficacy of pegIFNα is being attributed to the constantly high serum 
concentrations achieved with pegIFNα (unlike with unmodified IFNα), which may 
provide for un-interrupted antiviral activity through a permanent stimulation of the 
IFN signaling pathways. In vitro kinetics, however, showed a very rapid 
refractoriness of IFN signaling after an initial strong activation. Cultured cells became 
refractory to IFN within hours and remained unresponsive for up to 3 days (179). 
Continuous exposure to IFN resulted in a “desensitization” characterized by a return 
to pretreatment levels of ISG transcription. Moreover, during the 48 to 72 hours 
following the initial IFNα stimulation, any further IFN treatment failed to re-induce 
the transcription of ISGs in cell culture (179). The kinetic of in vivo IFN signaling has 
not been extensively studied. It is currently not known, whether refractoriness also 
occurs during IFN therapies in patients. Since the clinical experience shows improved 
therapeutic response rate with pegIFNα if compared to unmodified IFNα, and thus 
argues against the occurrence of desensitization in patients, we investigated whether 
the liver becomes refractory to IFNα in vivo by applying a mouse model. Due to 
inavailability of pegylated mouse IFNα, mice were repeatedly injected with 
unmodified mouse IFNα simulating the stable serum concentrations obtained in HCV 
patients. 
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Transient STAT activity in type I IFN-treated cells is mainly regulated by 
tyrosine phosphorylation (tyr-701 of STAT1, tyr-689 of STAT2, tyr-705 of STAT3) 
and dephosphorylation by active shut-off mechanisms. Tyrosine phosphorylation is 
essential for STAT dimer formation, nuclear translocation and DNA-binding. In our 
mouse model, we observed refractoriness in the activation of STAT1 and STAT2, but 
not STAT3. We hypothesized that prolonged STAT3 activation could be due to the 
presence of increased IL-10 levels that we found in the sera of the repeatedly injected 
mice. However, IFN signaling remained refractory to further doses in mice deficient 
in IL-10. We then investigated the possible involvement of known negative regulators 
of IFNα-induced Jak-STAT signaling, including SOCS and UBP43. The induction 
pattern of SOCS1 was consistent with its well-known role in the early negative 
feedback regulation of IFNα signaling. Since SOCS1 was not expressed to any 
detectable degree at late time-points (Figures 4C and 4D, see “refractoriness of Jak-
STAT signaling” manuscript), it is highly unlikely that SOCS1 is responsible for the 
long-lasting inhibition of STAT1 and STAT2 phosphorylation. In contrast, the 
expression levels of SOCS3 were elevated for a prolonged time period (in accordance 
to the observed STAT3 phosphorylation), arguing for a possible role of SOCS3 in the 
long-term inhibition of STAT1 and STAT2 activation. However, a persisting 
refractoriness was also observed in mice deficient in SOCS3. The recently described 
specific type I IFN signaling inhibitor USP18/UBP43 blocks Jak1 phosphorylation 
through a specific interaction with the IFNAR2 subunit of the receptor and thereby 
attenuates IFN signaling (125). We found a strong upregulation of USP18/UBP43 
after treating mice with subcutaneous injections of mIFNα (Figure 6A, see 
“refractoriness of Jak-STAT signaling” manuscript). Contrary to SOCS1 with its 
transient upregulation, USP18/UBP43 was still highly induced in late time-points of 
the kinetic. Remarkably, refractoriness of STAT1/2 phosphorylation could be 
overcome in USP18/UBP43 knockout mice. These data strongly indicate that UBP43 
is the decisive factor in inducing a long-lasting refractory state in the IFNα signaling 
pathway in vivo. Moreover, the second injection of mIFNα induced a strong 
phosphorylation of STAT1 in UBP43 deficient mice despite the very high expression 
of SOCS1 at the same time point. This surprising result provides strong evidence that 
the inhibitory activity of SOCS1 requires the presence of USP18/UBP43. 
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 Our results have potentially important consequences for the treatment of 
patients with chronic viral hepatitis with recombinant IFNα. If we assume that the 
human liver also becomes refractory to IFNα within hours after the first injection of 
recombinant IFNα and that the liver cells remain unresponsive to further IFNα 
stimulation, then the current practice of injecting pegIFNα with its very long half-life 
would lack a pharmacodynamic rational. Clearly, the mechanisms underlying the 
increased efficacy of pegIFNα compared to standard IFNα remain unsolved. The 
results presented here should therefore motivate an in-depth analysis of the 
pharmacodynamic effects of the current pegIFNα treatments in the livers of patients 
with CHC. 
 
 
5.4 Outlook: The role of miRNAs in liver disease and IFN signaling 
 
There is an additional level of regulation involving miRNAs can be considered 
relevant for treatment response in HCV infected livers. MicroRNAs (miRNAs) are a 
large family of ~21-nt-long regulatory RNAs expressed in metazoan animals (180). 
Nearly all miRNAs investigated to date regulate gene expression by base-pairing to 
the 3’-UTR of target mRNAs and inhibiting protein synthesis at the level of 
translation initiation or mRNA degradation (181). The first miRNAs, lin-4 and let-7, 
were discovered in Caenorhabditis elegans, as RNAs that regulate expression of 
mRNAs, which control the timing of larval development (182-184). More recently, 
hundreds of new miRNAs have been identified through cloning, and other methods. 
Biological processes regulated by miRNAs include developmental timing, cell 
differentiation and proliferation, neuronal asymmetry, apoptosis and different 
metabolic reactions. Existence of numerous tissue- and developmental stage-specific 
miRNAs, and the evolutionary conservation of many miRNAs, argue for plentiful 
additional, yet unidentified, functions of miRNAs (180). 
 
There is new evidence which links miRNAs with viruses and importantly also with 
the innate immune response. Some mammalian viruses such as CMV, Herpesviridae, 
and SV40 encode miRNAs in their own genomes, and these miRNAs may modify 
expression of the host genes (185). On the other hand, some of the host-encoded 
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miRNAs may have a profound effect on the life cycle of the infecting virus. MiR-122, 
expressed specifically in liver, is the most spectacular example of the latter category. 
The miRNA miR-122 base-pairs to the 5’-UTR of genomic RNA of HCV and 
positively regulates replication of HCV RNA (36). This observation raised much 
interest in a role of miR-122 in HCV infection and as a potential therapeutic target. 
Furthermore, it was reported recently that expression of miR-122 and several other 
miRNAs is regulated by IFN in Huh7 cells and primary mouse hepatocytes, and that 
miRNAs might mediate at least some effects of IFN on HCV-RNA replication in 
vitro (186). Therefore, it will be of interest to study the status of the miR-122 and 
other miRNAs expressed in liver during the course of HCV infection and following 
IFNα therapy. The availability of biopsy material collected for the studies mentioned 
above will allow us to study the proposed connection between miR-122 and HCV 
replication in a context of diseased tissue, and to test the effect of IFNα therapy on 
the level of miR-122 and other miRNAs in liver cells. Studies with biopsies could be 
accompanied by experiments with Huh7 hepatoma cultured cells expressing the HCV 
replicon or even using the in vitro HCV infectious system (both are available in our 
laboratory) (11-13). Importantly, IFN-induced effects on miR-122 expression could 
also be studied in the mouse liver samples, which had been generated for the study on 
refractoriness of in vivo IFNα signaling. 
 
 
5.5 Concluding remarks 
 
All above described experimental approaches generated important findings in the 
field of IFN signaling in the context of HCV infection. Most notably, our work has 
documented that CHC patients with pre-activation of their endogenous IFN system 
entirely lack a molecular response to pegIFNα. When aiming at finding better 
therapeutic options for this patient group, more efforts should be addressed not only 
to the generation of novel drugs including HCV protease and polymerase inhibitors, 
but also to reversing the mechanisms responsible for the observed IFN pre-activation. 
Most likely, the treatment of IFN-resistant patients with inhibitors of viral enzymes 
will lead to the development of rapid resistance, arguing for search of alternative 
approaches. Our finding that HCV genotypes 1 and 4 more often lead to pre-
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activation in patients and that there is a possible involvement of HCV mediated 
targeting of viral sensory pathways provides the basis for further studies on the 
mechanisms leading to pre-activation. 
  
We describe refractoriness of IFN signaling in vivo in the continuous presence 
of IFNα. Such knowledge is important for a rational design of IFN therapies, because 
dosing intervals shorter than the period of refractoriness would strongly reduce the 
efficacy of the injected IFN. This might have been the reason why classical IFNα 
treatment with injections every 48 hours had a limited therapeutic effect. Furthermore, 
it is not reasonable to administer modified IFNα with a prolonged serum half-life, i.e. 
pegIFNα, with the aim to achieve constant serum concentrations, if the hepatocytes as 
target cells remain unresponsive during most of the dosing interval. Of note, other 
human cells and tissues could show different response kinetics to IFNα and therefore 
side effects would be promoted without gaining any antiviral effects in the liver. 
 
Further progress in the treatment of CHC most likely will depend on a better 
understanding of the pharmocodynamic effects of IFNα in different tissues. The work 
presented in this thesis provides important insights in the host-virus interaction and its 
influence on IFNα induced signal transduction in the liver.   
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